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Abstract 
 
Two major reasons for the failure of central nervous system axon regeneration are (i) 
lack of neurotrophic factors available to CNS neurones and (ii) the presence of 
molecules that inhibit the growth of axons.  In this study a gene therapy approach 
using adeno-associated virus 8 (AAV8) was used to manipulate these two factors.   
 
The following major aims were addressed: (i) confirm the bioactivity of transgenes 
that would be packaged into the AAV8 vector; (ii) assess the cellular tropism of AAV8 
in the dorsal root ganglion (DRG); (iii) evaluate the inflammatory responses of the 
nervous system to AAV8 after intra-DRG and intrathecal injection; (iv) determine the 
axon regenerative effect of AAV8-mediated delivery of nt-3 (a neurotrophic factor) 
and shRNARhoA (a disinhibitory therapy) to dorsal root ganglion neurones after spinal 
cord injury in the rat.   
 
Delivery of the nt-3 transgene in vitro resulted in production of high levels of NT-3 
protein.  Transfection of shRNARhoA-containing plasmids into cell lines resulted in a 
marked decrease in the amount of RhoA detectable in cell lysates.  AAV8 was found 
to preferentially transduce large diameter, proprioceptive DRG neurones (DRGN) but 
in the context of a significant inflammatory response after intra-DRG injection 28d 
following intra-DRG injection.   Axon regenerative effects of AAV8-mediated 
transgene delivery before lesioning were ambiguous and further work need to be 
undertaken to clarify this matter.   
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1.1 Spinal cord injury – defining the problem 
Spinal cord injury (SCI) is an important source of chronic morbidity and mortality in 
the developed and developing world.  It is such an important problem because the 
majority of SCI patients were previously fit, healthy young people who frequently 
become condemned to a life of disability, pain, loss of dignity and inability to work.   
 
Worldwide, around 3 million individuals are living with a spinal cord injury, with an 
estimated incidence of 130 000 new cases per year (ICCP 2010).  Around 80% of 
cases of SCI are in men, with the peak age being 30-50 years.  In the developed 
world the majority of cases are due to road traffic accidents as opposed to the 
developing world, where falls account for the majority of injuries to the spinal cord 
(Chiu, Lin et al.). 
 
1.1.1 The extent of the problem 
SCI is not merely a physical problem.  It affects all aspects of the patient‟s life, with 
significant psychological, social and economic implications.  Patients with SCI 
frequently are not able to work and consume a significant proportion of the health 
service budget.  Current treatments are predominantly based around rehabilitation 
and symptom control, offering only minimal functional improvements over what the 
patient would experience spontaneously.  Having said this, however, the mortality 
rate from SCI has fallen considerably over the last 100 years as the multifactorial and 
highly complex nature of this condition has been increasingly recognised (Tremblay 
1995).   
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1.1.1.1 Mechanisms of injury 
The brain and spinal cord are protected from injury by the robust axial skeleton, 
composed of the skull and vertebrae.  The bony components of this structure are 
anchored to each other by strong ligaments and thick layers of muscle.  Thus, injury 
to the spinal cord typically results from high energy impacts such as road traffic 
accidents and falls from some height.  These injuries lead to fractures and/or 
dislocations of vertebrae, with resultant compression, twisting or pulling of the cord.  
 
As well as traumatic aetiologies, SCI can be caused by a variety of other pathologies 
including tumours, degenerative and inflammatory conditions, infections and 
ischemia (McDonald and Sadowsky 2002).  Regardless of the mechanism, however, 
functional deficits will often ensue after even relatively mild insults to the cord. 
 
1.1.1.2 At-risk groups and prevalence of morbidity 
SCI typically affects men in their twenties or thirties, with a much lower incidence in 
children and older age groups.  This pattern is usually attributed to the fact that 
young men are at a higher risk of engaging in activities such as outdoor pursuits and 
reckless driving.  Another important cause of SCI in young men is violent crime, seen 
at relatively high rates in some sectors of the community.  Having said that, the 
paediatric and elderly groups also contribute to the burden caused by central nervous 
system (CNS) injuries due to conditions such as cerebral palsy, strokes and falls.   
 
The effects of SCI, however, are much more wide-ranging than paralysis; so much so 
that SCI can be considered as a systemic disease with effects on almost all systems 
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of the body.  Long-term sequelae affect the cardiovascular, respiratory and genitor-
urinary systems, leading to pathologies such as pneumonia, urinary tract infections 
and bedsores (Zeilig, Dolev et al. 2000).   
 
1.1.1.3 How SCI research can inform other areas 
Some may argue that SCI, despite its grave consequences, is a relatively uncommon 
condition and so may not warrant very high levels of research funding.  This point of 
view, in the author‟s opinion, fails to acknowledge the far-reaching and eclectic 
impact of CNS regeneration research.  For example, work on myelin neutralisation 
therapies is showing considerable promise in stroke – a common and devastating 
illness (Gillani, Tsai et al. 2010).  Also, advances in the understanding of Rho 
proteins are being used in developing treatments for cancers and the modulation of 
angiogenesis (Merajver and Usmani 2005).   
 
1.1.2 Spinal cord injury in more detail 
One of the major illustrations of how research into SCI can inform other areas, such 
as stroke or cerebral palsy, is that the injury response of the CNS is fairly uniform 
across different regions such as the optic nerve, brain and spinal cord.  It is this 
generic response to CNS damage that the following section is devoted to.  The 
reader is referred to section 1.1.2.3.2.2 for more specific details concerning the 
dorsal column (DC) crush model. 
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1.1.2.1 The CNS injury response to penetrating trauma 
One of the best characterised models for examining CNS injury responses employs 
the cerebral stab method, whereby the brain is exposed and the cortex penetrated 
using a scalpel blade mounted in a stereotactic instrument (Logan, Green et al. 
1999).  This model has been used extensively to study the basic mechanisms of the 
CNS injury response, as well as to examine the efficacy of anti-scarring reagents.  
The phenomenology of the injury response using this model can be successfully 
extrapolated to the DC crush model (used as the experimental paradigm in the 
present study), since both breach the meninges, both involve sharp transection, both 
sever axons and both lead to extensive glial activation and scar formation.   
 
Three stages of the CNS injury response have been defined in adult rat models, 
based on time after lesioning: the acute (0-3 days post-lesion (dpl)), sub-acute (3-8 
dpl) and consolidation (8-20 dpl) phases.  The reader is referred to an excellent, 
although no longer current, volume describing the changes discussed below in much 
greater detail (Berry and Logan 1999).   
 
The acute phase 
The acute phase is characterised by extensive haemorrhage into the lesion site, with 
breach of the blood-brain barrier (BBB), the blood-cerebrospinal fluid (CSF) barrier 
and the brain-CSF barrier.  Blood and CSF are known to contain many components, 
both cellular and acellular, which are involved in initiating and modulating the CNS 
injury response.  For example, platelets carry Transforming Growth Factor β (TGF-β), 
which is known to have a significant role in scar-tissue formation.  Monocytes 
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deposited in the lesion become transformed into active macrophages.  Additionally, 
serum and CSF carry a number of growth factors which can lead to macrophage 
activation and fibroblast recruitment.  The influx of these molecules initiates a 
molecular cascade which serves to initiate, modulate and perpetuate the injury 
response.  Modification of this „cytokine cascade‟ is an active area of SCI research.   
 
The subacute phase 
The subacute phase is characterised by the clearance of necrotic debris from the 
lesion site by macrophages, and the increasing recruitment and activation of glial 
cells.  The lesion core becomes walled off (and hence the BBB restored) by an 
accessory glia limitans, orchestrated by activated astrocytes at the wound margin.  
Meningeal fibroblasts begin to invade the lesion core, depositing extracellular matrix 
(ECM) components such as collagens, chondroitin sulphate proteoglycans (CSPGs) 
and laminin, which will form the bulk of the glial scar.   
 
The consolidation phase 
This phase, variable in length, is characterised by contraction of the lesion core and a 
decreased level of glial activation.  The accessory glia limitans becomes increasingly 
thick and organised, and the number of cells within the lesion core decreases, 
leaving a collagen, CSPG and fibronectin-rich scar.  Axons are seen not to traverse 
the lesion core or to accumulate in great numbers at the lesion margins.  Thus, the 
CNS injury response is complete, and the lesion can be said to have entered the 
chronic stage.   
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1.1.2.2 Immediate versus late responses to CNS injuries 
With respect to most human cases of SCI, the events described above constitute 
only a small fraction of the length of time the patient is alive post-injury.  It is known 
that a number of additional events take place in the months to years following CNS 
injuries.  Some of these processes are advantageous to the patient (e.g. neural 
plasticity leading to limited spontaneous functional recovery), but most lead to further 
problems, and can be progressive unless treated, such as post-traumatic 
syringomyelia (Brodbelt and Stoodley 2003) and progressive demyelination (Blight 
1985).  Particularly worrying for the researcher hoping to use reparative growth 
factors as therapeutics is the possibility of exacerbating post-SCI neuropathic pain, a 
condition which is known to lead to significant morbidity within the spinally injured 
community.   
 
1.1.2.3 Injury models 
Animal models of CNS injuries have been in use for well over 100 years, and they 
continue to provide valuable new insights.  However, it must be born in mind that no 
single model of SCI currently in use is perfectly suited to answering all of the 
questions that remain to be answered.  Each model is particularly suited to 
answering a particular set of questions, and comes with its own unique strengths and 
limitations which must be considered when interpreting research data.  Furthermore, 
technical aspects of experimental design, such as species used, animal numbers, 
controls and outcome measures, have a vital bearing on the applicability of results to 
human SCI.  The reader is referred to two excellent review articles from the groups of 
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Tetzlaff and Tessier-Lavigne concerning technical aspects of in vivo SCI 
experimental design (Kwon, Oxland et al. 2002; Steward, Zheng et al. 2003).   
 
1.1.2.3.1 A brief survey of SCI models 
Animal models of SCI can be categorised as either sharp or blunt, which can be 
further split into complete or partial.  To perform competently, all require a great deal 
of technical skill and high quality apparatus to ensure that results are maximally valid 
and animal suffering is kept to a minimum. 
 
1.1.2.3.1.1 Complete transections 
Experiments employing complete transections of the cord form a relatively small 
proportion of all published reports of SCI work.  This is probably due to a number of 
factors, both technical and translational.  Firstly, most human SCI is partial due to the 
fact that the spinal cord is well protected within the vertebral column, and dislocations 
of the spine adequate to fully transect the cord are rare.  Thus, any results from 
complete transection models are unlikely to extrapolate to the SCI patient community 
as a whole.  Having said that, any axon regeneration seen using such a model is 
likely to be indicative of a highly robust treatment effect which would certainly warrant 
further investigation.   
 
From a technical point of view, complete transections tend to be much more labour 
intensive, and hence more costly, than partial lesions, due to the intensive care 
animals require after injury (e.g. manual voiding, locomotor problems).  However, this 
additional cost may be abrogated by the probable requirement for smaller animal 
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numbers, since complete lesions are inherently less variable in extent than partial 
ones.   
 
Another problem experienced with complete transections is that the two ends of the 
cord tend to naturally separate from one another after lesioning.  Such a situation 
almost certainly leads to a highly inhospitable environment for regenerating axons, 
and means that such experiments are likely to require bridging strategies to 
demonstrate any effect of a therapeutic on axon regeneration. 
 
Finally, ethical reasons must be considered when planning which kind of lesion to 
perform in animals.  Complete transections lead to significant loss of function, and 
animals need much more intensive care after such lesions.  Partial lesions tend to 
have much less profound functional consequences on experimental animals and are 
preferred from an ethical point of view.   
 
1.1.2.3.1.2 Partial transections 
These are by far the most popular type of lesion performed in the experimental spinal 
cord injury research community.  They are more representative of human SCI and do 
not necessitate bridging strategies or intensive postoperative care.  However, 
experiments using partial transection models require a highly rigorous design, and 
are frequently open to criticisms concerning the plausibility of any axon regeneration 
seen.   
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Partial transections usually involve a specific, defined tract or tracts within the white 
matter of the spinal cord.  This is advantageous, and such lesions lend themselves to 
neuroanatomical tract tracing methods, behavioural outcome measures and 
neurophysiological testing.  However, confounding factors abound in such 
experiments due to the phenomena of axon sparing and synaptic plasticity.   
 
Axon sparing refers to the preservation of some axons within a lesion.  This may be 
due to a lesion being incomplete (e.g. only transecting 1mm of a 1.5mm tract), or that 
axons within the core of the lesion have just been disrupted rather than transected 
(e.g. by applying an inadequate compressive force).  Either way, one may see axons 
distal to the lesion and conclude that they have regenerated.  It is possible to account 
for this if the experiment is designed rigorously.   
 
Before conducting any experiments, one must ensure that the lesion will transect all 
of the axons in question in an animal of a particular species at a particular age.  
Thus, one requires an appreciation of the location and physical dimensions of the 
tract of interest, its developmental dynamics and any interspecies neuroanatomical 
variation.  Ideally, the lesion should be performed using a mechanical device, 
appropriately calibrated, or at the very least by hand by an experienced operator with 
graduated instruments to ensure consistent lesion size.   
 
Axon sparing may be excluded at the analysis stage of an experiment by looking for 
the presence of an anterograde tracer at the distant target of the transected axon.  
For example, in the DC crush model (described below), cholera toxin B (CTB) is 
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injected into the sciatic nerve 2d before killing the animal.  This is adequate time to 
completely fill a large proportion of transected axons.  Providing that the time frame is 
appropriate (see below), no CTB should be seen in the gracile nucleus.  From this, 
one can conclude that the lesion was complete. 
 
As mentioned above, the amount of time between lesion and tracer injection/sacrifice 
must be chosen carefully (Steward, Zheng et al. 2003).  Killing the animal too soon 
after lesioning may give a spurious negative result, since axons are likely to require 
some time to recover after injury whether they ultimately regenerate or not.  In the 
case of an efficacious treatment where axons regenerate to their distant targets, 
waiting too long post injury may lead one to incorrectly conclude that the lesion was 
incomplete. 
 
Synaptic plasticity as a confounding factor in partial SCI models, tends to mainly 
affect experiments with behavioural outcome measures.  Virtually all spinal cord 
injuries, whether in man or other animals, show some degree of spontaneous 
recovery.  Even after complete transections, rats can walk with appropriate training 
and pharmacological intervention (Kwon, Oxland et al. 2002).  Of course, such 
effects can be controlled for, but one must be mindful of treatments given to stimulate 
axon regeneration but which are also able to affect plasticity.  Axon regeneration and 
plasticity are closely related phenomena (Cafferty, McGee et al. 2008).   
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1.1.2.3.1.3 Contusions 
The majority of blunt transections are performed by transiently compressing the 
exposed spinal cord using a known force (contusion).  Such injuries usually employ 
sophisticated pieces of apparatus which are capable of delivering a precisely 
controlled amount of energy, for example the New York University Impactor (Kwon, 
Oxland et al. 2002).  Spinal cord contusion models reflect human pathology very 
closely, not only in their mechanism of injury but also in the pathological features 
seen.  They are able to produce remarkably consistent and reproducible injuries, the 
effects of which can be monitored successfully using behavioural techniques.  
However, they are limited with respect to assessing anatomical axon regeneration 
since, although the clinical effects are consistent, specific tracts cannot be precisely 
and completely transected.  Thus, one is left with the issue of spared axons 
discussed above.   
 
1.1.2.3.1.4 Sharp transections 
Models using sharp transection techniques can deliver well-defined anatomical 
lesions to given white matter tracts, lending themselves to the use of 
neuroanatomical techniques to monitor axon regeneration.  Performed correctly, 
such lesions display minimal variability in extent.  However, there are a number of 
disadvantages to using these models.  Firstly, there is the issue that only a minority 
of human SCI is due to sharp transections (e.g. stabbing).  Thus, any experiments 
employing such techniques may need to be repeated using a more appropriate 
model (e.g. contusion).  Secondly, these lesions are often technically demanding 
requiring detailed knowledge of neuroanatomy.  In order to perform a sharp 
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transection, one must usually penetrate the dura and arachnoid maters, leaving a 
CSF leak which may confound experiments.   
 
1.1.2.3.2 The DC crush model 
The model used in this study to examine the axon regenerative effects of 
therapeutics is the DC crush.  This can be classified as a sharp, partial transection of 
the spinal cord.  Despite the term „crush‟, axons are seen to have been immediately 
transected after lesioning (see section 2.2.3).  This lesion transects two well defined 
white matter tracts and has been used previously in studies of cellular responses to 
injury and  axon regeneration (Dusart and Schwab 1994; Lagord, Berry et al. 2002; 
Alto, Havton et al. 2009). 
 
1.1.2.3.2.1 Anatomy relevant to the DC crush model 
The reader is reminded that further detail concerning rat and human neuroanatomy is 
available from a number of sources (Craigie, Innes et al. 1963; Standring and Gray 
2008; Watson 2009).  Unless otherwise stated, all neuroanatomy described is that of 
Rattus norvegicus.   
 
Spinal cord 
At its most fundamental level, the spinal cord can be described as a segmented, 
cylindrical extension of the brain containing a central core of grey matter surrounded 
by an outer layer of white matter.  The grey matter of the spinal cord is composed 
mainly of lower motor neurone cell bodies, directly innervating muscles; and second 
order sensory neurone cell bodies projecting to the thalamus.  The white matter of 
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the spinal cord contains descending projections which act to modulate the activity of 
lower motor neurones and sensory neurones, and ascending projections, which can 
be either from first or second order sensory neurones.  Furthermore, the spinal cord 
is known to contain many interneurones, which travel within propriospinal pathways.  
The white matter can be subdivided into three major regions (dorsal, lateral and 
ventral funiculi), containing defined subpopulations of neuronal projections (Figure 
1.1 A).   
 
The boundaries of the dorsal funiculus are the pial surface of the spinal cord dorsally, 
the dorsal horns laterally and the central grey matter containing the central canal 
ventrally.  In the rat, the dorsal funiculus contains two major axonal populations: the 
ascending dorsal columns and the descending corticospinal tracts.  In man, the 
corticospinal tracts are found in the lateral and ventral funiculi.  
 
Strictly speaking, a lesion of the dorsal funiculus has been performed in this study, 
since a lesion depth of 1.5 mm includes dorsal columns, corticospinal tracts and grey 
matter adjacent to the central canal (see section 2.2.3).  However, the author refers 
to a „DC lesion‟, since it is the neurones of the DC that have been examined for any 
evidence of axon regeneration.   
 
DRG and dorsal roots 
Each spinal cord segment has two corresponding dorsal root ganglia (DRG), 
connected to it by a pair of dorsal roots (Figure 1.1 B).  In simple histological 
preparations, one is able to observe many dorsal root ganglion neurones (DRGN), 
B 
Figure 1.1.  Arrangement of the white matter and immediate peripheral 
connections of the rat spinal cord.  A.  Transverse section at the L1 cord level, 
showing the funiculi and ascending and descending tracts.  CC: central canal, 
CST: corticospinal tract, DC: dorsal column, DF: dorsal funiculus, LF: lateral 
funiculus, RaST: raphespinal tract, ReST: reticulospinal tract, RST: rubrospinal 
tract, SCT: spinocerebellar tracts, STT: spinothalamic tract, VF: ventral funiculus, 
VST: vestibulospinal tract.  Dorsal funiculus in red, lateral funiculus in green and 
ventral funiculus in blue.  Adapted from figure 14.1, Watson 2009.  B.  Schematic 
of a transverse section through the lumbar cord, roots, DRG and spinal nerve 
showing the arrangement of white and grey matter and the trajectory of DRGN 
and motor neurone axons.  From Standring 2008.   
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each surrounded by a layer of satellite cells (Figure 1.2).  Also present are 
myelinated and unmyelinated fibres, blood vessels, connective tissue components 
and very occasional macrophages.  DRGN contact sensory end-organs and are of 
considerable interest since, despite the fact that they are part of the peripheral 
nervous system (PNS), they have projections to both CNS and PNS (see section 
1.4.4.2 for further details).   
 
DRGN are a heterogeneous population, and have been classified by many different 
and often overlapping methods such as size, protein expression, sensitivity to toxins 
and electrophysiology (Willis and Coggeshall 2004).  The commonest classification 
splits DRGN into small and large cell body diameter populations, with large diameter 
DRGN tending to have large, fast-conducting axons and small DRGN having small, 
slower conducting axons (Harper and Lawson 1985).  Fast-conducting axons are 
associated with functions such as proprioception and discriminative touch, whilst 
nociceptive fibres tend to have small, slow-conducting axons (Willis and Coggeshall 
2004).   
 
Satellite cells are by far the most common resident cell of the DRG (Landon 1976).  
They surround DRGN cell bodies and the initial segment of DRGN axons, usually in 
single layers (Pannese 1994).  The function of satellite cells is yet to be fully 
elucidated, although a large amount of data point towards roles in regulation of the 
extracellular milieu, responses to circulating substances, responses to injury and 
barrier functions (Hanani 2005).  See Chapter 4 for a more in-depth discussion of 
some of these points.   
100µm 
Figure 1.2.  Confocal microscopic appearance of the adult rat DRG after intra-DRG injection of AAV8egfp.  GFP
+ DRGN 
cell bodies (*) and axons (white arrowheads) are clearly visible, with associated nuclei of perisomatic satellite cells (white 
arrows) and periaxonal Schwann cells  (red arrowheads).   
GFP DAPI 
* 
* 
* 
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The dorsal roots contain central projections of DRGN, destined for the dorsal horn or 
DC.  Axons are myelinated by Schwann cells, surrounded by a connective-tissue 
layer.  The point of transition to CNS tissue, where axons are myelinated by 
oligodendrocytes, is at the dorsal root entry zone (DREZ), directly adjacent to the 
spinal cord.   
 
Spinal nerves 
The peripheral projections of DRGN, emanating from the DRG, converge with the 
ventral root just proximal to the intervertebral foramina and emerge as the spinal 
nerves.  Spinal nerves usually enter plexuses such as the sacral plexus, ultimately 
forming major branches such as the sciatic nerve (Figure 1.3).  Within spinal nerves, 
axons are myelinated by Schwann cells and there is a functional blood-nerve barrier 
which serves to protect the enclosed axons from chemical insults.  Spinal nerves 
regenerate damaged axons readily, although function is often not completely 
restored.   
 
It is not known why regeneration is less successful in the CNS compared with the 
PNS, although certain anatomical and molecular factors contribute including the 
presence of basal lamina tubes in the PNS along which axons can grow and 
differences in neuronal growth state and mechanisms of axon degeneration after 
PNS injury compared to CNS injury (Huebner and Strittmatter 2009).   
 
 
 
T1 
L1 
S1 
T1 
L1 
T8 
L6 
Vert Cord 
Figure 1.3 Basic anatomy of the rat spinal column, 
with special emphasis on the sciatic nerve.   Note 
how, due to differential growth rates of the spinal 
cord and spinal column, the L4-L6 cord levels are 
actually found at vertebral levels T13-L1.  In the rat, 
the sciatic nerve (A), formed in the sacral plexus by 
the confluence of spinal nerves (B) emerging from 
the L4-L6 vertebral levels.  Note also L4-L6 DRG 
(C), and for simplicity dorsal and ventral roots 
shown as a single line (D).   
A 
B 
C 
D 
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Central projections of DRGN 
Three major „classic‟ pathways exist that convey afferent information from the 
periphery to the brain: the DC pathway (Figure 1.4), the spinothalamic tract (STT; 
Figure 1.5) and the dorsal spinocerebellar tract (DSCT; Figure 1.6).  These pathways 
have been described in great detail elsewhere (Craigie, Innes et al. 1963; Willis and 
Coggeshall 2004; Standring and Gray 2008).  In addition to these there are a 
plethora of other pathways whose roles have not yet been elucidated 
comprehensively (Willis and Coggeshall 2004).  The following section aims just to 
describe the central projections of the first order neurone (i.e. the DRGN) in these 
pathways, since it is these that are predominantly transected in the DC crush model.   
 
First order projections of all three major pathways originate from sensory structures 
found in organs such as the skin (e.g. Pacinian corpuscles), joints (joint capsule 
endings), muscles (muscle spindles) and tendons (Golgi tendon organs).  These 
structures are innervated by the peripheral projection of DRGN, the impulse being 
conveyed to the spinal cord via the central projection in the dorsal root.  All first-order 
sensory neurones (i.e. DRGN) project ipsilaterally in the cord.  In the STT and DC 
pathway, the second order neurone is found in the dorsal horn and the dorsal column 
nuclei, respectively.  Second-order neurones decussate at approximately the level of 
entry of the first order neurone in the case of the STT, or in the internal arcuate fibres 
of the medulla in the DC pathway.  
 
The DSCT takes its origin from second order neurones lying in Clarke‟s column, a 
group of cells found deep within lamina V of the dorsal horn, in the thoracic and 
L1 
C4 
T8 
DRGN 
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Figure 1.4.  The dorsal column-medial lemniscus pathway.  Note that (i) DC fibres 
arising from successively rostral cord segments are added laterally to the DC; (ii) 
within the cord, the DC pathway is entirely ipsilateral; (iii) second-order neurones 
reside within the GN for the lower half of the body and CN for the upper half;  (iv) 
IAF project to the thalamus via the ML.  CN: cuneate nucleus; DRGN: dorsal root 
ganglion neurone; DC: dorsal column; GN: gracile nucleus; IAF: internal arcuate 
fibres; ML: medial lemniscus.  Dorsal funiculus in red, lateral funiculus in green, 
ventral funiculus in blue.   
L1 
C4 
T8 
DRGN 
Medulla 
STT 
Figure 1.5.  The spino-thalamic tract.  Note that (i) Fibres arising from second-order 
neurones from successively rostral cord segments are added medially to the STT; 
(ii) within the cord, the STT is contralateral to first-order neurones; (iii) second-order 
neurones reside within the dorsal horn.  DRGN: dorsal root ganglion neurone, STT: 
spino-thalamic tract.  Colour scheme showing funiculi is as described in Figure 1.1.   
L5 
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Figure 1.6.  The dorsal spino-cerebellar tract.  Note that (i) DRGN with central 
projections entering the lower lumbar cord ascend in the DC; (ii) CC is found in the 
lower cervical, thoracic and upper lumbar cord and contains second order neurones 
that project axons in the DSCT; (iii) DRGN whose central projections enter the 
upper and mid-cervical cord ascend in the DC to synapse with second-order 
neurones of the ACN in the medulla;  (iv) Neurones of the ACN project medial to the 
DSCT to the cerebellum.  ACN: accessory cuneate nucleus; CC: Clarke’s column; 
CCT: cuneocerebellar tract; CN: cuneate nucleus; DC: dorsal column; DRGN: 
dorsal root ganglion neurone; DSCT; dorsal spinocerebellar tract; GN: gracile 
nucleus.  Colour scheme showing funiculi is as described in Figure 1.1.   
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upper lumbar segments.  First order neurones project to Clarke‟s column within the 
dorsal funiculus; thus DC lesions transect first order neurones of both the DC 
pathway and projections to Clarke‟s column. 
 
Finally, it must be born in mind that there is considerable diversity in the central 
projections of DRGN.  For example, not all ascend once entering the spinal cord – a 
significant minority descend 2 or 3 segments before synapsing.  Also, there is 
considerable collateralisation within these pathways, such as branches to the ventral 
horn, lateral horn and higher structures.   
 
1.1.2.3.2.2 Cellular responses seen after DC crush 
DC crush leads to a set of cellular responses very similar to any other CNS injury, 
involving axons, glia, inflammatory cells and the extracellular matrix.  See Figure 1.7 
for characteristics of the lesion used in this study.   
 
Axons and neuronal cell bodies 
From as early as one day post lesion (1 dpl) axons are seen to be absent from the 
lesion core, indicating a complete transection.  At 28 dpl, axonal debris is seen in 
macrophages in the degenerating DC rostral to the lesion (Lagord, Berry et al. 2002).  
CNS axons do attempt to regenerate in the early stages after a lesion by producing 
short sprouts, but they fail to enter the lesion core and form so-called „dystrophic 
endballs‟ at their tips, thought initially by Cajal to be unresponsive and quiescent, but 
now recognised to be capable of further growth (Ramon y Cajal 1991; Yiu and He 
2006).   
Figure 1.7 The extent of the DC lesion used in this study. The lesion has a 
dorsal/ventral dimension of 1.5mm extending to the central canal, bounded 
laterally by the dorsal root entry zones. Spinal cord regions disrupted in this 
lesion include the dorsal funiculus (containing ascending dorsal column and
descending corticospinal axons), the dorsal horns and part of the ventral horns.
Image adapted from Watson , 2009.
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Available data indicate that there is minimal DRGN cell death after transection of the 
central process, contrasting with the large amount of apoptotic death occurring after 
transection of DRGN peripheral processes (Shi, Tandrup et al. 2001; Chew, Leinster 
et al. 2008).  This is possibly due to the large amount of peripherally derived 
neurotrophic factors acting upon DRGN.   
 
Glia 
The three major glial types found in the CNS are astrocytes, microglia and 
oligodendrocytes.  Astrocytes have diverse roles in the normal and pathological 
nervous system, including regulating synaptic transmission, maintaining the blood-
brain barrier and maintenance of extracellular ion concentrations (Verkhratski and 
Butt 2007).  Additionally, astrocytes respond to injury by up-regulating expression of 
glial fibrillary acidic protein (GFAP), developing thicker processes and laying down 
ECM components such as CSPGs (Properzi, Asher et al. 2003).   
 
Activated astrocytes are seen surrounding the lesion site from the first week post 
lesion, occasionally extending processes into the lesion by 3 weeks (Dijkstra, Geisert 
et al. 2000).  By 56 dpl astrocytes are seen lining the lesion cavity, and any cysts that 
may have formed.   
 
Microglia are the resident phagocytes of the CNS, derived from blood-borne 
monocytes that invaded the CNS parenchyma early in development (Verkhratski and 
Butt 2007).  They actively survey the CNS environment with their motile processes 
and respond to injury by developing shorter, thicker processes and up-regulating 
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their expression of phagocytic markers such as CD68 and CD11b (Ransohoff and 
Perry 2009).   
 
From the first week post lesion, activated microglia are seen surrounding the lesion 
site, with increasing numbers found rostral to the lesion by 21 dpl (Lagord, Berry et 
al. 2002; Agudo, Robinson et al. 2005).   
Oligodendrocytes are the myelinating cells of the CNS, with each oligodendrocyte 
contributing to the myelin sheath of up to 30 axons (Verkhratski and Butt 2007).  After 
CNS lesions, oligodendrocytes become dissociated from axons and develop fine 
processes that become ramified between degenerating axons (Berry and Logan 
1999).   
 
By 4 dpl, 2,3-cyclic nucleotide 3'-phospho-diesterase positive oligodendrocytes have 
disappeared from the lesion site, but are still found in the degenerating rostral tract 
(Lagord, Berry et al. 2002).  Oligodendrocyte numbers decline in the DC rostral to the 
lesion well into the chronic period, as Wallerian degeneration progresses (Almad, 
Sahinkaya et al. 2011).   
 
Inflammatory cells 
Haematogenous macrophages are seen from early time points after DC crush, 
migrating into the blood-filled core of the lesion, alongside lymphocytes and 
monocytes.  By 20 dpl, numerous macrophages are seen both within and rostral to 
the lesion site, and are probably actively involved in removing axonal and myelin 
debris (Lagord, Berry et al. 2002).   
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Scarring and cavitation 
During the first 3 dpl, fibroblasts positive for ECM components such as fibronectin 
can be detected in the lesion core.  At 7 dpl, this fibrotic region becomes capped by a 
laminin positive layer derived from meningeal fibroblasts (Lagord, Berry et al. 2002).   
 
At the lesion site from 4 dpl, a large cavity is seen filled with blood derived cells and 
cellular debris.  This cavity is seen to extend as time progresses, with secondary 
cavitation extending up to a total distance of around 4mm (Figure 1.8).  Cavities are 
typically filled with macrophages, fibroblasts, laminin fibronectin and collagen, and 
are lined by astrocytes constituting the accessory glia limitans (Lagord, Berry et al. 
2002).  .   
 
1.1.3 Why is CNS axon regeneration so limited? 
At this point, it is prudent to clarify what is meant by the term „regeneration‟ as it is 
encountered in this work.  The Oxford English Dictionary defines „regeneration‟ in its 
biological sense as “the formation of new animal tissue; the natural replacement of 
lost parts or organs”.  In the nervous system, it is important to differentiate between 
regeneration due to the replacement of lost cells (e.g. neurogenesis or replacement 
of lost glial cells) and regeneration due to the growth of existing cells (i.e. regrowth of 
a severed axon, axonogenesis).  In this study, regeneration will be discussed with 
respect to the process of axonogenesis.   
 
It has been known for centuries that compared with the PNS, the CNS has only a 
very limited capacity for axon regeneration.  Consequently, many researchers have 
Rostral 
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Figure 1.8.  Comparison of the gross appearance of the lesioned rat spinal cord 1 
and 3 months post injury.  Details of lesioning technique can be found in section 
2.2.3.  A.  3 months post DC lesion at T8 cord level.  Note the large, fluid-filled 
cystic cavity at the primary lesion site indicated by ink staining of the meninges (*) 
and the degenerating dorsal columns rostral to the lesion (†).   Arrowheads 
indicate dorsal roots.  B.  1 month post DC lesion at L1 cord level.  Note the much 
smaller primary lesion cavity than in A, filled with cells and debris.  There is no 
gross evidence of rostral degeneration or cavitation in the DC.   
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focussed on the essential differences between the two major divisions of the nervous 
system in terms of responses to injury and molecular characteristics.  Furthermore, it 
is known that in certain „lower‟ phylogenetic groups (e.g. fishes, amphibians), axon 
regeneration occurs readily in the CNS.  Many workers, the author included, believe 
that this could hold a vital key to achieving CNS axon regeneration in mammals.   
 
Four major factors are thought to contribute to the lack of CNS axon regeneration 
seen in mammals.  These are: lack of endogenously synthesised neurotrophic 
factors (NTF) in the CNS, the presence of axon growth inhibitory ligands (AGIL), the 
presence of a glial scar in CNS lesions and the death of CNS neurones after 
axotomy.   
 
Insufficient NTF synthesis in the CNS 
Three major lines of evidence converge on the conclusion that there are lower levels 
of NTF synthesis in the CNS compared with the PNS.  Firstly, the results of the 
intravitreal peripheral nerve grafts of Berry et al. (see below) show that by providing a 
rich source of NTF to CNS neurone cell bodies, axon regeneration can be achieved 
(Berry, Carlile et al. 1996).  Thus, it seems likely that levels of NTF in the intact or 
injured CNS are insufficient to elicit axon regeneration.  Secondly, studies on 
peripheral nerve regeneration have shown that NTF are released in appropriate 
temporal and spatial gradients in a way that is conducive to PNS axonal regeneration 
(Boyd and Gordon 2003).  Finally, a recent study demonstrates directly that CNS 
tissue contains lower titres of NTF than PNS tissue (Du, Yang et al. 2010).   
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However, it must be stressed that the CNS does contain abundant NTF, including 
NT-3, derived from target tissues such as skeletal muscle and sensory receptors 
(Zhou and Rush 1994; Curtis, Tonra et al. 1998; Hiltunen, Laurikainen et al. 2005; 
Wang, Meng et al. 2008).  However, the concentrations provided by endogenous 
sources are clearly not sufficient to stimulate axon regeneration on their own, 
necessitating the need to deliver higher concentrations to activate the growth state of 
axotomised neurones. 
 
 
AGIL 
In 1982, Berry was the first to hypothesise the existence of molecules found within 
CNS neuropil that are capable of inhibiting the growth of axons (Berry 1982).  This 
idea arose from the observation that retinal ganglion cell (RGC) axons transected 
within the retina (an environment devoid of myelin) are capable of profuse growth.  
Furthermore, all of the studies employing peripheral nerve grafts to connect two CNS 
regions never showed axonal penetration of the CNS neuropil despite extensive 
growth within the graft.   
 
The first demonstration that specific protein fractions from myelin contained an 
inhibitory activity came from Martin Schwab‟s group, who followed this lead up 
extensively culminating in the demonstration that the molecule that they named Nogo 
was a key player in axon growth inhibition (Caroni and Schwab 1988; Zorner and 
Schwab 2010).  Many other AGIL, derived from both myelin and the glial scar, have 
been identified since including myelin-associated glycoprotein (MAG) 
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(Mukhopadhyay, Doherty et al. 1994), oligodendrocyte-myelin glycoprotein (OMgp) 
(Wang, Koprivica et al. 2002) and a variety of CSPGs (Galtrey and Fawcett 2007).   
 
Scarring 
As has already been mentioned in section 1.1.2.2, the final stage in the evolution of 
many CNS injuries is the formation of a dense glial scar.  Windle proposed that the 
scar acted as a simple mechanical barrier to axon growth, but this has failed to stand 
up to evidence accumulated over the last 20 years (Windle and Chambers 1950).  It 
has since become clear that the glial scar contains many molecules with inhibitory 
effects on growth cones, such as CSPG, semaphorins and ephrins (Fitch and Silver 
2008).  Interestingly, some controversy still remains with respect to glial scarring, 
particularly surrounding the dynamics of scar deposition and its interactions with 
regenerating axons (Ahmed, Dent et al. 2005).   
 
 
Neuronal death 
An important consequence of axotomy in the CNS is neuronal death, and is currently 
the subject of intense research activity in translational SCI research.  CNS lesions 
lead to high levels of neuronal death which occurs in varying degrees depending on 
the level of collateralisation in the lesioned system (collateralisation correlates with 
the amount of target-derived neurotrophic support a neurone is receiving).  For 
example in the visual system, more than 90% of RGCs have died by apoptosis 14d 
after intra-orbital transection of the optic nerve (Berkelaar, Clarke et al. 1994).  RGCs 
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are particularly susceptible to cell death after transection of their axons, since no 
collaterals emerge from the optic nerve.   
 
DRGN, in part due to their possession of both central and peripheral projections (see 
section 1.1.2.3.2.1), are more robust than most CNS neurones with respect to cell 
death after axotomy.  Although relatively little studied, it seems clear that transection 
of the DRGN central processes does not lead to significant DRGN apoptosis (Chew, 
Leinster et al. 2008).  Transection of the peripheral process, however, is seen to lead 
to around a 40% loss of DRGN (Tandrup, Woolf et al. 2000).  The conclusion from 
these studies is that DRGN are more dependent upon growth factors derived from 
their peripheral targets than those from their central targets.  Furthermore, this is 
consistent with the evidence supporting a relative paucity of NTF in the CNS 
environment.   
 
1.1.4 Reasons to be optimistic about regenerative therapies 
In the period after Cajal‟s coining of the phrase ”abortive regeneration”, the 
neuroscience community felt resigned to what they believed was the inherent 
impossibility of CNS axon regeneration (Ramon y Cajal 1991).  However, it was the 
serendipitous discovery by Windle in the early 1950s that a bacterial polysaccharide 
could stimulate regeneration of axons in the transected spinal cord that led many 
researchers to reconsider what Cajal had proposed (Windle 1955).   
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CNS neurones are capable of extending axons 
In the 1980s, work from the laboratory of Albert Aguayo showed that axons from the 
spinal cord and optic nerve were able to grow readily for considerable distances into 
peripheral nerve grafts, refuting the dogma that CNS axons are incapable of further 
growth (Richardson, McGuinness et al. 1980; Aguayo, Vidal-Sanz et al. 1987).  Thus, 
it became a worthwhile pursuit looking for ways to attain axonal growth in the injured 
CNS. 
 
CNS neurones can regenerate axons if stimulated appropriately 
Two major possibilities arose from Aguayo‟s work.  CNS axons could have grown into 
the PNS graft because (i), there was a higher concentration of growth factors in the 
graft than in the adjacent CNS neuropil or (ii), the graft had a more permissive 
environment for axon growth than CNS neuropil.  Partly to address these 
hypotheses, Berry et al. inserted fragments of live and freeze-thawed peripheral 
nerve into the vitreous humour of eyes which had had their optic nerves transected 
(Berry, Carlile et al. 1996).  The result was a large number of regenerating axons 
found in the grafted animals, particularly those receiving a live graft.  Indeed, it has 
been shown that that Schwann cells are capable of synthesising a number of NTF 
(Funakoshi, Frisen et al. 1993).  These results demonstrated that CNS neurones are 
capable of extending axons when given appropriate neurotrophic stimulation. 
 
Regenerating CNS axons can navigate to appropriate targets 
Having demonstrated successful axon regeneration of CNS neurones, researchers 
became anxious to show whether these axons were capable of following the 
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developmental signposts that had guided them during embryogenesis.  To address 
this, Berry et al. examined the trajectories of regenerating axons in the optic nerve as 
they decussate at the chiasm (Berry, Carlile et al. 1999).  They were able show that 
regenerating RGC axons did indeed recapitulate the paths that they had taken during 
development.  This was an extremely exciting result, since it suggested that, 
providing axon regeneration was sufficiently robust, appropriate functional 
connections may be restored. 
 
1.2 Neurotrophic factors 
The term NTF refers to a number of small polypeptide molecules which have 
functions relevant to neuronal growth, differentiation and survival.  This should be 
contrasted with the term neurotrophins (NT) which refers to a family of molecules that 
are themselves NTF but which act specifically through a particular type of receptor. 
 
1.2.1 The neurotrophins 
This group of NTF contains four members found in mammals: nerve growth factor 
(NGF), brain-derived neurotrophic factor (BDNF) (Barde, Edgar et al. 1982), 
neurotrophin-3 (NT-3) (Kaisho, Yoshimura et al. 1990) and neurotrophin-4 (NT-4) 
(Hallbook, Ibanez et al. 1991).  NT-4 is also known as NT-4/5 or NT-5.  These 
molecules all act via the tropomyosin-like receptor kinases (Trks), which come in 
three subtypes: NGF binds TrkA; BDNF binds TrkB; NT-3 binds TrkC as well as TrkA 
and TrkB with lower affinity and NT-4 binds TrkB.  In addition to Trk receptors, NT are 
also able to act directly via the p75NTR receptor (Reichardt 2006).   
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In mammals, NT are widespread in the CNS, although their relative concentrations 
and detailed spatial distribution may differ according to developmental stage or 
presence of disease states (Heumann, Lindholm et al. 1987; Tanis, Newton et al. 
2007).  Since the remit of this project is axon regeneration of DRGN, the remainder 
of the discussion will focus on NT and Trk receptor distribution in DRG and spinal 
cord in the intact adult animal and following injury, with particular emphasis on NT-3.  
There have been a number of excellent reviews of this area, so a brief overview will 
be presented, emphasising those aspects believed to be of particular importance 
(Patapoutian and Reichardt 2001; Huang and Reichardt 2003; Reichardt 2006; 
Blochl and Blochl 2007). 
 
1.2.1.1 NT receptors and signalling cascades 
In vivo, NT exist as non-covalently bound homodimers, each monomer being capable 
of binding with high affinity to the membrane-proximal region of a single Trk molecule 
(Reichardt 2006).  Signalling is initiated by homodimerisation of Trk receptors after 
NT binding and subsequent transphosphorylation of intracellular tyrosine residues by 
tyrosine kinase domains (Jing, Tapley et al. 1992).  The phosphorylation of 
intracellular domains of Trk receptors provides docking sites at membrane-proximal 
and membrane-distal sites for a number of adaptor proteins, with the ultimate effect 
of activating one of three major pathways.  The major effectors of these pathways are 
Protein Kinase C (PKC), PI3-kinase/Akt and mitogen activated protein kinase 
(MAPK) (Figure 1.9).  A further, important downstream effector of NTF signalling is 
the mammalian target of rapamycin (mTOR), which has important functions in 
Figure 1.9.  The major neurotrophin signalling pathways activated by binding of NT.  The Trk receptors control three 
important signalling pathways.  Activation of MAPK following recruitment of the Ras pathway by Shc, Frs2 and Grb2/SOS 
augments neurite outgrowth.  PI3K, activated by the same upstream regulators as the Ras pathway but also involving 
GAB1, enhances growth cone motility and, through Akt, neuronal survival.  Recruitment of PLCɣ1 to the distal segment of 
the Trk intracellular domain leads to the generation of IP3 and DAG, with the subsequent activation of PKC leading to 
changes in synaptic plasticity and gene transcription.   
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sensing the availability of raw materials and trophic factors and regulating the growth 
responses of the cell (Park, Liu et al. 2010).   
 
p75NTR was the first receptor for NT to be identified, however its true significance to 
NT signalling is only now becoming fully apparent.  This receptor binds NT with a low 
but similar affinity across all subtypes, and has three main regions: the extracellular 
domain (p75ECD) which interacts with ligands, the intracellular domain (p75ICD) and a 
transmembrane domain (Reichardt 2006).  The intracellular domain can be 
enzymatically cleaved, and is able to initiate apoptosis – hence its alternative name 
of the „death domain‟.  Unlike Trk receptors, the p75NTR does not have any inherent 
catalytic activity, its signals being transduced by association with intracellular 
molecules such as Traf6, neurotrophin receptor interacting protein and Rho-GDP 
dissociation inhibitor (RhoGDI).  Additionally, p75NTR has been shown to augment the 
affinity and specificity of NT interactions with Trk (Chao 1994) 
 
1.2.1.2 Biological effects of neurotrophins 
The cellular effects of p75NTR activation include effects on growth-cone motility via 
Rho GTPases as well as causing cell survival or apoptosis dependent upon the other 
receptors present on the cell surface (Blochl and Blochl 2007).  Binding of 
proneurotrophins to the p75NTR receptor has been shown to stimulate apoptosis via 
an interaction with sortilin, a molecule involved in protein trafficking (Lee, Kermani et 
al. 2001; Teng, Teng et al. 2005).   
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As mentioned above, Trk phosphorylation leads ultimately to activation of one of 
three major effector systems: PKC, PI3-kinase/Akt and MAPK.  Between them, these 
pathways impinge upon gene transcription, cell survival, neurite outgrowth and 
growth cone motility.  For further details please refer to either of these excellent 
reviews (Huang and Reichardt 2003; Reichardt 2006).   
 
PKC 
Upon binding of phospholipase C-ɣ1 (PLC-ɣ1) to membrane-distal phosphotyrosine 
residues, it is itself phosphorylated and hence activated by the Trk tyrosine kinase 
domain.  Once activated, this important enzyme is able to convert the substrate 
PtdIns(4,5)P2 into IP3 and diacylglycerol (DAG).  IP3 causes release of Ca
2+ from 
intracellular stores which activates many Ca2+ -dependent kinases, and DAG 
activates various isoforms of PKC.  Additionally, Ca2+ release itself activates other 
PKCs leading to almost all isoforms of PKC becoming activated.  The major effects of 
activation of this pathway are via the nucleus through changes in gene transcription, 
particularly those for ion channels. 
 
PI3-kinase/Akt 
The recruitment of Shc and Frs2 to membrane-proximal phosphotyrosine residues 
leads to activation of the Grb2/SOS complex.  Grb2/SOS is able to activate PI3K by a 
Ras-dependent pathway or one involving GAB1.  Active PI3-kinase generates 3-
phosphoinositides which, via PDK-1 activate the protein kinase Akt, which has 
substrates involved in cell survival and the cell cycle.  Additionally, the 3-
phosphoinositides generated by PI3-kinase are able to recruit small GTPases such 
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as Cdc-42, Rac and Rho which, when active, can directly affect the cytoskeleton and 
hence cell motility including that of growth cones.   
 
MAPK 
Active Ras, generated by the events described in the previous section, is able to 
activate Raf, and in turn MEK leading to the activation of a variety of MAPK subtypes.  
MAPKs can activate intermediates such as CREB, ultimately affecting gene 
expression via transcription factors such as Egr-1, which have been shown to 
stimulate neurite outgrowth in phaeochromocytoma-12 (PC12) cells after application 
of NGF.   
 
1.2.1.3 The relevance of NT-3 to spinal cord injury  
Transcript for the major NT-3 receptor, TrkC, is seen in around 15-20% of neurones 
in the dorsal root ganglion of intact adult rats, the majority of these being of medium 
to large diameter (Kashiba, Noguchi et al. 1995; Kashiba, Ueda et al. 1996).  This 
pattern of expression, alongside in vitro data showing expression of TrkC in neuronal 
cell lines can lead to neurite outgrowth in the presence of NT-3, has led a number of 
investigators to examine the potential therapeutic effects of administering NT-3 in 
spinal cord injured animals (Tsoulfas, Soppet et al. 1993).  The following account 
focuses on studies examining the effects of NT-3 administration on axon 
regeneration of sensory neurones projecting to the spinal cord of adult animals.  
However, the reader should be made aware that many other studies have looked at 
other CNS pathways including the motor and auditory systems (Schnell, Schneider et 
al. 1994; Gharabaghi and Tatagiba 2005; Fortun, Puzis et al. 2009; Petruska, Kitay et 
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al. 2010).  Also, much of the preliminary work showing NT-3 to be important was 
performed using immature animals, whose neurones are much more dependent 
upon NT for survival. 
 
NT-3 has been shown to have a number of roles in the developing nervous system, 
particularly with respect to the development of proprioceptive axons and synaptic 
plasticity of primary afferent synapses (Mendell, Munson et al. 2001; Taylor, Vancura 
et al. 2001; Taylor, Vancura et al. 2001; Wright, Williams et al. 2002; Taylor, 
Holdeman et al. 2005).   
 
One of the first reports that NT-3 has axon regenerative activity in adult animals in 
vivo was from Tuszynski‟s group, who injected NT-3 expressing fibroblasts into the 
central grey matter of the rat spinal cord (Nakahara, Gage et al. 1996).  In the 
absence of any previous injury, it was seen that a large number of sensory axons 
projected into the fibroblast grafts.  This study demonstrated not only that NT-3 is 
axogenic in vivo, but also that neurones retain the ability to respond to NTF into 
adulthood.   
 
NT-3 was shown to be active in promoting axon regeneration in a study employing 
the dorsal root injury model.  Adenoviral-mediated delivery of NT-3 promoted the 
regeneration of sensory neurones not only across the DREZ, but into the grey matter 
of the cord towards the site of injection (Zhang, Dijkhuizen et al. 1998).  Thus, NT-3 
was shown to act both to promote axon regeneration and to guide axon growth, 
effects which would be further exploited in future studies. 
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The logical next step was to examine the effect of NT-3 delivery on regeneration of 
axons within a white matter tract.  This was performed by Bradbury et al. using a DC 
crush model and continuous infusion of recombinant NT-3 for 4 weeks at the lesion 
site (Bradbury, Khemani et al. 1999).  Compared with control and other growth 
factors tested, NT-3 led to many axons sprouting into, and some beyond, the lesion 
site within the spinal cord.   
Despite these promising results, it remained clear that NT-3 was unlikely to be viable 
as a monotherapy for SCI since the number of regenerating axons seen was typically 
modest.  Also, no study ever saw axons regenerating all the way to their distant 
targets (but see experimental design section 1.1.2.3).   
 
1.3 Axon growth inhibitory ligands 
As mentioned in section 1.1.3, it has been known for more than 20 years that a 
number of molecules exist that are capable of inhibiting axon growth, specifically by 
causing the collapse of growth cones.  Since this realisation, a tremendous amount 
of work has been carried out examining the roles of these molecules in normal and 
pathological situations, particularly with respect to their molecular signalling 
mechanisms and potential neutralisation strategies. 
 
1.3.1 The growth cone 
It is believed that Cajal was the first to describe “concentration[s] of protoplasm of 
conical form, endowed with amoeboid movements”; entities that we now refer to as 
growth cones (Ramon y Cajal 1890).  Growth cones have major roles in development 
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when the nervous system is being built, but also into adulthood in the processes of 
axon regeneration and neuronal plasticity.  The modern view of growth cones is that 
they are highly dynamic structures, capable of integrating a whole host of molecular 
signals leading to a relatively simple decision: whether to collapse or not, whether or 
not to grow, and if so in which direction and how fast.  Growth cone collapse is an 
active process, and is not simply growth cone stasis.  Collapsed growth cones shrink 
considerably and become quite refractory to stimuli.   
 
The signals which growth cones use for guidance are highly diverse, ranging from 
attractive substances such as neurotrophins, repulsive substances such as 
semaphorins and collapsing substances such as Nogo.  The following section will 
focus on the role of myelin-derived AGIL (Nogo, OMgp and MAG), their signalling 
pathways and distribution in the intact and injured CNS.  The reader is referred to a 
comprehensive review for further details (Sandvig, Berry et al. 2004).   
 
1.3.2 Expression of myelin-derived AGIL in the normal and injured CNS 
In the majority of reports, myelin-derived AGIL are found within the myelin sheaths of 
axons, and in the cell bodies of oligodendrocytes (Sandvig, Berry et al. 2004).  
However, their mere presence may not necessarily be sufficient to inhibit the growth 
of axons.  An interesting study conducted through collaboration between Jerry Silver 
and Geoff Raisman demonstrated that adult DRGN, when atraumatically 
transplanted into the CNS are able to extend neurites through white matter for 
distances of around 6mm (Davies, Fitch et al. 1997).  Their conclusions focussed 
primarily on the glial scar, however the results of this study quite clearly show that 
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intact white matter is not inhibitory to adult DRGN.  The explanation for this may be 
that myelin-derived AGIL must be solubilised in order to interact with receptors such 
as nogo receptor (NgR) on the growth cone.  Such solubilisation is likely to occur 
through primary and secondary effects of the lesion such as tissue disruption and 
Wallerian degeneration.   
 
A second, seemingly paradoxical observation is that some neurones express AGIL 
themselves, and are even seen at the growth cone (Hunt, Coffin et al. 2002).  The 
significance of this neuronal AGIL expression is not yet fully appreciated, although it 
is probable that molecules such as Nogo have roles in growth cone guidance and the 
inhibition of formation of inappropriate connections (Llorens, Gil et al. 2011).   
Expression of Nogo in the intact and injured spinal cord 
Of the three different Nogo subtypes, Nogo-A is believed to have the most important 
role in the CNS.  In the spinal cord, Nogo-A protein is seen in motor neurones and 
oligodendrocytes – particularly in their cells bodies and myelin sheaths, particularly in 
the myelin adjacent to axons (Huber, Weinmann et al. 2002).   
 
Very little modulation of Nogo-A is seen after SCI, although this is not necessarily 
evidence that Nogo-A has a limited role in CNS axon regenerative failure (Huber, 
Weinmann et al. 2002).   
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Expression of MAG in the intact and injured spinal cord 
MAG is found in the myelin sheaths of both the CNS and PNS, and has been 
detected in a soluble form in degenerating tracts post injury (Sandvig, Berry et al. 
2004).   
 
Expression of OMgp in the intact and injured spinal cord 
It has recently been demonstrated that OMgp is found in both neurones and 
oligodendrocytes of the spinal cord, and that there is an increase in mRNA and 
protein levels after injury (Guo, Li et al. 2007; Dou, Huang et al. 2009).   
 
1.3.3 Myelin-derived AGIL signalling 
Nogo-A, MAG and OMgp all signal through Nogo Receptor 1 (NgR1), and MAG is 
known also to bind to NgR2 (Tuszynski and Kordower 2008).  Additionally, all known 
myelin-derived AGIL bind to paired immunoglobulin-like receptor B (PirB), a molecule 
known to have roles in neural plasticity and the immune system (Atwal, Pinkston-
Gosse et al. 2008).  Regardless of the AGIL, the common downstream signalling 
molecule responsible for growth cone collapse is RhoA.  Since most is known about 
NgR1 signalling to RhoA and the cytoskeleton, this will be the focus of the following 
discussion. 
NgR1 is expressed on the surface of neurones, including growth cones, and is 
thought to be the major receptor mediating myelin-derived AGIL induced growth cone 
collapse (Fournier, GrandPre et al. 2001).  Alone, NgR1 is not able to transduce 
signals to the growth cone cytoskeleton since it does not possess an intracellular 
signalling domain.  In order for signal transduction to occur, NgR1 associates with a 
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number of membrane-spanning proteins including p75 NTR (Wang, Kim et al. 2002), 
leucine-rich repeat and Ig domain containing (LINGO-1) (Mi, Lee et al. 2004) and 
TNFRSF (tumor necrosis factor receptor superfamily) expressed on the mouse 
embryo (TROY) (Park, Yiu et al. 2005).   
 
NgR1 forms a trimer with LINGO-1 and p75NTR or TROY, which is able to activate 
RhoA via p75NTR (Figure 1.10).  RhoA exists in a dynamic equilibrium between and 
inactive GDP-bound (Rho-GDP) form and an active GTP-bound form (Rho-GTP).  
Guanine-nucleotide exchange factors (Rho-GEFs) activate RhoA by converting Rho-
GDP to Rho-GTP, whilst GTPase activating proteins (Rho-GAPs) inactivate RhoA by 
converting ho-GTP to Rho-GDP.  Rho-GDP (inactive) can be sequestered from Rho-
GEFs by binding to Rho-GDI, taking it „out of the loop‟ and impairing its activation.  
Binding of AGIL to NgR1 leads to displacement of Rho-GDI from Rho-GDP by 
creating a binding site on p75NTR with a higher affinity for Rho-GDI than Rho-GDP.  
Thus, Rho-GDP is released and can be activated by Rho-GEFs.   
Activated RhoA is able to activate a number of pathways involved in growth cone 
arrest, turning and collapse via the important intermediate protein Rho-associated 
kinase (ROCK).  There are at least two subtypes of ROCK, but for clarity and brevity 
they shall be considered together (Schmandke and Strittmatter 2007).  ROCK has 
two major functions with respect to growth cone collapse and turning – inhibition of 
actin depolymerisation and formation of stress fibres.   
 
Growth cones are highly dynamic structures, achieving this motility mainly by the co-
ordinated formation of actin fibres and microtubules.  All dynamic cytoskeletal 
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Figure 1.10.  The major signalling cascade activated by NgR binding to myelin-derived AGIL.  AGIL-binding leads to 
displacement of Rho-GDI from RhoA-GDP allowing activation of RhoA by GEF.  Activated RhoA then activates ROCK, 
leading to (i) the formation of actomyosin stress fibres via activation of MLCK and inhibition of MLCP; and (ii) inhibition of 
actin fibre depolymerisation via  LIMK and cofilin.  The net effect  of i and ii is growth cone collapse and inhibition of its 
motility.  Adapted from an original figure provided by Professor Ann Logan and adapted by by Dr Kevin Morrison.   
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elements are maintained by the balance between formation and destruction.  In the 
case of actin, an equilibrium exists between the free, globular or G-actin and the 
filamentous F-actin (Geraldo and Gordon-Weeks 2009).  Actin polymerisation is 
regulated by many pathways; one of the most important involves LIM-domain 
containing protein kinases 1 and 2 (LIMK) and cofilin (Schmandke and Strittmatter 
2007).  ROCK activation leads to phosphorylation of LIMK, which in turn deactivates 
cofilin by phosphorylation.  Normally, cofilin is an important catalyst for 
depolymerisation of F-actin which is vital for actin turnover and cytoskeletal motility.  
This „actin paralysis‟ is not sufficient, however, to explain growth cone collapse.  
Myosin light chains (MLC) associate with actin fibres to generate contractile forces, 
which are able to lead to growth cone collapse (Zhao and Manser 2005).  ROCK is 
able to directly phosphorylate MLC and to inhibit the activity of myosin light chain 
phosphatase, allowing stress fibres to form.   
 
A note on the subtlety of growth cone dynamics 
The picture painted above is one of an ostensibly simple story, leading to a logical 
choice of therapeutics.  However, it must be stressed that the events occurring within 
the growth cone are phenomenally complex.  It is the opinion of the author that a 
single therapeutic intervention (e.g. knocking down a single molecule in the AGIL 
signalling cascade) is unlikely to be successful.  Furthermore, examination of any 
recent review will highlight some contradictions and new directions that may be of 
importance, such as the growth-promoting effects of RhoA activation via mDia and 
the enigmatic citron kinase (Schmandke and Strittmatter 2007).   
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1.3.4 Disinhibitory therapies 
As discussed in section 1.3, engagement of AGIL to cell-surface receptors such as 
NgR1 and NgR2 result in activation of the small GTPase RhoA and its downstream 
effector ROCK.  In order to dissect the role of these molecules in the pathway, much 
work has been done in the last decade to examine the effects of inhibiting or 
activating various components on axon regeneration both in vitro and in vivo.   
 
1.3.4.1 Knockout studies 
Experiments examining the axon regenerative effects of genetic deletions (i.e. gene 
knockouts) can be highly informative, but must be interpreted with a great deal of 
caution.  This is mainly due to the fact that knockout animals have undergone 
development in the presence of the deletion, meaning that normally redundant 
systems could come into play and have a significant, confounding role.   Also, it is not 
always possible to conduct knockout studies if the gene under scrutiny is essential to 
life. 
 
NgR1 knockouts 
Knocking out the NgR1 receptor has been shown to have, at best, a modest effect on 
axon regeneration in vivo (Kim, Liu et al. 2004; Zheng, Atwal et al. 2005).  This is in 
the context of a comparatively more robust effect of Nogo inhibitors such as the 
antibody IN-1 (Teng and Tang 2005).  The conclusion of these studies as a whole 
seemed to be that another receptor for Nogo existed, since inhibiting the ligand had a 
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greater effect than inhibiting its (known) receptor.  This prediction was borne out in 
2008 when Tessier-Lavigne‟s group reported that a new receptor for AGIL had been 
identified – PirB (Atwal, Pinkston-Gosse et al. 2008).   
 
RhoA knockouts 
At the time of writing, no reports of RhoA knockdown could be found.  This is 
probably due to embryonic lethality of total RhoA deletion, since this molecule is 
believed to be a crucial intermediary in regulating development of the nervous 
system.   
 
ROCK knockouts 
By deleting ROCKII, the major nervous system ROCK isoform, Strittmatter‟s group 
were able to show modest increases in the amount of axon regeneration seen in the 
raphespinal and corticospinal tracts (Duffy, Schmandke et al. 2009).  However, the 
nature of this regeneration must be considered carefully: spontaneous regeneration 
of raphespinal fibres is a recognised phenomenon, and no corticospinal tract (CST) 
axons were seen traversing the lesion site (Kiernan 1979).  Thus, ROCKII knockout 
is unlikely to be sufficient to effect axon regeneration on its own.  Irrespective of 
these caveats however, the genetic deletion experiments described above did indeed 
show that ROCKII has a role to play in axon regenerative failure.   
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1.3.4.2 Knockdown studies 
RNA interference (RNAi) has made genetic dissection of pathways increasingly 
accessible, but its advantages are far greater than merely eliminating the need for 
knockout animals.  RNAi can be delivered either as RNA molecules directly to the 
cytoplasm (small-interfering RNA, siRNA) or within a plasmid to the nucleus, which is 
then transcribed into an RNA molecule (short hairpin RNA, shRNA).  This technology 
allows genes to be „deleted‟ in fully developed, adult animals.  The crucial advantage 
to this is that, unlike in a knockout, the animal has not had the opportunity to bring 
into play redundant pathways.  Also, RNAi is usually delivered to a specific tissue so 
lethality, even when knocking down crucial genes, is not a significant issue.   
 
However, there are disadvantages including lack of specificity of knockdown, 
unpredictable effects on cellular metabolism and the need to deliver RNAi constructs 
to the appropriate cellular compartment (Ehlert, Eggers et al. 2010; Olejniczak, Galka 
et al. 2010).   
 
NgR1 knockdown 
The consensus is that knockdown of NgR1 leads to augmentation of neurite 
outgrowth in the presence of myelin-derived AGIL in vitro, although the precise mode 
of action of this effect is debatable (Ahmed, Dent et al. 2005; Chivatakarn, Kaneko et 
al. 2007).  Chivatakarn et al. propose that NgR1 has a role in acute growth-cone 
collapse but not in chronic inhibition of neurite outgrowth when presented as a 
substrate.  Ahmed et al. show, however, that DRGN neurite outgrowth is disinhibited 
by NgR1 knockdown (equivalent to the „chronic inhibition‟ described above).  For 
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technical reasons, the two studies are not easy to reconcile but provide the same 
basic conclusion – NgR1 knockdown is capable of augmenting regeneration in vitro.   
 
RhoA knockdown 
RhoA is a pivotal protein in the AGIL pathway (see section 1.3.3).  Targeting this 
molecule holds much promise as it is an important nodal point, integrating signals 
from most of the AGIL. 
 
RNAi-mediated knockdown of RhoA has been demonstrated to lead to disinhibited 
neurite outgrowth in DRGN and rat PC12 cells by two independent groups (Ahmed, 
Dent et al. 2005; Fan, Pang et al. 2008; Suggate, Ahmed et al. 2009).   
ROCK knockdown 
At the time of writing, no reports of the effects of RNAi-mediated knockdown of 
ROCK on neurite outgrowth have been reported in the literature.  This is probably 
due to the availability of the pharmacological inhibitor Y27632 (see section 1.3.4.3).   
 
1.3.4.3 Peptide and small molecule inhibitors of the AGIL signalling pathway 
It is the ultimate goal of SCI research to develop therapies which are highly 
efficacious and which can be delivered non-invasively.  Therapies based on small 
molecules may offer this, since they offer the potential for oral administration and 
long-term delivery.  Part of the development of small molecule inhibitors involves the 
generation of peptide-based agents, which have themselves shown some promise in 
animal models of SCI and stroke. 
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NgR1 inhibitors 
As of writing, no small molecule inhibitors of NgR have been reported in the 
literature.  However, a number of workers have described peptide inhibitors of NgR 
which they employed during studies of NgR signalling.  These include the NEP-1 
peptide, comprising the first 40 amino acids of Nogo-66 (GrandPre, Li et al. 2002); 
and the NgR(310)ecto-Fc molecule (Fournier, Gould et al. 2002).  NEP-1 
antagonises NgR by competing with Nogo for the ligand-binding domain, and has 
been shown to stimulate axon regeneration in the injured CST.  NgR(310)ecto-Fc 
acts a soluble NgR, effectively „mopping up‟ and sequestering any soluble myelin-
derived AGIL, and has also been shown to improve regeneration of severed axons in 
the CST (Li, Liu et al. 2004).   
RhoA inhibitors 
A membrane-permeable form of the bacterial enzyme C3-transferase has been 
shown to have efficacy in animal models, and is now undergoing phase I/II clinical 
trials with promising results (Lord-Fontaine, Yang et al. 2008; Fehlings, Theodore et 
al. 2011).  C3-transferase works by Adenosine diphosphate (ADP)-ribosylation of the 
RhoA effector domain, rendering RhoA unable to activate its downstream targets 
such as ROCK (Winton, Dubreuil et al. 2002).   
 
ROCK inhibitors 
The ROCK inhibitor Y27632 has a strong disinhibitory effect on cortical neurones in 
vitro and the CST in vivo, but requires the presence of NTF to stimulate outgrowth 
from RGCs exposed to myelin in vitro (Dergham, Ellezam et al. 2002; Ahmed, Berry 
et al. 2009).  Despite the fact that ROCK inhibitors are being used in many areas of 
44 
 
biomedical research, there were no published clinical trials describing its use at the 
time of writing.   
 
1.4 Therapeutic delivery technologies 
Regenerative agents are usually delivered to the CNS by direct injection into neural 
tissues such as the brain, spinal cord or DRG.  Such injections tend to be hampered 
by the fact that the CNS is extremely well protected by bone and tough meningeal 
layers.  Agents injected into the circulation are frequently prevented from entering the 
CNS neuropil by the presence of the BBB and the blood-cerebrospinal fluid barrier.  
Furthermore, the friable nature of the brain and spinal cord mean that they are liable 
to injury during injections.   
 
However, there are certain advantages of the CNS as a target, including the fact that 
it has a relatively attenuated immune response compared with the periphery.  Thus, 
delivery of an immunogenic agent such as a virus or protein is likely to lead to only a 
very slow rate of clearance by the immune system.  Additionally, the anatomy of CNS 
is very well characterised in most species meaning that lesions and injections can be 
performed very precisely using stereotactic instruments if available.  Such knowledge 
also facilitates tracing of regenerated fibres.   
Whatever the method of delivery, the agent must be supplied for a prolonged period 
of time if one is to achieve long tract regeneration.  It is this problem which has led 
many groups to use gene therapy as a way of achieving sustained delivery of their 
therapeutic of choice.  Whereas peptides delivered by single injections have only 
very short half-lives (around 30 min) in vivo (Krewson and Saltzman 1996), peptides 
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produced by gene delivery can be detected many months following the initial injection 
of the gene (Wu, Meyer et al. 2005).  Thus, one must either deliver a peptide by 
continuous infusion which is difficult and costly, or generate a (usually) viral vector 
containing the gene of interest.  The most common gene therapy vectors used in the 
nervous system are described below, with particular emphasis on adeno-associated 
viral (AAV) vectors, which were used in this study. 
 
1.4.1 Non-viral gene delivery methods 
Non-viral gene delivery may be desirable if, for example one is concerned about 
potential pathological effects of viral vectors, illustrated tragically by the case of 
Jesse Gelsinger, the first person to die in a gene therapy trial (Raper, Chirmule et al. 
2003).  However, these methods have a number of serious limitations, yielding low 
levels of gene expression which tend to decrease rapidly compared with viral vectors.  
This is due to the fact that non-viral deoxyribonucleic acid (DNA) payloads are 
cleared quickly from tissues, especially those containing many dividing cells (Glover, 
Lipps et al. 2005). 
 
Three major methods exist for the non-viral delivery of genes – naked DNA, cationic 
polymers and liposomes.  Naked DNA can be introduced in a number of ways, 
usually employing physical methods such as microinjection, ballistic delivery or 
electroporation (Glover, Lipps et al. 2005).  Naked DNA has been successfully used 
in the CNS, giving high, sustained levels of expression in the brain (Yurek, Fletcher 
et al. 2009).   
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Cationic polymers and liposomes exploit the phenomenon that DNA is able to form 
highly condensed complexes when mixed with polymers or lipids containing many, 
repeated positively charged sites (Elsabahy, Nazarali et al. 2011).  Upon contacting 
the cell membrane, these complexes become endocytosed, subsequently entering 
the nucleus and leading to gene expression.  However, these technologies yield very 
low transfection rates in neurones, since they rely on the breakdown of the nuclear 
envelope during mitosis to gain entry to the nucleus (Barrett, Berry et al. 2004).   
 
1.4.2 AAV based vectors 
AAV vectors were originally discovered serendipitously, co-purifying with adenovirus 
(Ad), and have been used in gene therapy for more than twenty years in a large 
variety of tissues including the CNS (Chamberlin, Du et al. 1998).  AAVs belong to 
the parvovirus family, and are small (25nm) polyhedral encapsidated, non-enveloped 
particles which are highly dependent upon other viruses for their normal life-cycle 
(Daya and Berns 2008).  The genomes of all AAV-based vectors are composed of 
single stranded DNA (ssDNA), containing an expression cassette spanned by 
inverted terminal repeats (ITRs), usually from AAV2 (Figure 1.11).  Capsid proteins 
from serotypes other than AAV2 are able to assemble around AAV2 ITRs, forming a 
so-called transencapsidated vector.  Such vectors are described by giving the origin 
of the ITRs followed by the origin of the capsid genes (e.g. AAV2 ITRs with AAV8 
capsid is designated AAV2/8).  The capsid proteins expressed determine the 
interaction of the vector with its host cells, and hence the majority of its tropism.  
However, it is known that other factors downstream of viral entry, can contribute to 
differential expression of delivered transgenes (Duan, Yue et al. 2000).  In this study, 
Figure 1.11.  Life cycle and genome structure of AAV and AAV-based vectors.  A.  
Infection of cells by wtAAV particles  can lead to (i) a lytic phase involving replication 
of AAV particles and lysis of infected cells in the presence of helper viruses such as 
adenovirus (red arrows) or (ii) integration of AAV genomes into the host genome in the 
absence of helper viruses (green arrow).  Subsequent infection of cells with integrated 
AAV genomes can lead to reactivation of the lytic phase (blue arrow).  Adapted from 
Daya 2008.  B.  Genome structure of wild-type AAV.  The P5 region and some genes 
found in the Rep complex are involved in viral integration.  The rest of the Rep genes 
facilitate replication of the genome.  The Cap region encodes the serotype-specific 
capsid proteins.  C.  Generic structure of the genome of recombinant AAV vectors 
used in this study.  To generate these vectors, the wild type virus is genetically 
‘gutted’, leaving space for inserts of up to 1.7kb in the presence of the CMV promoter 
and an hrGFP reporter gene. 
Rep Cap P5 wt 
rAAV PCMV hrGFP 
Gene of 
interest 
Whole genome 4.7 kb 
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for clarity, AAV2/8-based vectors (which are used throughout) will be referred to as 
AAV8.   
 
1.4.2.1 AAV vector manufacture 
AAV vectors can be manufactured in a variety of ways, but all rely upon the presence 
of three key elements (Goncalves 2005).  Further details can obtained from the 
comprehensive review by Goncalves et al.  Firstly, one requires the viral genome 
containing the transgene of interest spanned by ITRs.  Secondly, the genes encoding 
the appropriate capsid and Rep proteins must be supplied.  Thirdly, since AAV 
requires „helper‟ genes to be supplied for successful replication, these must also be 
supplied.  Helper genes are typically involved in facilitating AAV genome replication, 
and work by interacting with proteins encoded by the rep complex.  These elements 
are usually transfected into an appropriate cell line (such as human embryonic kidney 
(HEK) cells).  The cells take up the transgenes and produce AAV vector particles, 
which can be purified from the medium.  Originally, helper genes were supplied by 
including Ad in the medium, which when it infects cells produces proteins that can 
assist AAV replication: E1A, E1B, E2A, E4ORF6 and VA .  However, this posed a 
number of challenges to purification since AAV and Ad are very similar in their 
molecular characteristics.  The inability to get a highly pure, Ad-free AAV preparation 
led workers to deliver the helper genes not by Ad infection, but by transfecting them 
into cells within a so-called „helper plasmid‟.   
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The triple-transfection technique described above is a laborious method, using large 
volumes of culture medium and yielding relatively low levels of viral particles.  In 
response to this, insect cells which are highly efficient at generating recombinant 
proteins, were employed to manufacture AAV particles (Urabe, Ding et al. 2002).  
See Chapter 3 for more details on AAV manufacture in insect cells.   
 
Regardless of the method of production, viral particles must be purified from the cell 
culture medium.  This is most commonly achieved by caesium chloride density 
ultracentrifugation, where the vector accumulates as a single band which can be 
aspirated.  However, with greater insights into AAV biology, more selective and 
efficient methods are being developed such as column chromatography which can 
exploit the capsid‟s natural affinity for a receptor (Goncalves 2005).   
 
1.4.2.2 AAV vector advantages 
AAV has a number of distinct advantages over many other viral vectors.  It is not 
associated with any known human diseases and, at least in the case of AAV2, has 
been shown to be well tolerated when injected into the human CNS (Marks Jr, 
Ostrem et al. 2008).  Part of its lack of pathogenicity is due to the inability of AAV 
vectors to integrate into the genome.  Wild-type AAV contains two gene complexes 
designated rep and cap (Figure 1.11).  The rep complex is involved in viral replication 
and integration into the host genome, and the cap complex contains genes encoding 
capsid proteins.  If a wild-type AAV infects a cell in the absence of a helper virus 
such as Ad, then it may integrate into chromosome 19, ready to start replicating if 
conditions become more favourable (infection by Ad, cellular stress etc.).  Current 
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AAV vectors lack this ability, since rep and cap have been removed to allow insertion 
of an expression cassette (Daya and Berns 2008).  In future, AAV vectors may be 
designed that are capable of integrating, to give long-term gene expression.  
However, the side-effects of genome integration must be examined thoroughly to 
avoid potentially fatal adverse events such as neoplasia.   
Another advantage of AAV vectors over many others is the great diversity of 
serotypes, and hence cellular tropisms, available to work with.  The tropism of an 
AAV particle is determined largely by the capsid proteins encoded by the cap gene 
complex.  To date, 12 human serotypes have been identified, showing a wide variety 
of tropisms which often overlap.  For example, AAV2 has a predilection for RGCs 
whereas AAV5 has been shown to transduce DRGN (Harvey, Hellstrom et al. 2009; 
Mason, Ehlert et al. 2010).  Not only are researchers restricting themselves to the 
available serotypes, they are also increasingly modifying cap genes to yield vectors 
with even more finely tuned tropisms (White, Mazur et al. 2008).   
 
The third major advantage of AAV vectors over many others is that they are able to 
effect long-term and high level transgene expression (Lo, Qu et al. 1999).  This is 
particularly pertinent to the treatment of CNS injuries, since it is known that 
regenerating neurones require prolonged growth stimulation for them to successfully 
re-innervate distant targets. 
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1.4.2.3 AAV vector disadvantages 
When working with AAV vectors, several limitations must be borne in mind, many of 
which are the subject of intense research.  Firstly, AAV vectors can only accept 
relatively small inserts meaning that very large genes such as dystrophin cannot be 
expressed in a single vector (although AAV vectors are being deployed for muscular 
dystrophy, using a variety of ingenious methodologies (Miyagoe-Suzuki and Takeda 
2010)).  Conveniently, the genes used in this study fall well under the ~4kb maximum 
capacity for an AAV genome.   
 
A second limitation to AAV vectors is that the kinetics of expression from most 
serotypes is slow, resulting from the need to convert the ssDNA AAV genome into 
double-stranded DNA (dsDNA) from which genes can be transcribed (Ferrari, 
Samulski et al. 1996).  With most AAV serotypes in DRGN, it typically takes 2-4 
weeks for expression to reach maximal levels (Mason, Ehlert et al. 2010).  When 
using AAV vectors in acute models of CNS injury, this usually necessitates injecting 
the viral vector before performing the lesion.  Clearly, this is not appropriate for 
therapeutic use in humans, leading to a number of methods of modifying AAV 
vectors to give faster expression kinetics (McCarty, Monahan et al. 2001).   
 
1.4.3 Adenoviruses 
Ads are polyhedral, encapsidated non-enveloped viruses that contain a linear dsDNA 
genome (Verma and Weitzman 2005).  Despite the fact that they are responsible for 
51 
 
a diverse range of human diseases, they have been deployed as successful gene 
therapy vectors for many years.  There are over 50 serotypes of Ad capable of 
infecting humans, with tropisms for most body tissues including the CNS.   
 
Ads can accommodate an insert of around 8kb, around twice that of AAV (Verma and 
Weitzman 2005).  However, their expression kinetics are quite different to AAV: a 
rapid onset of high-level expression, which is seen to decay over the course of a few 
weeks (Xu, Mizuguchi et al. 2005).  Thus, from the point of view of CNS axon 
regeneration, Ad based vectors are likely to be less useful in the context of chronic 
injuries and more useful in the acute setting.  A large component of the transience of 
Ad expression is due to clearance by the immune system.  A number of groups have 
developed ways to circumvent this, such as by coating the particles to evade immune 
recognition (Sims, Ahmed et al. 2009).   
 
1.4.4 Lentivirus 
In contrast to AAV and Ad, lentivirus (LV) is a retrovirus, possessing an RNA genome 
surrounded by core proteins and a lipid envelope (Verma and Weitzman 2005).  LVs 
include Human Immunodeficiency Virus and Simian Immunodeficiency Virus.  After 
reverse transcription of their genomes, LV are able to integrate into the host genome 
giving a long duration of expression.  Despite the fact that LV only exist in a limited 
number of serotypes, they lend themselves well to pseudotyping and have been 
employed successfully in the nervous system, including SCI models (Alto, Havton et 
al. 2009; Cannon, Sew et al. 2011).   
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1.5 Combinatorial therapies 
Possibly with the exception of AG1478, no feasible monotherapy to date has resulted 
in convincing axon regeneration in the CNS (Koprivica, Cho et al. 2005).  When the 
mechanisms of action of successful single interventions are examined in detail, it 
frequently becomes clear that multiple pathways are being manipulated.  AG1478 
was found, by an unknown mechanism, to stimulate the release of multiple NTF from 
retinal cells and to increase the level of cyclic adenosine monophosphate (cAMP) 
within RGC (Douglas, Morrison et al. 2009).  It was already known from experiments 
employing intravitreal peripheral nerve grafts that multiple NTF could elicit axon 
regeneration in the optic nerve by activating the „growth state‟ of RGC in addition to 
causing the release of scar-dissolving enzymes from growth cones (Berry, Carlile et 
al. 1996; Ahmed, Dent et al. 2005; Ahmed, Suggate et al. 2006).  These 
observations, and many others, have led the CNS regeneration community to the 
conclusion that combinatorial therapies are probably the most promising approaches 
to this most difficult of biomedical problems (Lu and Tuszynski 2008).   
 
1.5.1 Multiple NTF 
It has been shown in the injured optic nerve, using two different delivery strategies, 
that NTF act synergistically leading to increased RGC survival and axon regeneration 
(Berry, Gonzalez et al. 2001; Logan, Ahmed et al. 2006).  That multiple NTFs should 
have effects over and above the total of the effects for each individual NTF should 
not come as a surprise, since most growth factors tend to converge on the same 
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second messenger systems.  Thus it is likely that multiple NTF would bring a large 
number of neurones above a „trophic threshold‟ necessary for growth and survival. 
 
1.5.2 NTF plus disinhibitory therapies 
One of the earliest reports of the effect of combining NTF delivery with disinhibition 
came from Schwab‟s laboratory (Schnell, Schneider et al. 1994).  In this study, NT-3 
was delivered as a single injection just rostral to a DC lesion alongside continuous 
intrathecal delivery of the IN-1 antibody.  It was shown that elongation of CST fibres 
beyond the lesion site was significantly enhanced by the combined treatment, 
compared with the effect of delivering each singly.  NT-3 alone resulting in short 
distance sprouting, whereas IN-1 alone resulted in a modest amount of elongation 
compared with the combined treatment.  Schwab‟s group went on to replicate this 
experiment in the same injury model, but in the chronic situation (von Meyenburg, 
Brosamle et al. 1998).  Similar findings have also been demonstrated in the auditory 
system (Tatagiba, Rosahl et al. 2002).   
 
In vitro, strong synergistic effects have also been shown when fibroblast growth 
factor 2 (FGF-2) and the TNFα converting enzyme (TACE) are delivered in the 
presence of CNS myelin to DRGN (Ahmed, Mazibrada et al. 2006).  TACE disinhibits 
neuronal growth by digesting p75NTR, effectively abolishing a major component of the 
AGIL signalling pathway.  Each treatment alone resulted in very little growth 
promotion. 
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1.5.3 NTF containing bridges 
An important challenge in the treatment of SCI, particularly in the chronic stage, is 
the presence of a significant gap between the proximal and distal cord stumps and 
cavities within the remaining peri-lesion tissue (see section 1.1.2.3.2.2).  Such 
spaces impair regeneration since axons are unable to grow in the absence of a 
suitable substrate.  To overcome this problem, a number of cell and bioengineering 
approaches have been taken, often incorporating NTF in an attempt to stimulate 
axon growth into the graft.   
 
A report from Tuszynski‟s group demonstrated the efficacy of BDNF-expressing 
marrow stromal cell (MSC) grafts inserted into acute DC lesion cavities (Lu, Jones et 
al. 2005).  Compared to control GFP-expressing MSC grafts, BDNF expressing grafts 
were invaded by large numbers of DRGN central projections, but only limited 
numbers of CST axons.  Unfortunately, this study showed no convincing behavioural 
improvement in any of the grafted animals.  This is probably due to the fact that, like 
in many other similar grafting experiments, axons penetrate the MSC grafts by never 
leave them.  This effect is probably due to the BDNF-expressing grafts forming a 
„neurotrophin sink‟, keeping axons in the lesion by positive chemotaxis.  The authors 
mentioned that such problems may be overcome by using approaches to deliver a 
gradient of NTF, encouraging regenerating axons to enter CNS tissue adjacent to the 
graft. 
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1.5.4 Manipulation of the neuronal growth state 
Despite the optimism generated by Aguayo‟s peripheral nerve grafting experiments 
(see section 1.1.4), it was still apparent to many that CNS neurones seemed to have 
a poorer intrinsic growth capacity than their peripheral counterparts.  This was 
formally demonstrated in a study from Fawcett‟s group, where the rate of 
regeneration of RGCs was compared with that of DRGN in vitro (Chierzi, Ratto et al. 
2005).  Fewer RGCs regenerated than DRGN, and in those that did RGCs 
regenerated three times more slowly than DRGN.   
 
The growth state of neurones is determined by a complex gene network with multiple 
points of regulation.  Factors which can influence the neuronal growth state in a 
positive way are diverse, including: presence of NTF, neuronal injury, perineuronal 
inflammation, intracellular cAMP and the presence of suitable substrates for growth 
(Tuszynski and Kordower 2008).  These signals are integrated by a number of 
metabolic pathways including mTOR, PI3-kinase and MAPK ultimately impinging on 
neuronal transcription factors such as cAMP response element binding, c-Jun and 
activating transcription factor 3 (Liu, Tedeschi et al. 2011).   
 
DRGN and the conditioning effect 
DRGN possess a peculiar anatomical feature unique to primary sensory neurones – 
they have peripheral and central axonal processes, projecting to peripheral sense 
organs and the cord, respectively (Willis and Coggeshall 2004).  This leads to an 
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inevitable, and seemingly paradoxical situation where the same single neurone 
possesses one axon which is capable of regeneration (peripheral) and one axon 
which is not (central).  This simple observation has, through some ostensibly simple 
experiments, led to a number of important discoveries. 
It has been known for almost 40 years that if a peripheral nerve is transected (the 
„conditioning‟ lesion), and then re-transected some days later between the original 
lesion and the DRG, regeneration of DRGN peripheral processes is enhanced in the 
peripheral nerve (McQuarrie and Grafstein 1973).  Furthermore, if such a 
conditioning lesion is performed prior to a spinal cord lesion containing a peripheral 
nerve implant, regeneration of DRGN central processes is enhanced into the 
peripheral nerve graft (Richardson and Issa 1984).  The culmination of this work 
came when Neumann and Woolf demonstrated that conditioning lesions enhanced 
regeneration of DRGN central processes in the absence of any permissive grafts in 
the spinal cord (Neumann and Woolf 1999).  The conclusion of these experiments, 
taken together, is that the conditioning lesion activates the growth program of DRGN 
allowing their central processes to regenerate.  It has since become clear that 
increased levels of neuronal cAMP and inflammatory responses within the DRG have 
important roles in the conditioning effect, although some anomalies still exist such as 
the lack of a conditioning effect from lesions to the dorsal root (Silver 2009).   
 
1.5.5 Putting it all together – the state of the art of combinatorial therapies 
Unsurprisingly, researchers have attempted extensive combinatorial treatments in 
animal models of SCI.  One of the most interesting examples is from Tuszynski‟s 
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group, where three treatments were combined in animals receiving a high cervical 
(C1) DC lesion: a conditioning lesion was performed, a MSC graft was inserted into 
the lesion site and a LV expressing NT-3 was injected rostral to the lesion (Alto, 
Havton et al. 2009).  Axons regenerated across the MSC graft and into the medulla, 
and electron-microscopic (although not electrophysiological) evidence of synapses 
was observed.  The results of this study are encouraging, but still of limited 
usefulness in the clinical setting since the synapses are not functional and the 
conditioning lesions are unfeasible (and unethical) in human subjects.   
 
There are still many obstacles that need to be crossed before SCI can be effectively 
treated in human subjects.  Axon regenerative therapies have been so unsuccessful 
over the last 100 years that some researchers feel that this may have become a 
sterile field, and that the community as a whole should put the majority of its energy 
into rehabilitative measures.  However, the author hopes that the preceding pages 
and those to come will provide at least some evidence that spinal cord axon 
regeneration is indeed worthwhile pursuing from the points of view of both clinical 
and basic research.   
 
1.6 Rationale, hypothesis and aims 
It is clear from the literature that combinatorial approaches, providing neurotrophic 
support to neurones and targeting AGIL, are likely to provide successful therapies for 
SCI.  This study aims to examine the effect of AAV8-mediated delivery of NT-3 and 
shRNARhoA on axon regeneration in the lesioned DC of adult rats.   
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1.6.1 Main hypothesis 
AAV8hrgfp-nt3-shrna-rhoa and AAV8hrgfp-nt3 transduction of DRGN in vivo mediates neurone 
disinhibited regeneration of DC axons 
 
1.6.2 Main aims 
 To generate and evaluate plasmids that contain NT-3 and shRNARhoA, that will 
ultimately be used to generate the vectors AAV8hrgfp-nt3-shrna-rhoa and AAV8hrgfp-
nt3 
 To examine the cellular tropism of AAV8 in the DRG 
 To assess the glial and inflammatory responses to AAV8-mediated delivery of 
GFP in the DRG and spinal cord 
 To examine the effect of AAV8-mediated delivery of NT-3 and shRNARhoA on 
axon regeneration in the lesioned DC of adult rats 
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Chapter 2 
Materials and methods 
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2.1 In vitro methods 
2.1.1 Preparation of dissociated DRG cultures 
Adult male Sprague-Dawley rats (weight 150-250g) were killed by cervical 
dislocation.  The whole spinal column from cervical to sacral levels was removed and 
kept on ice.  Paraspinal musculature was removed and the spinal cord and DRG 
visualised by cutting through the pedicles with rongeurs and removing the lamina of 
each vertebra.  Lumbar DRG from L2-L5 were removed under direct vision at 20X 
magnification and kept in ice cold Neurobasal A medium (NBA; Gibco, Paisley, UK).  
 
When the dissection was complete DRG were washed in warm NBA, then placed in 
0.125% collagenase (Sigma-Aldrich, Poole, UK) in NBA, snipped in half and 
incubated for 2 hours (h) at 37°C, 5% CO2 in a humidified atmosphere.  DRG were 
then washed in NBA to remove excess collagenase, and resuspended in 2ml of 
warmed NBA.  They were then triturated 15-20 times through a cut-off 500μl pipette 
tip followed by a further 15-20 triturations through an intact pipette tip.  Each 1ml of 
the cell suspension was then carefully layered onto 2ml of warm 15% bovine serum 
albumin (BSA) in NBA and spun at 120g for 10min at room temperature.  The 
supernatant was carefully removed and the resulting pellet resuspended in 100μl 
warmed trypsin inhibitor cocktail, from which 10μl was taken for cell counting.  Cells 
were finally resuspended in an appropriate amount of NBA supplemented with 2% 
B27 supplement, 200mM L-glutamine and 0.2% gentamycin before plating.  Cells 
were plated onto 8-well chamber slides at a density of 500 DRGN per chamber in a 
volume of 300µl.   
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2.1.2 COS-1 cell culture 
COS-1 cells, originally derived from the kidney of the green monkey, were used for 
the expression of recombinant NT3 and NT3-FLAG proteins (Gluzman 1981).  COS-1 
cells were maintained as monolayers in 75cm2 and 175cm2 tissue culture flasks 
(Sarstedt, Leicester, UK) in Dulbecco‟s modified Eagle medium (DMEM, GIBCO) 
supplemented with 10% foetal bovine serum (FBS) and containing 1% 
penicillin/streptomycin.  Cells were split at a ratio of 1:10 using 0.05% trypsin in 
sterile PBS, and never maintained beyond passage number 10 (all reagents above 
from Gibco).   
 
2.1.3 Transfection of cells using Lipofectamine 2000 
2.1.3.1 Principles 
Cationic lipids are established vectors for the introduction of plasmid DNA into 
eukaryotic cells.  Purified plasmid DNA is mixed with Lipofectamine 2000 at a given 
ratio, resulting in the formation of micelles, containing the DNA enclosed between an 
inner core and outer shell of lipid.  These micelles enter cells by endocytosis, and, by 
mechanisms which are not fully understood, their DNA payload enters the cytosol.  
Once in the cytosol, the DNA enters the nucleus by passive diffusion, facilitated in 
dividing cells by the transient breakdown of the nuclear envelope during 
prometaphase.  (Elsabahy, Nazarali et al. 2011) 
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2.1.3.2 Protocol 
COS-1 cells were plated at a density of 500 000 cells/well of 6-well plates in DMEM 
with 10% FBS and 1% penicillin/streptomycin and allowed to settle for 24h.  The 
medium was removed and replaced with 2ml serum and antibiotic free DMEM.  In the 
meantime, for each well, 4μg plasmid DNA and 10μl Lipofectamine 2000 (Invitrogen) 
were diluted in 250μl DMEM at room temperature (rt) and allowed to equilibrate for 
5min.  The diluted Lipofectamine 2000 was added to the diluted plasmid DNA and 
incubated at room temperature (rt) for 20min to allow lipid-DNA complexes to form.  
The complexes were added to cells, and incubated for 5h in a humidified atmosphere 
at 37°C, 5% CO2.  After this, the medium was removed and replaced with 2ml DMEM 
supplemented with FBS and penicillin/streptomycin.  If COS-1 cells were being grown 
on for 6 days (d) to produce recombinant protein, an additional 1ml of medium was 
added after 3d.  
 
2.1.3.3 Production of conditioned medium 
COS-1 cell were transfected with appropriate plasmids and maintained under 
appropriate conditions for 7d.  After 7d, conditioned medium was removed from cells 
and spun at 13000G for 5min.  The resulting supernatant was decanted and stored at 
-18ºC.   
  
2.1.4 Histological techniques 
Immunocytochemistry (ICC) and immunohistochemistry (IHC) are used to detect 
cellular antigens in dissociated cell preparations by exploiting the ability of antibodies 
to bind strongly and specifically to a given protein antigen.  These so-called primary 
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antibodies can be either monoclonal (usually derived from mouse, specific for a 
single epitope from a single protein) or polyclonal (from a number of species, specific 
to multiple epitopes from the same protein).  A secondary antibody, usually with a 
conjugated fluorophore is applied to enable visualisation of the location of the 
antigen-bound primary antibody.  
 
In the present study, every experiment using ICC or IHC included a control where the 
primary antibody was omitted in order to exclude binding of secondary antibodies to 
the tissue or cells.  Unless stated otherwise, no staining was observed in tissue or 
cells exposed to secondary antibody alone.  Other, relevant controls for ICC and IHC 
include looking for a similar staining pattern with a different antibody, Western 
blotting using the antibody of interest (fewer bands on a tissue lysate indicate higher 
antibody specificity) and incubation of the primary antibody with a blocking peptide to 
demonstrate specificity.  These additional controls were not usually carried out in the 
present study, since the Molecular Neuroscience Group has extensive experience of 
using these antibodies in the spinal cord, brain and optic nerve.  Hence, their 
specificity was well established.   
  
2.1.4.1 Protocol for βIII-tubulin immunocytochemistry on DRG cultures 
Mixed DRG cultures grown in 8-well chamber slides for 2d on poly-D-lysine (PDL) 
with and without laminin were removed from the tissue culture incubator and allowed 
to cool at rt for 5min.  Medium was removed and each well fixed in 500μl 4% 
formaldehyde (TAAB Laboratories, Aldermaston, Berkshire, UK) for 15min.  Wells 
were washed 5min x3 with 500μl phosphate buffered saline (PBS) before adding 
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500μl blocking solution to each well for 10min at rt (blocking solution contained 3% 
BSA (Bio-Rad, Hertfordshire, UK) and 0.1% Triton X-100 (Sigma) in PBS).  
Antibodies were diluted in antibody diluting buffer containing 3% BSA and 0.05% 
Tween-20 (Sigma).  The antibodies used are listed in Table 2.1.  To each well 100μl 
primary antibody was added and incubated at rt with gentle shaking for 1h.  Three 
5min washes were then performed with PBS followed by addition of 100μl diluted 
secondary antibody.  This second incubation was done in the dark to avoid bleaching 
of the fluorophore.  After 3 washes in PBS the plastic chambers were removed 
followed by the addition of Vectashield with 4',6-diamidino-2-phenylindole (DAPI, Vector 
laboratories Ltd., Peterborough, UK) and application of a coverslip prior to 
microscopic examination.   
 
2.1.4.1.1 Quantification of neurite outgrowth and neuronal survival from 
dissociated DRG cultures 
After immunocytochemistry, each individual chamber from chamber slides was split 
into 9 equal areas in 3x3 grid.  Within each of these areas, three randomly selected 
fields of view were photographed at x10 magnification thus yielding 27 micrographs 
representing a sample of the DRGN population in that specific chamber.  At least 2 
chambers were used per condition.   
 
The number of DRGN per image were counted, as well as the length of the longest 
neurite per DRGN using ImagePro software (Media Cybernetics Inc., Maryland, 
USA).  Neurites less than a cell body‟s diameter were not measured.   
 
Primary 
antibody 
Source Species 
Concentrati
on for ICC 
Concentrati
on for IHC 
Concentrati
on for WB 
CD68 Serotech Mouse N/A 1:200 N/A 
CD11b Serotech Mouse N/A 1:200 N/A 
GFAP Sigma Mouse N/A 1:500 N/A 
PV Sigma Rabbit N/A 1:8000 N/A 
eGFP AbCam Rabbit 1:4000 1:4000 N/A 
βIII-tubulin Sigma Mouse 1:200 1:1000 N/A 
3X FLAG Sigma Mouse N/A N/A 10µg/ml 
CTB List Goat N/A 1:100 N/A 
      
Secondary 
antibody 
 
 
   
AlexaFluor 
488 anti-
mouse IgG 
Molecular 
Probes 
Goat 1:200 1:500 N/A 
AlexaFluor 
594 anti-
mouse IgG 
Molecular 
Probes 
Goat 1:200 1:500 N/A 
AlexaFluor 
488 anti-
rabbit IgG 
Molecular 
Probes 
Goat 1:200 1:500 N/A 
AlexaFluor 
594 anti-
rabbit IgG 
Molecular 
Probes 
Goat 1:200 1:500 N/A 
Anti mouse 
IgG HRP 
GE 
Healthcare 
Sheep N/A N/A 1:1000 
Anti rabbit 
IgG HRP 
GE 
Healthcare 
Donkey N/A N/A 1:1000 
AlexaFluor 
594 anti goat 
Molecular 
Probes 
Donkey N/A 1:400 N/A 
 
Table 2.1.  Antibodies used in this study.  Abbreviations: ICC Immunocytochemistry; IHC 
Immunohistochemistry; WB western blotting; HRP Horseradish peroxidise; N/A not 
applicable 
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2.1.4.2 Protocol for immunohistochemistry 
In order to perform IHC, four major steps must be performed.  First, tissue must be 
dissected, fixed and embedded; secondly the embedded tissue must be cut into 
sections; thirdly, the sections must be stained using appropriate primary and 
secondary antibodies; finally, stained tissue must be visualised and quantified, if 
appropriate.   
 
2.1.4.2.1 Preparation of tissue 
Animals were sacrificed by CO2 narcosis and transcardially perfused with 4% 
formaldehyde (TAAB laboratories, Aldermaston, Berkshire, UK) in PBS.  L4/L5 DRG, 
dorsal and ventral roots, spinal cords (separated into segments containing L4/L5 
DREZ, rostral lumbar segments of the cord, thoracic cord, cervical cord and lesion 
sites with 5mm rostral and caudal to the lesion) and medullas were removed and 
post-fixed in 4% formaldehyde in PBS overnight at 4ºC.  Tissue specimens were 
cryo-preserved by equilibration in sucrose at 10, 20 and 30% w/v concentration, 
embedded in optimal cutting temperature (OCT) mounting medium, and stored at -
80ºC. 
 
2.1.4.2.2. Tissue sectioning 
Frozen tissue sections were cut at a thickness of 15µm or 25µm (lesion sites) using a 
Bright cryostat.  DRG sections were cut in a longitudinal orientation, parallel to the 
axis of entry of roots and exit of spinal nerves of the ganglion.  Dorsal and ventral 
roots were cut in the transverse plane, the spinal cord cut in both coronal and 
horizontal planes and medullas cut in the coronal plane at the level of the gracile 
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nucleus.  Lesion sites were cut in the sagittal plane, and sections approximately 
200µm to the left of the midline were examined using IHC.   
 
2.1.4.2.3 Immunostaining 
Thawed sections were washed X2 for 5min in PBS, X1 for 5min in PBS+0.1% triton 
X-100  or PBS+1% triton X-100 (PBST) and then incubated in a humidified chamber 
for 1h at room temperature (rt) in either 3% bovine serum albumin (BSA; Sigma, 
Poole, UK), or 2% BSA+10% normal donkey serum (NDS) in PBST, incubated 
overnight at 4ºC with either primary antibody (Table 2.1) diluted in 3% BSA, or 2% 
BSA in PBST, washed X3 for 5min in PBST and then incubated with secondary 
antibody (Table 2.1) diluted in 3% BSA in PBST for 1h at rt, washed X3 for 5min in 
PBST, and mounted in Vectashield mounting medium with DAPI (Vector laboratories 
Ltd., Peterborough, UK).   
 
2.1.4.2.4 Visualisation and quantification 
Sections were photographed throughout using a Zeiss Axioplan 2 microscope 
connected to a PC running AxioVision 4.6 software (Carl Zeiss Ltd., Hertfordshire, 
UK).   
 
2.1.4.2.4.1 Analysis of enhanced green fluorescent protein (GFP) expression in 
DRG allowing assessment of transduction rate 
For analysis of AAV8gfp tropism in the DRG, approximately 35 fields of view per DRG 
section were captured using the x10 objective and merged to create a single 
composite image using the Photomerge feature in Adobe Photoshop CS3 (Adobe 
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Systems Incorporated).  For analysis of GFP expression, DAPI and FITC channels 
were converted to greyscale and examined using ImagePro image analysis software 
(Media Cybernetics Inc., Maryland, USA).  DRGN were identified in the DAPI channel 
as large, round cell bodies visible as empty areas with large, round pale DAPI+ 
nuclei, encircled by satellite cells with small elongated DAPI+ nuclei.  DRGN were 
identified during 4 passes of each composite image at 25% and 100% digital zoom 
levels.  The diameters and positions of each GFP+ DRGN were recorded and saved 
as a mask which was then applied to the FITC channel to compute frequencies and 
diameters.  Assessment of the total number of DRGN in each section allowed 
estimation of the percentage transduction of DRGN by AAV8 (the transduction rate).  
The same procedure was used to analyse parvalbumin+ DRGN using the rhodamine 
and DAPI channels. 
 
2.1.4.2.4.2 Analysis of coronal sections of spinal cord 
Coronal sections of the spinal cord were examined by producing composite images 
in Photomerge using fields of view taken through a X10 objective lens.  Grey matter 
was demarcated using tissue auto-fluorescence and images were contrast adjusted 
to demonstrate GFP+ axons. 
 
2.1.4.2.4.3 Analysis of glial activation 
Coronal sections of rostral lumbar cord from intact, intra-DRG PBS injected and intra-
DRG AAV8gfp injected animals were stained for either GFAP, or CD11b as described 
above and photographed under identical conditions.  For each animal, two 
micrographs (ipsilateral and contralateral) were taken from one of three regions 
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within the rostral lumbar cord – the dorsal column, the superficial dorsal horn and the 
deep dorsal horn.  Using Adobe Photoshop CS3, the threshold level at which CD11b 
and GFAP staining disappeared was determined in three intact animals for the 
regions specified and a mean value determined.  This value was then used to 
threshold micrographs from experimental animals, so that any staining observed 
could be attributed to up-regulation of CD11b or GFAP.  The number of pixels in 
these images after thresholding was counted, giving a measure of glial activation. 
 
2.1.4.3 Oil-Red-O staining  
Oil-Red-O staining was used to visualise myelin breakdown products.  Signal is 
obtained when myelin degenerates, leading to the deposition of red staining lipid 
droplets.  Horizontal sections of spinal cord were thawed, rinsed in 60% isopropanol, 
stained in freshly prepared Oil-Red-O for 15min at rt, rinsed in 60% isopropanol, 
counterstained with haematoxylin for 10sec, rinsed in distilled water and mounted in 
Vectamount (Vector Laboratories). 
 
2.1.5 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
and western blotting 
 
2.1.5.1 Principles of protein electrophoresis and western blotting 
It is possible to separate proteins based upon their molecular mass by denaturing 
them, giving them a known negative charge and then passing them through a 
polyacrylamide gel of known density.  The gel itself can be stained for total protein 
using a reagent such as Coomassie blue, and the size of protein bands determined 
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by comparison with standards of known molecular weight.  Alternatively, if one 
wishes to probe for a specific protein, the contents of the gel can be transferred to a 
nitrocellulose membrane which can then be incubated with an antibody of choice and 
visualised using a secondary antibody linked to an appropriate reporter. 
   
2.1.5.2 Protocol for protein electrophoresis and Western blotting 
2.1.5.2.1 Gel casting and running SDS-PAGE 
All apparatus for gel casting, running and transfer were from Invitrogen (Paisley, UK) 
and all reagents were from Sigma (Poole, UK), unless otherwise stated. 
 
Gels composed of 12% polyacrylamide were cast in 1mm disposable cassettes.  
Each resolving gel was composed of 2.75ml Protogel (Geneflow, Fradley, UK), 
1.65ml 1.5M Tris-HCl pH 8.8, 2.2ml water, 66μl 10% SDS, 23.1μl 10% ammonium 
persulphate (APS) and 9.9μl Tetramethylethylenediamine (TEMED, VWR 
International, Lutterworth, UK).  Layering of 70% ethanol onto the resolving gel 
excluded air during polymerisation.  Each stacking gel was composed of 0.4ml 
Protogel (Geneflow), 1.85ml 0.5M Tris-HCL pH 6.8, 0.75ml water, 30μl 10% SDS, 
15μl 10% APS, 7.5μl TEMED (VWR International).  A 1mm comb was inserted and 
the gel allowed to polymerise at rt.   
 
Samples were prepared by first adjusting the protein concentration by dilution in 
MilliQ water if appropriate, followed by addition of an equal volume of 2X sample 
loading buffer, containing 2-mercaptoethanol (Sigma).  The diluted samples were 
boiled for 4min at 90°C, and 20μl was added to each well.  A volume of 10μl of pre-
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stained protein ladder (Invitrogen) was added to assigned wells.  Gels were run at 
125V, 18mA, 2.1W for 1h 50min under buffer containing 25mM Tris-base, 192mM 
glycine and 0.1% SDS.   
 
2.1.5.2.2 Western blotting 
When the samples had run an appropriate distance, the gel was released from its 
cassette and transferred onto a Polyvinylidene difluoride (PVDF) membrane, which 
had been activated by soaking in 100% methanol for 1min followed by a 1min wash 
in water.  Gel and membrane were kept in close opposition using foam pads, the 
transfer process being carried out at 25V for 2h in a chilled buffer containing 25mM 
Tris-base, 192mM glycine, 20% methanol and 0.02% SDS.   
 
All subsequent washes were carried out in TTBS (10mM Tris-base, 150mM NaCl, 
0.05% Tween-20) and all blocking/antibody steps carried out in either 5% Marvel, or 
3% BSA in TTBS, depending on the antibody used. 
 
After transfer, the membranes were soaked in TTBS for 5min then incubated in 
blocking solution for 1h at rt.  The blocking solution was removed and primary 
antibody added at an appropriate concentration followed by incubation at 4°C 
overnight.  The membranes were washed x3 for 10min each before the addition of 
appropriate secondary antibody and incubation at rt for 1h.  Membranes were 
washed as described above, dried gently on blotting paper and incubated for 1min at 
rt in 2ml enhanced chemiluminescence (ECL) solution.  Excess ECL was blotted off, 
the membranes placed in bags and exposed onto Kodak Biomax film (Kodak).   
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2.1.6 Enzyme linked immunosorbent assay (ELISA) 
2.1.6.1 Principles 
ELISA is a highly sensitive, quantitative assay for determining the concentration of a 
specific protein.  There are many variations, but all involve the adsorption of an 
antibody or antigen to a sample plate followed by the addition of further antibodies.  
The final antibody is usually an horseradish peroxidase (HRP) conjugate allowing a 
colorimetric assay to be used for quantification.  The ELISA used in the experiments 
described here to detect NT-3 was the NT-3 Emax Immunoassay System (Promega, 
Madison, WI, USA).  The NT-3 Emax kit exploits the technique known as „sandwich 
ELISA‟ in which a sample plate is coated with a polyclonal antibody against NT-3.  
After coating, samples were placed in appropriate wells and following a washing step 
a monoclonal antibody against NT-3 from mouse was added.   Antibody-bound NT-3 
was quantified by the addition of an HRP-conjugated secondary antibody which 
oxidised 3,3´,5,5´-tetramethylbenzidine (TMB) to a coloured product, which was 
measured colorimetrically using absorbance at 450nm.  To get accurate estimations 
of concentration in each unknown sample, multiple dilutions were performed as well 
as a standard curve where absorbances of known concentrations of recombinant NT-
3 were measured.   
 
2.1.6.2 Protocol 
All reagents were from Promega unless otherwise stated.  All antibodies, standards 
and Block and Sample Buffer were provided in the NT-3 Emax Immunoassay System 
72 
 
(Promega, Madison, WI, USA).  Quantities used were for a single Nunc Maxisorp 96-
well plate (Thermo Fisher, Waltham, MA, USA).   
 
Anti-human NT-3 polyclonal antibody (pAb) was diluted to a concentration of 1µg/ml 
in carbonate coating buffer (0.025M sodium bicarbonate, 0.025M sodium carbonate 
adjusted to pH 9.7) and 100μl added to each well.  The plate was sealed with 
Parafilm M (Pechiney Plastic Packaging Company, Chicago, IL, USA) and incubated 
at 4°C overnight.  The contents of each well were then flicked out and the plate 
washed once by filling all wells with TBST wash buffer (20mM Tris-HCL, 150mM 
NaCl, 0.05% Tween-20, pH 7.6).   
 
The plate was blocked by adding 200μl 1X Block and Sample Buffer (exact 
composition proprietary), followed by incubation at rt for 1h.  After blocking, the plate 
was washed once with TBST and samples and standards were added at appropriate 
dilutions in duplicate in a volume of 100μl per well.  Typically, the initial dilution of 
each sample was 1:4 with serial 1:2 dilutions.  The concentrations of the NT-3 
standard ranged from 300pg/ml to 4.7pg/ml by serial 1:2 dilutions, with an additional 
set of wells containing no standard.   
 
The plate containing samples was incubated at rt for 6h with shaking at 500rpm.  
After this, the wells were washed x5 with TBST and 100μl anti-NT3 monoclonal 
antibody (mAb) at a dilution of 1:4000 was added to each well before incubating at 
4°C overnight.  Wells were washed x5 with TBST and 100μl anti-mouse IgG HRP 
conjugate added to each well at a dilution of 1:100.  The plate was incubated at rt 
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with shaking at 500rpm for 2.5h followed by 5 washes with TBST.  Each well 
received 100μl TMB One solution (containing TMB, exact composition proprietary 
information) followed by incubation with shaking at rt for 15min.  After this, the 
reaction was stopped by adding 100μl 1N HCl to each well.  The absorbance of the 
plate was read at 450nm within 30min of addition of HCl on a Victor3 Multilabel 
counter (Perkin-Elmer, Waltham, Massachusetts, USA).   
 
Each plate was analysed by deriving a linear regression line from the standard curve, 
re-arranging the equation for this line to give concentration of NT-3 in terms of 
absorbance and applying this to the unknown values (Figure 2.1).  Only sample 
absorbances which lay within the range seen on the standard curve were used to 
ensure that accurate estimates were obtained.  Initial and serial dilutions were 
accounted for, and the value derived was taken as the mean of the most appropriate 
duplicate for each sample.   
 
2.1.7 Molecular cloning 
2.1.7.1 Principles of molecular cloning 
The term „cloning‟ refers to a set of techniques used to precisely manipulate nucleic 
acid molecules.  Such manipulations include transferring a sequence of DNA from 
one vector to another (the vector usually being a plasmid), introducing mutations at 
specific points in a DNA sequence and producing „libraries‟ of genes from a specific 
tissue.   
 
NT3 Concentration pg/ml
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Figure 2.1 A typical standard curve for NT-3 ELISA using the Emax kit.  The 
line of best fit was generated by Sigmaplot v.10 software, which also 
generated a linear equation allowing estimation of unknown concentrations.   
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Fragments of DNA can be cut at specific sites („digested‟) with restriction 
endonucleases, often termed „restriction enzymes‟.  These enzymes have allowed 
not only the accurate and reproducible digestion of DNA molecules, but have also 
allowed DNA sequences to be mapped, given a knowledge of the actual and 
predicted sites of cleavage by a chosen enzyme or enzymes.   
 
After cleavage of DNA by restriction enzymes, fragments can be separated using 
agarose gel electrophoresis and visualised with ethidium bromide (EtBr).  Such 
separation enables DNA fragments to be isolated, allowing further manipulations to 
be performed. 
 
Cleaved pieces of DNA can be re-attached using DNA ligases that can join 
overlapping („sticky‟) ends or non-overlapping („blunt‟) ends of DNA fragments.  This 
is commonly performed when inserting a fragment into a recipient plasmid during the 
process of sub-cloning.   
 
Another commonly performed procedure is the polymerase chain reaction (PCR).  
This technique uses short oligonucleotide primers to amplify a segment of DNA 
defined by the position of the forward and reverse primers.  In addition, PCR can be 
used to introduce mutations into DNA sequences using a variety of techniques.  All of 
these methods of site directed mutagenesis use primers which contain a mutation.  
Since it is part of the primer, the mutation will be included in all of the amplified 
segments.  The mutated segment can then be sub-cloned into an appropriate vector.   
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2.1.7.2 Protocol for restriction digestion of DNA 
In a typical restriction digest, 1µg of plasmid DNA was digested using 10 units of 
restriction enzyme in the presence of the appropriate buffer, with or without BSA at 
37ºC for 2h.  All enzymes used in cloning are listed in Table 2.2.  The products of 
each reaction were usually run on a 0.7% agarose gel.   
 
2.1.7.3 Protocol for dephosphorylation of restriction digest products 
If a plasmid was to become the recipient for a sub-cloning procedure, following its 
digestion, it was dephosphorylated to ensure that its own sticky ends did not ligate 
together.  The resulting self-ligation results in a high level of vector background, as 
well as decreasing the efficiency of any sub-cloning procedure.  Dephosphorylation 
was achieved by adding 5 units of antarctic phosphatase per microgram of DNA, 
along with an appropriate amount of antarctic buffer (both supplied by New England 
Biolabs, Ipswich, MA, USA) and incubating at 37ºC for 30min.  The resulting 
dephosphorylated fragments were then run on an agarose gel, purified and stored for 
future use.   
 
2.1.7.4 Protocol for agarose gel electrophoresis 
Agarose (0.7%) was dissolved by heating in TAE-EtBr (2M Tris-acetate, 100mM 
Na2EDTA (Geneflow), 1µg/ml ethidium bromide (Promega)) before pouring into a gel 
casting unit, and inserting a comb.  Samples were diluted in 6X gel loading buffer, 
and up to 20µl of sample loaded into each well alongside an appropriate DNA ladder.  
The gels were run at a current of 50mA for 60-90min, or until the bands were seen to 
Enzyme Supplier Sequence cut Buffer BSA 
BamHI NEB 
5’-GGATCC-3’ 
3’-CCTAGG-5’ 
3 100µg/ml 
NotI NEB 
5’-GCGGCCGC-
3’ 
3’-CGCCGGCG-
5’ 
3 100µg/ml 
ScaI NEB 
5’-AGTACT-3’ 
3’-TCATGA-5’ 
3 Not required 
SnaBI NEB 
5’-TACGTA-3’ 
3’-ATGCAT-5’ 
4 100µg/ml 
XhoI NEB 
5’-CTCGAG-3’ 
3’-GAGCTC-5 
4 100µg/ml 
T4 DNA 
ligase 
Promega N/A 
Ligase 
buffer 
Not required 
Taq 
polymerase 
Roche N/A 
PCR 
buffer 2 
N/A 
 
Table 2.2 Enzymes used in molecular cloning.  Buffer 3: 100 mM NaCl, 50 mM Tris-HCl, 
10 mM MgCl2, 1 mM Dithiothreitol, pH 7.9 @ 25°C.  Buffer 4: 50 mM potassium acetate, 
20 mM Tris-acetate, 10 mM Magnesium Acetate, 1 mM Dithiothreitol, pH 7.9 @ 25°C.  
Ligase buffer: 300mM Tris-HCl (pH 7.8 at 25°C), 100mM MgCl2, 100mM DTT and 10mM 
ATP.  Composition of PCR buffer 2 not available.   
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have migrated a sufficient distance.  Progress of each run was monitored using the 
Multigenius gel documentation system (Syngene, Cambridge, UK).   
 
2.1.7.5 Protocol for ligation of DNA fragments 
Purified fragments of interest, resulting from restriction enzyme digests of 1µg of 
plasmid (the insert) were inserted into dephosphorylated plasmid backbones (the 
vector) by incubating in the presence of T4 DNA ligase (Promega, Madison, WI, 
USA).  Insert was usually incubated with vector in the presence of ligase buffer at the 
ratios of 0:1, 1:1 and 3:1 at rt for 30 min or overnight at 4ºC.  After this, 5µl of the 
ligation mix was gently mixed with 50µl of XL10 competent cells (Agilent 
Technologies, Santa Clara, CA, USA).  The cells were incubated on ice for 30 min 
followed by a heat shock at 42ºC for 45s then placed on ice for 2 min.  After this, cells 
were spread on lysogeny broth (LB) agar plates with ampicillin and incubated at 37ºC 
overnight.  Colonies were picked and used for preparation of plasmid DNA the 
following morning.   
 
If the ligation efficiency was low, cells were subjected to a „rescue step‟, where they 
were cultured for 1h in 5ml antibiotic-free LB broth before being spread on LB agar 
plates. 
 
2.1.7.6 Polymerase chain reaction 
Primers were designed by Dr Michael Douglas, and synthesised by Alta Biosciences 
(Birmingham, UK), see Table 2.3.  Primers were diluted in 0.22 µm filtered MilliQ 
Primer name Sequence (5’-3’) 
SnaBIfor CAT-CTA-CGT-ATT-AGT-CAT-CGC-TAT-TAC-CAT-G 
NotIOL2 GCC-CGG-GCT-AGA-GCG-CGC-GCC-ACC-GCG-GTG-GA 
NotIOL1 TCC-ACC-GCG-GTG-GCG-CGC-GCT-CTA-GCC-CGG-GC 
LONGpAAVrev TGC-CAA-AAG-ACG-GCA-ATA-TGG-TGG 
 
Table 2.3 Primers used in PCR reactions 
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water to a working stock concentration of 20 pmol/µl.  Reactions were performed in a 
volume of 50µl in a Bio-Rad i-Cycler PCR machine (Bio-Rad).   
 
2.1.7.6.1 PCR on plasmid DNA 
PCR reactions were performed using the Expand High Fidelity PCR System (Roche 
Diagnostics, West Sussex, UK).  Plasmid DNA (20-30ng) was mixed with 40 pmol 
forward primer and 40 pmol reverse primer in the presence of 80µM 
deoxyribonucleotide triphosphates (dNTP) and 1X PCR buffer 2 at a total volume of 
50µl.  The reactions were performed using a melting temperature of 96ºC, an 
annealing temperature of 50ºC and an extension temperature of 72ºC.  Extension 
was allowed to proceed for 1 – 1.5 min and the cycle repeated 14-18 times.  When 
complete, the PCR mix was run on a gel and the appropriate band selected and 
purified (see section 2.1.7.8). 
 
2.1.7.6.2 Overlap extension PCR 
Overlap extension PCR (OEPCR) uses three PCR reactions to introduce a point 
mutation into a defined region of a DNA sequence.  The first two reactions (PCR1 
and PCR2) use primers spanning the region to be mutated and overlapping primers 
containing a single point mutation at their centres.  Thus, PCR1 and PCR2 will yield 
amplicons containing overlapping, mutated regions at one of their ends which will be 
complementary to one another.  The full-length mutated sequence is created in 
PCR3 when the products of PCR1 and PCR2 are mixed in the presence of the 
terminal primers.  The PCR reactions described below used reagents and apparatus 
described in section 2.1.7.6.  
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PCR1 
The reaction mixture contained 28ng plasmid DNA, 2µl SnaB1for, 2µl NotIOL2, 2µl 
2mM dNTP, 5µl PCR buffer 2, 1µl Taq polymerase and 37µl water.  The reaction 
mixture was melted at 96ºC, annealed at 50ºC, extended at 72ºC for 1 min for 14 
cycles.   
 
PCR2 
The reaction mixture contained 28ng plasmid DNA, 2µl NotIOL1, 2µl LONGpAAVrev, 
2µl 2mM dNTP, 5µl PCR buffer 2, 1µl Taq polymerase and 37µl water.  The reaction 
mixture was melted at 96ºC, annealed at 50ºC, extended at 72ºC for 1 min for 14 
cycles.   
 
The products of PCR1 and PCR2 were run on a 0.7% agarose gel.  The bands were 
identified under UV light and purified as in section 2.1.7.8. 
 
 
PCR3 
The reaction mixture contained 1µl purified PCR1 product, 1µl purified PCR2 product, 
2µl SnaBIfor, 2µl LONGpAAVrev, 5µl PCR buffer 2, 1µl Taq polymerase and 37µl 
water.   
 
The products of PCR3 were run on a 0.7% agarose gel.  The bands were identified 
under UV light and purified as in section 2.1.7.8. 
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2.1.7.7 Preparation of purified plasmid DNA from E.coli 
Plasmid DNA was prepared at three different scales, depending upon its intended 
use.  Standard kits of three sizes were used – QIAprep Spin Miniprep Kit and 
QIAfilter Midi and Maxi kits (QIAGEN, Crawley, West Sussex, UK).  Minipreps were 
used to produce small amounts of plasmid DNA for analysis; midipreps were used for 
moderate amounts of plasmid DNA for testing and maxipreps were used to produce 
large amounts of DNA for routine use.  The specific protocols for each of these are 
publicly available from www.qiagen.com so a general overview of the protocol will be 
provided followed by the detailed protocol for the QIAfilter Maxi kit.  
 
Preparation of plasmid DNA can be split into five main stages.  Firstly, transformed 
E.coli must be cultured in selective medium (usually LB Broth + ampicillin) to provide 
a sufficient amount of plasmid DNA.  Following a successful ligation, a colony was 
aspirated using a P200 pipette tip and used to inoculate an appropriate volume of 
broth.  The broth was then incubated in a rotary shaker at 37ºC overnight.   
 
The next stage involved pelleting the cells by centrifugation and then resuspending 
them in an appropriate buffer.  Resuspension must be complete as any lumps will not 
lyse efficiently.  Lysis buffer was added and the mix was agitated gently.  Lysis buffer 
contains SDS which breaks down cell walls and membranes allowing cell contents, 
including plasmid DNA to escape.  After lysis, a third buffer was added which 
precipitates out bacterial cell walls and genomic DNA, leaving a solution containing 
plasmid DNA.   
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The precipitate was filtered out or pelleted and the resulting supernatant was passed 
through an equilibrated ion-exchange column which binds plasmid DNA.  After 
washing, the plasmid was eluted off of the column and then precipitated out in 
isopropanol.  The precipitated DNA was pelleted and then gently washed in 70% 
ethanol.  Finally, the DNA pellet was air dried and resuspended in an appropriate 
buffer.   
 
2.1.7.7.1 Protocol for preparation of plasmid DNA using a QIAfilter Maxi kit 
Five hundred millilitres of an overnight LB culture were centrifuged at ~6000g for 15 
min at 4ºC.  The resulting pellet was homogenously resuspended in 10ml buffer P1 
(containing  50 mM Tris·Cl, pH 8.0, 10mM EDTA and 100µg/ml RNAse A) and placed 
in a 50ml Falcon tube.  Buffer P2 (200mM NaOH, 1% SDS, 10ml) was added and the 
solution mixed by inversion until homogenous then incubated at rt.  After 5 min, 10ml 
chilled buffer P3 (3M potassium acetate, pH 5.5) was added and the solution 
thoroughly mixed.  The resulting solution, containing a white precipitate, was poured 
into the barrel of a QIAfilter cartridge and allowed to stand upright for 10 min.  During 
this incubation, a QIAGEN tip 500 was equilibrated by passing 10ml buffer QBT (750 
mM NaCl; 50 mM MOPS, pH 7.0; 15% isopropanol (v/v); 0.15% Triton® X-100 (v/v) 
through it.  After equilibration of the QIAGEN tip, the cap was removed from the 
QIAfilter cartridge and the plunger inserted.  The filtrate was applied directly to the 
equilibrated QIAGEN tip and allowed to pass through by gravity flow.  Once all filtrate 
had passed though the QIAGEN tip, it was washed by passing 2x30ml buffer QC 
(1.0M NaCl, 50mM MOPS, pH 7.0, 15% isopropanol)  through it.  It was ensured that 
waste was not able to touch the end of the QIAGEN tip.  Plasmid DNA was eluted 
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from the washed QIAGEN tip by applying 15ml buffer QF (1.25M NaCl, 50mM Tris-
Cl, pH 8.5, 15% isopropanol) and collecting the eluate in a sterile tube.  DNA within 
the eluate was precipitated by the addition of 10.5ml isopropanol at rt followed by 
gentle mixing.  The precipitated DNA was pelleted by centrifugation at ~11000g for 
30 min at 4ºC.  The supernatant was discarded and the resulting pellet washed in 
~1ml 70% ethanol, then transferred to a 1.5ml Eppendorf tube.  The washed pellet 
was spun again at ~15000g for 10 min.  The supernatant was removed and the pellet 
air-dried for ~10 min, then resuspended in an appropriate volume of buffer (usually 
500µl buffer EB (10mM Tris-Cl, pH 8.5)).   
 
2.1.7.8 Extraction of DNA from agarose gels 
Gel extraction was performed using the QIAEXII gel extraction kit (QIAGEN), which 
contained all necessary reagents.  The basic principle of this process was to melt the 
gel in a suitable buffer, hence releasing and solubilising a DNA fragment.  DNA-
binding beads were added to the mixture which were then washed and finally the 
DNA was eluted from them into a suitable buffer.   
 
DNA bands were visualised within agarose gels under ultraviolet light and cut out as 
accurately as possible using a clean razor blade.  The isolated band, containing a 
fragment of DNA of a given weight was then placed in a sterile 1.5ml Eppendorf tube.  
The gel sample was resuspended in 750µl buffer QXI in the presence of 10µl 
QIAEXII bead suspension.  The mix was heated at 50ºC and vortexed for 5 min until 
the gel was dissolved.  Then, 5 cycles of heating at 50ºC for 2 min followed by 
vortexing briefly were carried out.  After this, the solution was centrifuged at ~5000g 
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for ~30 s.  The resulting supernatant was poured off and the beads resuspended in 
750µl buffer QXI (exact composition unknown).  This was repeated twice but on the 
second time the beads were resuspended in 500µl buffer PE (exact composition 
unknown), which was repeated once.  All buffer PE was removed and the beads 
allowed to air dry with the tube lid open for 5 min.  Once dry, the beads were 
resuspended in 20-30µl buffer EB and heated at 50ºC for 5 min.  The solution was 
centrifuged at ~5000g for ~30 s and the supernatant, containing a purified DNA 
fragment, carefully decanted. 
 
2.2 In vivo methods 
Groups of 3-6 adult male Sprague-Dawley rats (Charles River; 200-220g) were 
operated upon under license by Professor Martin Berry according to the UK Animal 
Act 1986 guidelines.  Anaesthesia was induced with 4% isoflurane and maintained at 
2% throughout the procedure.  Buprenorphine, at a dose of 0.03mg/kg was used for 
analgesia, given at the start of the procedure and twice daily for a further 2d following 
surgery as required.  After the procedure, animals were allowed to recover on a 
heated table.  Aseptic conditions were used throughout. 
 
2.2.1 Intra-DRG injection 
Injections were performed using a modification of a method previously described (Xu, 
Gu et al. 2003).  Rats were placed on a heat pad in a custom-made stereotactic 
apparatus allowing the whole animal to be moved through all degrees of freedom, 
ensuring that the spine was kept rigid at all times.  A 2cm incision was made in the 
midline over the lumbar region and held open with a retractor.  The ligamentous 
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insertions of erector spinae were visualised and a small mark made on the 
contralateral side at the level of L4.  A 2cm paramedian incision was made, with L4 
as its midpoint, around 1mm to the left of the spinous processes down to the 
articulating surfaces of the facet joints.  Ligamentous attachments to the articular 
surfaces were severed, followed by further blunt dissection to reveal the lateral 
vertebral processes which were removed to reveal the underlying ventral L4/L5 rami, 
which were dissected proximally to expose the L4/L5 DRG in the intervertebral 
foramina.  Haemorrhage was stopped using Spongostan gel foam (Ferrosan, 
Soeborg, Denmark).   
 
A solution of 1010 AAV2/8eGFP viral genomes (vg) in a volume 10μl, diluted in sterile 
PBS was injected into each DRG using a pulled borosilicate glass micropipette 
(Harvard apparatus, external diameter 1.5mm, internal diameter 0.86mm) attached to 
a 20ml syringe containing air.  Injection was deemed successful if the DRG was 
observed to swell.  The muscle was closed using catgut and the skin closed with 
staples.  Animals were observed closely post-operatively until they recovered from 
anaesthetic, and then checked daily for any signs of autotomy.   
 
2.2.2 Intrathecal injections 
Perioperative care was identical to the above  Injections were performed using a 
modification of a procedure described by De la Calle et al. (De la Calle and Paíno 
2002) .  Rats were placed in the prone position, and a 2cm incision made between 
the L5 and S1 vertebrae.  The L6/S1 interspinous ligament was incised, allowing the 
L6 spinous process to be removed and reflected rostrally, allowing direct visualization 
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of the ligamenta flava.  A blunt 25G needle was inserted between the ligamenta flava 
into the lumbar cistern at an angle of 60º to the horizontal.  Access to the intrathecal 
space was confirmed by CSF in the needle cup, and the presence of a tail flick.  CSF 
could also be expressed by gentle tail traction.  The injectate (vehicle or 1012 vg in 
30µl PBS) was pipetted into the needle cup, and injected gently with air from a 5ml 
syringe.  See Figure 2.2 for intra-operative images. 
 
Alternatively, injections were performed using pulled glass micropipettes.  The 
surgical exposure was identical to that described above.  A pulled glass micropipette 
was filled with 10µl PBS or 109 or 1012 vg AAV8gfp in 10µl PBS.  The tip of the 
micropipette was inserted through the ligamentum flavum and into the subarachnoid 
space.  Successful access to the subarachnoid space was confirmed by entry of CSF 
into the micropipette by capillary action.  Injection was performed by connecting a 
20ml syringe filled with air and gently injecting until all of the injectate was introduced 
into the subarachnoid space.  The micropipette was left in situ for 10s and then 
withdrawn.  Closure and post-operative care were identical to that described 
previously.   
 
2.2.3 Dorsal column crush 
In light of the results discussed in Chapter 4, it was decided to perform a DC crush at 
the L1 cord level in order to maximise the number of transected axons belonging to 
AAV2/8 transduced DRGN, since most AAV2/8 transduced DRGN project to Clarke‟s 
column which extends to approximately the T13 cord level (Figure 2.3). 
 
B D C 
* 
* 
† 
L5 
L6 S1 
S2 
IC 
A 
Figure 2.2 Intra-operative images of intrathecal injection into an adult rat using a 25G needle.  A.  Bony anatomy of 
the region of interest in the rat, labels indicating vertebrae.  Spinal cord ends at approximately the L1 vertebral level  
B.  A 2cm incision in the skin has been performed followed by deeper incisions in the parasagittal plane just lateral 
to the spinous processes.  The asterisk marks the L5 spinous process.  C.  Forceps pointing to the exposed 
ligamentum flavum.  Arrowhead indicates L6 spinous process.  D.  25G needle inserted through ligamentum flavum.  
Blood-stained CSF (†)is visible in the needle cup.   
T1 
L1 
S1 
T1 
L1 
T8 
L6 
Vert Cord 
Sciatic nerve projections to Clarke’s column 
Cord segments / DRG of sciatic nerve 
Sciatic nerve with associated spinal nerves 
DC lesion day 28 
L4/L5 DRG injection day 0 
CTB injection day 54 
Figure 2.3 Lesioning paradigm 
and anatomical rationale 
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In the adult rat, the L1 cord level is found at approximately the T12 vertebral level.  
The T13 vertebra was identified by palpating the 13th rib and hence the T13 spinous 
process.  T12 could then be easily located allowing an approximately 1.5cm mid-line 
skin incision to be made over the T11, T12 and T13 spinous processes.  Two 
parasagittal incisions just lateral to the T11-T13 spinous processes and extending 
down to the laminae were made in the erector spinae muscles, which were then 
retracted laterally.  As much muscle as possible was removed from the T12 lamina 
before it was removed using fine rongeurs.  Removal of the lamina revealed the 
spinal cord overlain by the arachnoid and dura mater.  A 25G needle was inserted 
through the meninges at the location of each L1 dorsal root entry zone.  The tips of a 
pair of fine watchmakers forceps which had been calibrated appropriately, were 
inserted through the meningeal puncture holes into the cord to a depth of 1.5mm.  
The blades were fully closed for 2s to create a complete lesion of the DC.  After 
withdrawal of the forceps, the lesion could be visualised easily as a grey area 
between the dural puncture sites.  Closure of the erector spinae muscles was 
achieved with absorbable sutures and the overlying skin using staples.   
 
2.2.4 Injection of sciatic nerve with CTB  
Approximately 2d before sacrifice the sciatic nerve was exposed by making a 5mm 
incision in the left posterior thigh inferior to the greater trochanter.  The gluteal 
muscles were split and a retractor inserted to reveal the underlying nerve.  A suture 
was tied around the distal portion of the nerve before 2µl of a 1% solution of CTB 
(Sigma-Aldrich, Poole, UK) was injected using a glass micropipette attached to a 
20ml syringe containing air.  The micropipette was inserted around 10s before 
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injection and left in for 10s after injection to minimise leakage.  Injection was deemed 
successful if the nerve was seen to swell.  The skin was closed using staples. 
 
2.3 Statistical methods 
All statistical analyses were performed using SPSS version 15.  Multiple comparisons 
were analysed using one-way ANOVA or multiple t-tests with application of the 
Bonferroni correction (carried out by dividing the usual value for alpha, 0.05, by the 
number of comparisons performed).  Before each test, homogeneity of variance and 
normality of the data set was assessed.  If variances differed significantly, a Games-
Howell post-hoc test was applied.  Otherwise, Dunnett‟s post-hoc test was applied.  
Single comparisons were performed using a t-test, and assumptions above tested 
before the test was performed. 
 
Non-parametric data were analysed using different methods, specifically the Mann-
Whitney U-test was performed to compare the size distributions of total and GFP+ 
DRGN using data pooled from all injected animals. 
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Chapter 3 
Production and validation of AAV constructs 
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3.1 Introduction 
The context in which NT-3 and myelin neutralisation therapies for SCI find 
themselves has already been discussed in sections 1.2.1.3 and 1.3.4.  The reader is 
directed to Chapter 6 for more detail on the use of AAV vectors to deliver the 
neurotrophin 3 gene (nt-3) and myelin neutralisation therapies to the injured spinal 
cord.  This chapter concentrates on the validation of nt-3 and shRNARhoA constructs 
in vitro and then describes the mechanics of the production of plasmids containing 
these sequences for production using a baculoviral system.  In this context, the use 
of the term „construct‟ refers to a plasmid that will be used to generate an AAV-based 
gene therapy vector.  Thus, if activity of the construct can be shown, it is likely that 
the viral vector made using it will display a similar activity.   
 
Before proceeding, the reader is reminded of the convention whereby proteins are 
referred to in capital letters, whereas genes are referred to in lower case italics.  
Plasmids are named pABCDEF, with the genes contained within them written in 
capitals (mainly for clarity of reading).  Genes for shRNAs are referred to here without 
italicisation, also for the purposes of clarity.  rhNT-3 is a recombinant human NT-3, 
used as a positive control in experiments looking at biological activity of NT-3.  Use of 
the term “NT-3” refers either to neurotrophin-3 in its generic sense or neurotrophin-3 
that has been produced from transfection of cells using a particular plasmid.  Also, 
two types of green fluorescent protein have been used in this study – “GFP” and 
“hrGFP”.  Strictly speaking, “GFP” is enhanced green fluorescent protein (eGFP) but 
the e has been dropped for clarity.  hrGFP is humanised Renilla green fluorescent 
protein, derived from the sea pansy Renilla reniformis.   
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3.1.1 Demonstrating neurotrophic activity in vitro 
Before describing more contemporary work, it is worth putting NTF into some 
historical context, particularly since the discovery of many NTF relied upon first the 
study of in vivo phenomenology followed by rigorous in vitro experiments to show 
particular aspects of neurotrophic activity.  The emphasis in this chapter is on 
demonstrating neurotrophic activity in vitro. 
 
It was in the laboratory of Viktor Hamburger that a number of important discoveries 
concerning the developmental control of the nervous system were made.  In 1934, 
Hamburger demonstrated that removal of the wing bud from a chick embryo resulted 
in hypoplasia of motor and sensory neurones supplying the excised appendage 
(Hamburger 1934).  It was thought that this phenomenon could be explained by two 
hypotheses.  Either an influence from the limb bud cells was keeping existing 
neurones alive, or there was an effect on the recruitment of neuronal precursors.  
Further work in the Hamburger lab was inspired by experiments done by Bueker who 
implanted mouse sarcoma tissue into chick embryos (cited in (Levi-Montalcini 1987)).  
The results of these experiments showed invasion of the tumour grafts by sensory 
neurones and increase in size of DRGs supplying the tumour.  Continuing this work, 
Levi-Montalcini observed increased innervation in organs distant from the graft in 
animals implanted with mouse sarcoma cells.  This suggested the presence of a 
soluble factor, being released from the sarcoma and stimulating nerve growth.   
 
This activity was demonstrated in vitro, using chick DRG explants.  A robust neurite 
outgrowth response was observed in explants placed near to sarcoma tissue (Levi-
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Montalcini, Meyer et al. 1954).  Following on from this, a nucleoprotein fraction of the 
sarcoma tissue was identified as containing the active component.  Attempts to 
degrade the nucleic acid component with snake venom, which contains 
phosphodiesterases, resulted in a paradoxical increase in neurite outgrowth 
promoting activity which led to the serendipitous discovery that mammalian salivary 
glands produce the so-called nerve growth factor in large amounts (snake venom 
glands are homologous to mammalian salivary glands).  Following this work, the 
sequence of NGF was determined in 1971 (Cohen 1960; Angeletti and Bradshaw 
1971).   
 
The above account illustrates that NTF can have potent effects both in vitro and in 
vivo.  Most of the published work looking at NTF activity has incorporated in vitro 
methods, mainly because these techniques allow experiments to be performed that 
tend to be cheap, convenient, versatile and more easily interpreted compared with in 
vivo experiments.   
 
3.1.2 Protein knock-down using RNA interference 
In order to understand how therapeutic RNAi works, it must first be appreciated that 
there are endogenous RNAi pathways at work in most organisms that are 
responsible for regulating gene expression.  RNAi was discovered by Craig Mellow 
and Andrew Fire in the late 1990s following a series of confusing experimental 
results in plants.  They went on to be awarded the Nobel Prize in 2006, having 
generated a significant amount of interest in most areas of biological science. 
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The basic concept of RNAi is of small RNA sequences, complementary to the mRNA 
of interest, that are able to inhibit transcription.  The following describes the 
endogenous pathway for RNAi (i.e. that which occurs physiologically in organisms), 
and the reader is referred to a useful review aimed at neuroscientists for an 
accessible description of RNAi (Boudreau and Davidson 2010).   
 
Endogenous RNA interference is mediated by so-called microRNAs (miRNAs) that 
are encoded in the genome.  Newly transcribed miRNA molecules are known as 
primary miRNAs, with hairpin-loop structures arising as a consequence of self-
complementarity within the single-stranded miRNA molecule.  Within the nucleus, the 
enzyme Drosha trims the primary miRNA to a length of 60-70 nucleotides, which is 
now termed a pre-miRNA.  The pre-miRNA is exported from the nucleus to the 
cytoplasm, where it is acted upon by the enzyme Dicer.  Dicer removes the hairpin 
loop, generating a mature miRNA duplex consisting of a sense and an antisense 
strand (sense referring to the sequence of the messenger RNA (mRNA) in question, 
antisense being the complementary sequence to that).  The antisense sequence of 
the miRNA duplex is fed into the RNA-induced silencing complex (RISC), which 
mediates silencing of mRNA translation.  If the miRNA has a high level of 
complementarity to the target mRNA sequence, then degradation of the transcript 
ensues.  Lower levels of complementarity lead to translational inhibition without 
degradation of the transcript.   
 
With knowledge of these events, scientists have been able to exploit this pathway 
using two major types of synthetic miRNA: siRNAs and shRNAs.  shRNA can be 
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thought of as an exogenous pre-miRNA.  Thus, any method used to deliver shRNA 
must be able to access the nucleus.  siRNA can be thought of as an exogenous 
mature miRNA duplex, necessitating delivery to the cytoplasm.  shRNAs are 
processed identically to pre-miRNAs, ultimately forming a mature miRNA duplex that 
is fed into the RISC complex.  Cytoplasmically delivered siRNAs enter the RISC 
complex immediately to mediate gene silencing.   
 
Superficially it would seem that siRNA and shRNA are functionally equivalent.  
However, it has to be borne in mind that siRNAs must be delivered to the cytoplasm 
for them to work.  This usually involves complexing the siRNA with a non-viral gene 
therapy vector (e.g. Lipofectamine, a cationic lipid).  Once in the cytoplasm, the 
siRNA has a relatively short half-life precluding prolonged treatment effects.  
Conversely, shRNA can be delivered using viral vectors, some of which are known to 
be capable of mediating expression over months and even years.  Thus, shRNA-
based therapies are likely to hold more promise in the treatment of diseases that 
require prolonged treatment effects such as SCI.   
 
3.1.3 The importance of testing gene therapies in vitro  
Before proceeding to experiments in vivo, it is necessary to test reagents 
(specifically, plasmids that will be used to generate viral vectors) in vitro for three 
major reasons: technical, ethical and financial.   
Any plasmid containing transgene(s) that will be used to produce a viral vector 
should be tested to show that it is capable of mediating the expression of the 
transgene(s).  Testing ideally involves transfection of the plasmid into an appropriate 
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cell line and demonstration of the biological activity of the transgene payload.  In 
plasmids containing the gfp gene (gfp) or other reporter genes, the first step usually 
involves observation of reporter gene expression in transfected cells.  This confirms 
that the plasmid has entered cells and is mediating protein expression.  One must 
then look for evidence of production of other transgenes of interest within the plasmid 
(e.g. by Western blotting or ELISA).  Failure of expression of a transgene may be 
due, for example, to a mutation within the plasmid (it is often not practicable to 
sequence an entire plasmid).  Once transgene expression has been confirmed, 
biological activity should ideally be assessed, and compared with a suitable positive 
control such as a commercially available recombinant protein.  If the transgene is 
being expressed, it is unlikely that its biological activity has been compromised, 
however this cannot be guaranteed and is particular relevant to scenarios where the 
transgene has been tagged with an additional sequence that could potentially affect 
its biological activity.   
 
From an ethical point of view, it is necessary to test gene therapies in vitro before 
going in vivo in order to minimise animal use and any potential animal suffering.  It is 
not desirable to inject gene therapies in vivo when no knowledge of their activity has 
been gained.  The same argument applies to the financial point of view.  Production 
of a recombinant AAV vector costs around £2000 per virus.  Thus, plasmids need to 
be tested first before this costly investment is made. 
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3.1.4 Baculoviral production of AAV vectors 
Experience in our lab has shown that in-house production and purification of AAV8 is 
challenging and not cost-effective.  This is due mainly to the time-consuming and 
costly need to optimise all steps of the viral production process, since a commercially 
available kit for production of AAV8 is not available.  Thus, it was decided that it 
would be more cost- and time-effective to outsource AAV8 production.  The author 
would like to thank at this point  Dr Michael Douglas who, as well as giving invaluable 
advice and supervision for the entire project, generated pAAV-CMV-NT3-IRES-
hrGFP and pAAV-CMV-NT3-FLAG-IRES-hrGFP; designed the primers used in the 
following series of experiments and performed the second (successful) ligation of the 
NotI mutant sequence into the pAAV backbone.   
 
3.1.4.1 Background to the baculoviral expression system as a means of 
producing AAV 
Due to difficulties in manufacture of AAV8 viruses in house, it was decided to 
outsource the viral manufacture to the Gene Transfer Vector Core at the University of 
Iowa, USA.  This facility makes use of a baculoviral system which is capable of 
producing high titres of AAV8 particles with relatively little plasmid DNA (Urabe, Ding 
et al. 2002).  AAV vectors can be produced by transducing Sf9 cells (of insect origin) 
with three separate baculoviruses containing the AAV rep and cap gene complexes, 
adenoviral helper genes and the AAV ITR-spanned coding region (pFBGR, see 
below).  In order to generate baculoviruses, the coding regions described above must 
first be subcloned into a baculoviral donor plasmid, where they are spanned by Tn7 
elements allowing transposon-mediated insertion into an engineered baculoviral 
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genome („bacmid‟) within E.coli.  The resulting recombinant bacmid is then purified 
and transfected into insect cells where baculoviral particles containing the 
appropriate AAV construct are manufactured.  The three resulting baculoviruses are 
then co-infected into insect cells, resulting in production of high titres of recombinant 
AAV which can be purified using standard protocols.  See Figure 3.1 for summary of 
the above. 
 
3.1.5.1 Specific hypotheses 
 Delivery of nt-3 to DRGN in vitro augments survival and stimulates neurite 
outgrowth  
 Knockdown of RhoA by transfection of an shRNA against RhoA will lead to 
diminution of RhoA protein levels and disinhibited neurite outgrowth 
3.1.5.2 Specific aims 
 To generate plasmid constructs suitable for use in baculoviral-based 
production of AAV8.  These constructs will contain gfp, hrgfp, nt-3 and 
shRNARhoA in various combinations 
 To demonstrate an effect of rhNT-3 on survival and neurite outgrowth of 
DRGN in vitro 
 To demonstrate biological activity of NT-3 produced from the plasmids of 
interest 
 To demonstrate that the shRNARhoA construct is capable of knocking down 
RhoA in vitro 
 
 
A 
D 
C 
B 
Figure 3.1. Basic principles of AAV production using the baculoviral method. A. The gene of interest is cloned into the 
baculoviral ITR-containing plasmid, pFBGR-MCS. B. pFBGR-GOI is transformed into E.coli containing the Attn7 site, 
which is able to accept transposons spanned by Tn7L and Tn7R (shown in red). C. The purified, transposed bacmid is
transfected into Sf9 cells, resulting in the production of a baculovirus containing the ITR-spanned AAV genome 
sequence with the gene of interest (Bac-ITR-GOI). D. Transduction of Sf9 cells with Bac-ITR-GOI alongside 
baculoviruses containing capsid proteins specific to the serotype (Bac-cap) and helper genes (Bac-Helper) results in
the formation of mature rAAV particles which can be subsequently harvested and purified from Sf9 conditioned medium 
and lysate.  
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Section 3.1.6 Brief description of methods 
Dissociated cultures of adult rat DRG were prepared and exposed to recombinant 
NT-3 or conditioned media comtaining human NT-3.  Briefly, conditioned media were 
generated by transfecting COS-1 cells with plasmids either containing GFP alone, or 
containing the nt-3 gene.  COS-1 cells were left for 7d before harvesting conditioned 
media.  DRG cultures exposed to NT-3 were stained immunocytochemically for beta-
III tubulin, allowing quantification of neuronal survival and neurite outgrowth.   
 
Additionally, conditioned media were analysed for the presence of NT-3 using 
Western blotting, ELISA and silver staining of SDS-PAGE gels.   
 
Plasmids containing nt-3 and shRNA constructs were generated using standard 
molecular biology techniques including restriction enzyme digestion, DNA ligation, 
PCR and plasmid amplification and purification.   
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Results 
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3.2.1 rhNT-3 supported survival but not neurite outgrowth of adult rat DRGN in 
vitro 
A dose-response experiment was performed examining the effects of rhNT-3 on 
survival and neurite outgrowth of adult rat DRGN.  Concentrations used were 
between 1 and 50ng/ml, which lie in the range of values reported to be used in vitro 
in the literature (Mohiuddin, Fernandez et al. 1995; Kimpinski, Campenot et al. 1997).  
At a concentration of rhNT-3 of 10ng/ml, approximately twice as many DRGN 
survived compared to control (Figure 3.2A; one-way ANOVA, p=0.013).  The dose-
response curve displayed a bell-shaped appearance, with the highest concentration 
giving a lower amount of survival compared with the optimal dose.   
 
Surprisingly, there was no effect of rhNT-3 on the size of the longest DRGN neurite in 
vitro (Figure 3.2B).  All doses led to approximately the same level of neurite 
outgrowth, the differences not reaching statistical significance.   
 
3.2.2 The addition of a mitotic inhibitor had no effect 
It was possible that NTF produced by satellite cells present in the mixed DRG 
cultures was causing maximal growth stimulation of DRGN, leading to the lack of an 
effect of additional rhNT-3.  To counter this, the mitotic inhibitor 5-fluorodeoxyuridine 
(5-FDU) was added to the cultures to suppress the proliferation of cells including 
satellite cells and Schwann cells (Ahmed, Mazibrada et al. 2006).  In the pilot 
experiment performed, 5-FDU was seen both to fail to uncover an effect on neurite 
outgrowth of rhNT-3 and to abolish the survival effect of rhNT-3 on DRGN in vitro 
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Figure 3.2  The effect of rhNT-3 on growth and survival of adult rat DRGN after 2d 
in vitro.  A.  rhNT-3 supports maximal survival of DRGN at a concentration of 
10ng/ml (one-way ANOVA, p=0.013).  B.  There is no effect of rhNT-3 on neurite 
outgrowth in vitro (one-way ANOVA, p=0.705).  * represents post-hoc Dunnett’s test 
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(Figure 3.3).  Due to the apparent lack of promise of this approach, this experiment 
was not repeated.   
 
3.2.3 Demonstration of biological activity of NT-3 produced by transfection of 
COS-1 cells with pAAV-CMV-NT3-FLAG-IRES-hrGFP was difficult 
Having shown that rhNT-3 is able to lead to a biological effect in DRGN, it was 
decided to attempt to show this using NT-3 produced „in-house‟ from transfection of 
COS-1 cells using various plasmids either containing nt-3 or containing gfp as a 
control.  The basic aim of the experiments described below was to first show that NT-
3 had been produced after transfection of COS-1 cells, then to attempt to apply it to 
DRGN in vitro (either as raw conditioned medium or purified) in order to show that it 
had similar effects to rhNT-3, which has already been shown to support DRGN 
survival. 
 
3.2.3.1 FLAG-tagged NT-3 was detected by both Western blotting and ELISA 
In order to facilitate both purification and detection, it was decided to tag nt-3 using a 
commonly used system – the FLAG tag.  Genes inserted into the multiple cloning site 
(MCS) of pAAV-IRES-hrGFP are transcribed with a FLAG-tag by default, unless a 
stop codon is inserted before the FLAG coding region.  The FLAG tag can be 
detected using highly specific commercially available antibodies.   
 
A high proportion of COS-1 cells were transfected by all of the plasmids used in this 
study, as shown by their strong expression of GFP (Figure 3.4Aii).  The cells 
appeared grossly normal, and grew readily in vitro after transfection.   
A 
B 
Figure 3.3 Effects of rhNT-3 on survival (A) and neurite outgrowth (B) of DRGN in 
vitro in the presence of 30µM 5-FDU. 
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Figure 3.4 COS-1 cells transfected with plasmids encoding nt3-flag produced 
readily detectable quantities of NT-3.  A.  Since all plasmids used contained gfp, 
transfected COS-1 cells were identifiable by their expression of GFP.  A high 
percentage of COS-1 cells were GFP+.  (i) Phase-contrast image showing COS-1 
cells; (ii) fluorescence microscopy (FITC channel) image of the same field of view 
as in (i).  Scale bar 10µm.  B.  Western blot on samples of conditioned medium 
from COS-12 cells transfected with various plasmids including an untransfected 
control, stained using the anti-FLAG antibody to detect NT3-FLAG.  A strong band 
at ~17kDa (*) demonstrates the presence of a large quantity of NT3-FLAG in 
conditioned medium from COS-1 cells transfected with pAAVCMV-NT3-FLAG-
IRES-hrGFP.   
* 
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COS-1 cells transfected with the nt3-flag containing construct produced readily 
detectable quantities of NT3-FLAG.  Western blotting using an anti-FLAG antibody 
revealed a prominent band in conditioned medium from COS-1 cells transfected with 
pAAV-CMV-NT3-FLAG-IRES-hrGFP (a plasmid yielding NT3-FLAG) at the predicted 
weight of NT3-FLAG (17kDa; Figure 3.4B).  A subsequent ELISA assay on the same 
batch of conditioned medium revealed a concentration of NT3-FLAG of 64ng/ml.  No 
NT-3 was detected in conditioned media from untransfected COS-1 cells or those 
transfected with pAAV-IRES-hrGFP.       
 
3.2.3.2 No conclusive biological effect could be attributed to NT3-FLAG 
conditioned medium 
Dissociated cultures of adult rat DRG were prepared as usual and allowed to settle 
overnight before supplemented Neurobasal-A medium, DMEM with 10% FBS and 
1% penicillin/streptomycin or conditioned media were used to replace their usual 
medium (supplemented Neurobasal-A).  The conditioned media were from 
untransfected, pAAV-GFP, pAAV-CMV-NT3-IRES-hrGFP or pAAV-CMV-NT3-FLAG-
IRES-hrGFP transfected COS-1 cells left for 3d.  The DRG cultures were left for 48h 
and then the survival of DRGN was assessed by immunocytochemistry and 
microscopy.  Figure 3.5A shows the results of the experiment described above.  
Although very little can be gleaned from an experiment using cells from only a single 
animal, two major features are worthy of comment.  Firstly, there appears to be a 
certain degree of toxicity to DRGN associated with COS-1 cell conditioned media, 
particularly when COS-1 cells were untransfected or transfected with pAAV-IRES-
hrGFP.  Secondly, it appears that COS-1 cell conditioned media that contain NT-3 
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Figure 3.5 A pilot experiment showing the effect of various conditioned media on 
DRGN survival in vitro.  A. Effect of whole conditioned media from COS-1 cells 
transfected with various plasmids on adult rat DRGN survival.  B.  Dose-
response characteristics of 10X concentrated conditioned media on survival of 
adult rat DRGN in vitro.    
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are able to rescue DRGN from toxicity, since the amount of survival is similar when 
using conditioned media from COS-1 cells transfected with pAAV-CMV-NT3-IRES-
hrGFP or pAAV-CMV-NT3-FLAG-IRES-hrGFP.   
 
In response to the apparent toxicity of conditioned media in general, it was decided to 
concentrate the conditioned media by a factor of 10 in a 10 000 Da cut-off micro-
concentrator.  Concentrating the samples has two major effects on the composition 
of conditioned media – it increases the concentration of NT-3, and should decrease 
the amount of small-molecule toxins since they would pass through the filter and be 
removed as waste.  A pilot dose-response experiment, on a culture from one animal, 
was performed using between 0 and 50µl of 10X concentrated conditioned media 
covering a range of approximately 0-100ng/ml (Figure 3.5B).  The results of this 
experiment are difficult to interpret (see discussion), although some findings may be 
relevant: (i) conditioned media containing NT3-FLAG always yielded greater DRGN 
survival than media from untransfected COS-1 cells; (ii) NT3-FLAG containing media 
always gave higher levels of DRGN survival than NT-3 containing media and (iii) 
there was little correspondence between the experiment using whole conditioned 
media compared with that using concentrated media.  The results which make this 
experiment difficult to interpret are: (i) when no conditioned media were added to 
DRG cultures, survival should have been the same in all.  Instead, the DRG cultures 
„exposed‟ to 0µl of untransfected COS-1 cell medium showed considerably less 
survival than the other groups and, (ii) in all cases, conditioned media from COS-1 
cells transfected with gfp-only containing constructs led to more survival than 
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conditioned media from COS-1 cells transfected with pAAV-CMV-NT3-FLAG-IRES-
hrGFP.   
 
3.2.3.3 Purification of NT3-FLAG from conditioned media was not efficient 
enough to yield usable quantities of NT3-FLAG 
As should be apparent from the results described above, the use of conditioned 
media in assessing the efficacy of NT-3  generated from transfection of COS-1 cells 
with nt-3 is not simple.  Given these problems, it was decided that a useful approach 
may be to purify the NT3-FLAG from the conditioned media and then directly apply 
this pure preparation to DRG cultures, thus directly replicating the experiment 
described in section 3.4.1.  The most suitable approach to this problem was by 
immune-affinity chromatography.   
 
The approach employed used a FLAG-affinity column, where conditioned medium 
was passed through a column containing beads coated with anti-FLAG antibody, 
allowing NT3-FLAG to bind to the beads and then be eluted off (Figure 3.6).  Whole 
conditioned medium from pAAV-CMV-NT3-IRES-hrGFP transfected COS-1 cells was 
passed through a FLAG-affinity column and the effluent collected for analysis.  
Elution was performed using a low pH solution, yielding a very faint band at ~17kDa, 
the predicted weight of NT3-FLAG.  A positive control, 1µg rhNT-3, gave a strong 
band at ~14 kDa.   
 
Despite the success of purification of NT3-FLAG by the above method, it was felt that 
this method was probably far from ideal due to two major factors.  First, acid elution 
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Figure 3.6 Purification of NT3-FLAG from COS-1 cell conditioned medium by immunoaffinity 
chromatography.  Silver-stained gel showing samples from an entire experiment.  Whole conditioned 
medium (Pre-column) was passed through a FLAG-affinity column and the effluent collected (Post-
column).  The column was washed three times (Wash 1, 2, 3) before being eluted three times (Elution 
1, 2, 3).  A sample of rhNT-3 was added as a positive control, and can be seen clearly on the gel (light 
arrow).  The band corresponding to NT3-FLAG (dark arrow) is barely visible at around 17kDa.   
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had the risk of denaturing the eluted NT-3 thus rendering it unusable in bioassays.  
Secondly, the quantities produced by the method were very small and unlikely to 
yield enough NT-3 to use in assays.  To overcome the potential acid denaturation 
problem, competitive elution using a FLAG peptide was performed.  Unfortunately, 
this proved unsuccessful as the NT3-FLAG would not dissociate from the beads, 
even with heating and varying concentrations of peptide.   
 
3.2.4 Production of human NT-3 containing constructs 
3.2.4.1 The starting materials 
Primers were designed to enable amplification of the human hnt-3 gene (hnt-3), 
including its signal sequence and pre- and pro-domains from an existing plasmid 
containing the full-length human form designated “nt-3 gene” (Maisonpierre, Belluscio 
et al. 1990).  These primers also contained XhoI and BamHI restriction sites, allowing 
sub-cloning into pAAV-IRES-hrGFP, yielding pAAV-CMV-NT3-IRES-hrGFP, and 
were performed by Dr Michael Douglas (Figure 3.7).  Note that pAAV-CMV-NT3-
IRES-hrGFP contains a stop codon, preventing a 3X FLAG tag being conjugated to 
the C-terminal of hnt-3.  pFBGR, provided by Dr Maria Scheel of the Gene Transfer 
Vector Core, is the plasmid that receives the construct of interest allowing a 
baculovirus to be produced that can be used to manufacture AAV8 in insect cells 
(see introduction).  
 
 
 
1 
pAAV-CMV-NT3-IRES-hrGFP 
6905 bp 
L-ITR 
P CMV 
Beta-globin intron 
Human NT-3 
3 X FLAG 
IRES 
hrGFP 
hGH pA 
R-ITR 
f1 ori 
Amp 
Figure 3.7 Map of pAAV-IRES-hrGFP (A) and after insertion of human NT-3 
sequence (B).  pAAV-CMV-NT3-IRES-hrGFP does not express NT3-FLAG due 
to the inclusion of a stop codon.  pAAV-IRES-hrGFP map courtesy of 
Stratagene. 
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3.2.4.2 The AAV sequence from pAAV-CMV-NT3-IRES-hrGFP could not be 
inserted into pFBGR by a simple cut-and-paste approach 
On examination of the plasmid maps it seemed most reasonable to subclone the NotI 
spanned fragment from pAAV-CMV-NT3-IRES-hrGFP into the NotI spanned region 
of pFBGR, preserving the ITRs.  Digestion of pFBGR with NotI and subsequent 
dephosphorylation of the 4963bp fragment was successful, yielding a product called 
“pFBGR vector”.  However, digestion of pAAV-CMV-NT3-IRES-hrGFP with NotI 
yielded one smaller fragment at 1.2kb containing the cytomegalovirus (CMV) 
promoter and beta-globin intron, and 2 unresolvable overlapping bands at 2.8kb, one 
containing the nt3-ires-hrgfp segment and the other containing the rest of the pAAV-
CMV-NT3-IRES-hrGFP backbone (Figure 3.8).  Thus, in order to resolve the nt-3 
containing segment from the backbone segment, it was decided to digest this doublet 
band of 2.8kb with ScaI, which is known to cut in the ampicillin resistance gene.  
However, digestion of pAAV-CMV-NT3-FLAG-IRES-hrGFP and pAAV-CMV-NT3-
IRES-hrGFP (data not shown) with ScaI yielded two fragments, showing that ScaI is 
not a unique site in these plasmids, and so not useful for resolving the overlapping 
2.8kb bands.  Indeed, digestion of the 2.8kb bands resulting from digestion of pAAV-
CMV-NT3-IRES-hrGFP and pAAV-CMV-NT3-FLAG-IRES-hrGFP resulted in complex 
sets of digestion products which were too difficult to interpret for use in subsequent 
cloning.   
 
Since the above problems were caused by the presence of an additional NotI site 
within pAAV-CMV-NT3-IRES-hrGFP, it was decided to use a site-directed 
mutagenesis approach to ablate the additional NotI site, allowing straight-forward 
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Figure 3.8.  A. Schematic showing the steps involved in producing pAAV-
CMV-NT3-IRES-hrGFP.  B.  Digestion of pAAV-CMV-NT3-IRES-hrGFP 
(pAAV-NT3) with NotI yields 3 fragments, 2 of which are unresolvable at 
~2.8kb.   
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sub-cloning of the NotI site spanned MCS-containing segment of pAAV-IRES-hrGFP 
into “pFBGR vector”, to yield a pFBGR-IRES-hrGFP-MCS plasmid, into which the 
hnt-3 sequence could be subsequently sub-cloned. 
 
3.2.4.3 Production of pFBGR-IRES-hrGFP-MCS  
The following section is split into three main parts.  Firstly, site-directed mutagenesis 
of the additional NotI site in pAAV-IRES-hrGFP.  Secondly, insertion of the mutated 
cassette back in pAAV-IRES-hrGFP.  Thirdly, sub-cloning of the mutated cassette 
from pAAV-IRES-hrGFP(NotI mut) into pFBGR. 
 
3.2.4.3.1 Optimisation of overlap extension PCR 
OEPCR was performed in three stages, involving three separate PCR reactions.  The 
first PCR (PCR1) used a forward primer of designed using the sequence spanning an 
SnaBI site within the CMV promoter region (SnaBIfor).  That this site was unique 
within pAAV-IRES-hrGFP was confirmed by restriction digest of pAAV-IRES-hrGFP 
with SnaBI (Figure 3.9).  The reverse primer for PCR1, based around the additional 
NotI site near the MCS of pAAV-IRES-hrGFP contained a single mutation within the 
NotI site itself (NotIOL2, Figure 3.10A).   
 
The second PCR (PCR2) employed a forward primer which was complementary to 
NotIOL2 (NotIOL1) and a reverse primer based upon a sequence at the 5‟ end of the 
IRES sequence within pAAV-IRES-hrGFP (LONGpAAVrev, Figure 3.10A). 
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Figure 3.9.  Digestion of pAAV-IRES-hrGFP (pAAV-GFP) and pAAV-CMV-
NT3-IRES-hrGFP with SnaBI shows that the SnaBI site is unique in these 
plasmids 
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Figure 3.10.  Overlap extension PCR to ablate a NotI site in pAAV-IRES-hrGFP 
(pAAV-GFP).  A.  PCR1 (template pAAV-GFP, primers SnaBIfor and NotIOL2) and 
PCR2 (template pAAV0GFP, primers NotIOL1 and LongpAAVrev).  B.  PCR3 
(template PCR1+PCR2 products, primers SnaBIfor and XhoIrev).  Lane “pAAV-
GFP” was a positive control using primers for PCR3.  “x” refers to lanes used to 
amplify products from a previous, inefficient PCR3. 
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In PCR3 the products of PCR1 and PCR2 were gel purified and combined together 
along with SnaB1for and LongpAAVrev.  A successful result would yield an amplicon 
of ~1200bp.  Unfortunately, PCR3 failed to yield any products. 
 
In order to increase the efficiency of PCR3, two strategies were assessed.  First, 
dimethylsulphoxide (DMSO, which is known to linearise DNA secondary structures) 
was added to the PCR mix.  Secondly, a primer designed around the XhoI site within 
the MCS of pAAV-IRES-hrGFP was used.  This primer would yield a shorter product 
in PCR3, with the intention of decreasing secondary structure within the amplicon.  
The use of XhoIrev resulted in a low level of amplification in PCR3, necessitating 
further optimisation in the form of increased number of cycles (from 14 to 18) and the 
addition of extra magnesium to the PCR mix.  Figure 3.10B shows the successful 
product of PCR3. 
 
3.2.4.3.2 Reconstitution of pAAV-IRES-hrGFP containing the NotI mutation 
The product of PCR3 was digested with SnaBI and XhoI to yield a fragment 
(designated NotImut Insert) with „sticky‟ ends for ligation into pAAV-IRES-hrGFP, 
which had been digested with these same enzymes and subsequently 
dephosphorylated (designated pAAV vector, Figure 3.11).  After gel purification, 
ligation of NotImut Insert into pAAV vector at a volume ratio of 1:1 and 3:1 was 
performed.  The negative control plate (i.e. 1µl vector to 0µl insert) had 1 colony, the 
1:1 ligation plate had 1 colony and the 3:1 ligation plate had 3 colonies.  Thus, 
despite a low „background‟ in the negative control plate, the ligation failed with at 
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Figure 3.11.  Production of pAAV-IRES-hrGFP (pAAV-GFP) vector and NotI 
mutant insert by digestion with SnaBI and XhoI.  1.  Undigested pAAV-GFP.  2.  
Digestion and dephosphorylation of pAAV-GFP yielded a vector fragment at 
~7100bp.  3 and 4.  Two individual digestions of the PCR3 amplicon spread 
across 4 lanes.    
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least 10X fewer colonies than expected.  Higher insert-to-vector ratios, up to 15:1 
were performed, yielding similar results.   
 
More NotImut Insert was prepared following the steps described above and the 
ligation repeated using 1:1 and 3:1 insert to vector ratios.  This yielded 0 background 
colonies, 2 colonies on the 1:1 plate and 1 colony on the 3:1 plate.  Given that this 
ligation appeared to be of low efficiency it was decided to miniprep all colonies and 
screen for the presence of insert by digestion with SnaBI and XhoI.  No colonies 
contained the insert.  The next step was to repeat the ligation but to increase the 
transformation efficiency by performing a rescue step.  The rescued ligation yielded 4 
colonies on the background, 6 colonies on the 1:1 plate and 12 colonies on the 3:1 
plate.  Screening of 8 colonies from the 3:1 plate by restriction digest showed that 
none of the ligations had been successful.   
 
One reason for the poor efficiency of ligation may have been that SnaBI cut the 
product from PCR3 inefficiently.  In order to increase the efficiency of SnaBI 
digestion, a primer was designed to replace SnaBIfor which binds 5‟ from the SnaBI 
site, yielding an amplicon from PCR3 with a longer „cap‟ segment 5‟ to the SnaBI site.  
Digestion of this amplicon, subsequent ligation and miniprepping of colonies yielded 
1 successful ligation out of 6 (Figure 3.12).  This plasmid, designated pAAV-IRES-
hrGFP(NotImut) was sequenced, confirming the presence of the mutation. 
 
 
Figure 3.12.  One miniprep out of 8 (very dim band at ~1000bp in number 4) 
contained the insert carrying the mutated NotI site. 
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3.2.4.3.3 Sub-cloning the NotI mutant cassette from pAAV-IRES-
hrGFP(NotImut) into the NotI sites of pFBGR 
By means of confirmation, pAAV-IRES-hrGFP(NotImut) was digested with NotI.  As 
expected, digestion of pAAV-IRES-hrGFP yielded 3 fragments while pAAV-IRES-
hrGFP(NotImut) yielded two fragments (Figure 3.13A).  Unfortunately, the two 
fragments from the latter digest were too close to resolve.  This problem was 
overcome by digestion of pAAV-IRES-hrGFP(NotImut) with both NotI and ScaI, 
resulting in the conversion of the larger unresolvable fragment into two smaller, 
resolvable fragments and allowing the fragment of interest (designated pAAV-
NotImut Insert) to be isolated  (Figure 3.13B).   
 
pAAV-NotImut Insert was ligated into the NotI sites of the pFBGR backbone (pFBGR 
vector) at ratios of 1:1 and 7:1.  This ligation, under standard conditions, was 
unsuccessful, but yielded 20 colonies in the 7:1 ratio after a rescue step.  Three of 
these 20 colonies were midiprepped and subjected to NotI digestion (Figure 3.14).  
Two clones out of three were found to be positive for insert and were designated 
pFBGR-IRES-hrGFP-MCS.   
 
3.2.4.4 Sub-cloning the hnt-3 sequence into pFBGR-IRES-hrGFP-MCS yielded a 
functional plasmid 
pFBGR-IRES-hrGFP-MCS and pAAV-CMV-NT3-IRES-hrGFP were digested with 
BamHI and XhoI yielding a „vector‟ and „insert‟ respectively (Figure 3.15).  Ligation 
followed by a rescue step yielded 8 colonies on the 3:1 plate, which were screened 
for the presence of the hnt-3 insert by digestion with BamHI and XhoI (Figure 3.16).  
bp 
5090 
4072 
3054 
2036 
1636 
1018 
517 
5090 
4072 
3054 
2036 
1636 
1018 
517 
bp 
- 
- 
+ 
+ 
+ 
+ 
- 
- 
NotI 
ScaI 
+ + NotI 
Figure 3.13.  A.  Digestion of pAAV-IRES-hrGFP(NotImut) with NotI yields 2 
unresolvable fragments, compared with 3 fragments from the unmutated plasmid.  
B.  The NotI mutated cassette, spanned by NotI sites, can be isolated at ~3500bp 
by digestion with NotI and ScaI.   
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Figure 3.14.  Clones 2 and 3 were positive for the presence of the pAAV-
NotImut insert.  Clone 2 was kept and designated pFBGR-IRES-hrGFP-MCS 
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Figure 3.15.  Preparation of vector from pFBGR-IRES-hrGFP-MCS (pFBGR-MCS) 
and insert from pAAV-CMV-NT3-IRES-hrGFP (pAAV-NT3).  1, 2 and 3.  BamHI and 
XhoI are single cutters in pFBGR-MCS.  4.  The dephosphorylated pFBGR-MCS 
vector.  5 and 6.  The ~700bp hNT-3 containing insert is easily isolated. 
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Figure 3.16.  One clone out of 6 (number 2) contained the hNT-3 insert, 
spanned by BamHI and XhoI sites. 
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Clone 2 contained the insert, and was designated pFBGR-CMV-NT3-IRES-hrGFP 
(Figure 3.17).  Transfection of pFBGR-CMV-NT3-IRES-hrGFP into COS cells 
resulted in strong GFP expression in ~90% of cells and very high levels of NT-3 in 
the conditioned medium, as determined by ELISA.  The levels of NT-3 could not be 
accurately quantified as the highest dilution of conditioned medium had a higher 
concentration than the top standard in the ELISA assay. 
 
3.2.5 Production of shRNARhoA containing constructs 
3.2.5.1 The starting materials 
As well as kindly supervising all of the following, Dr Michael Douglas provided the 
shRNARhoA sequence (driven by a mouse U6 promoter) within pAAV-U6-shRNARhoA-
CMV-CNTF-IRES-hrGFP and designed the primers to determine the orientation of 
the shRNARhoA insert.  The biological activity of the shRNARhoA sequence used in this 
study was confirmed by Dr Douglas by transfecting a plasmid containing the 
sequence into COS-1 cells that overexpressed rat RhoA.  Western blotting of the 
lysate from these cells at an appropriate time-point revealed effective knockdown of 
RhoA compared with two published sequences (Ahmed, Dent et al. 2005; Pille, 
Denoyelle et al. 2005) and a GFP shRNA (Figure 3.18) 
 
3.2.5.2 Generation of pFBGR-IRES-hrGFP-NT3-shRNARhoA 
pFBGR-IRES-hrGFP-NT3-shRNARhoA was produced in three main steps.  The 
shRNARhoA sequence designed by Dr Michael Douglas was released from pAAV-
IRES-hrGFP-shRNARhoA and ligated into pFBGR-IRES-hrGFP-NT3 at an MluI site 
found between the 5‟ ITR and the NotI site.  After this, the orientation of the insert 
1 
pFBGR-CMV-NT3-IRES-hrGFP 
8170 bp 
L-ITR 
P CMV 
Beta-globin intron 
Human NT-3 
3 X FLAG IRES 
hrGFP 
hGH pA 
R-ITR 
ori 
Amp 
 Feature  Nucleotide position  
 L-ITR†  662-837 
 CMV promoter*  859-1521 
 Beta-globin intron*  1529-2021 
 Human NT-3  2101-2870 
 3 X FLAG*  2879-2950 
 IRES*  2986-3572 
 hrGFP*  3570-4286 
 hGH pA*  4344-4822 
 R-ITR†  4866-5041 
 Amp / ori†  5042-8170 
 NotI cleavage site  852, 5041 
*From pAAV-IRES-hrGFP 
†From pFBGR 
Figure 3.17.  Map of pFBGR-CMV-NT3-IRES-hrGFP 
Figure 3.18.  Preliminary validation of shRNA constructs performed by Dr M. Douglas.  Sequence A, giving 
maximal knockdown, was designed by Dr M. Douglas (sequence unavailable).  Sequences B and C were 
based on published sequences (see Pille 2005 and Ahmed 2005, respectively). 
Ahmed et al.  5’-AAGGATCTTCGGAATGATGAG-3’ 
Pille et al.  5'-GACATGCTTGCTCATAGTCTT-3' 
110 
 
was confirmed by PCR to ensure that transcription of the shRNARhoA occurred from 
the same strand as hrgfp and nt-3.  Production of pFBGR-IRES-hrGFP-shRNARhoA 
was unsuccessful for unknown reasons.  
 
3.2.5.2.1 Ligation of the shRNARhoA insert into pFBGR-CMV-NT3-IRES-hrGFP 
was successful, but attempts at producing an shRNARhoA only plasmid failed 
pAAV-IRES-hrGFP-shRNARhoA was digested with MluI to release the shRNARhoA 
sequence (spanned by MluI sites, designated “shRNA insert”), and pFBGR-IRES-
hrGFP-MCS and pFBGR-CMV-NT3-IRES-hrGFP were digested and 
dephosphorylated to prepare vectors designated “pFBGR-MCS vector” and “pFBGR-
NT3 vector” (Figure 3.19).   
 
The shRNA insert was ligated into pFBGR-MCS and pFBGR-NT3 vectors, and 
transformed into E.coli.  Four colonies were picked from each plate and miniprepped, 
followed by digestion with MluI to confirm presence of insert (Figure 3.20).   
 
In order to establish that both the shRNA and hrgfp or hrgfp-nt3 expression cassettes 
would be transcribed from the same strand, primers were designed based upon the 
AAV ITR sequence (pAAVITRf) and the MluI sequence (MluIrev).  PCR screening of 
the successful ligation products with these primers yielded one positive (i.e. correctly 
orientated) clone amongst the NT-3 containing constructs, whilst none of the pFBGR-
IRES-hrGFP-MCS constructs had the shRNA in the correct orientation (Figure 3.21).  
A number of further ligations were attempted to generate a correctly orientated 
pFBGR-IRES-hrGFP-MCS, to no avail.  
Figure 3.19.  pFBGR-IRES-hrGFP-MCS (pFBGR-MCS) and pFBGR-CMV-NT3-
IRES-hrGFP (pFBGR-NT3) were digested with MluI and dephosphorylated.  The 
shRNARhoA construct was released from pAAV-IRES-hrGFP-shRNARhoA (pAAV-
shRNA) for sub-cloning into the pFBGR vectors.   
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Figure 3.20.  Restriction digest to confirm the presence of the shRNARhoA insert.  
Positive colonies from ligation of shRNARhoA insert into pFBGR-MCS vector (M1-
M4) and pFBGR-NT3 vector (N1-N4) were picked and miniprepped, then digested 
with MluI to detect the ~500bp insert, which was present in M2, M4 and N1-N4.     
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Figure 3.21.  Determination of shRNARhoA insert orientation.  N3 was the only 
correctly oriented clone, giving a PCR product at the expected ~500bp size.   
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3.3.1 Biological activity of rhNT-3 in vitro 
rhNT-3 bioactivity was confirmed by the demonstration of a DRGN survival promoting 
effect.  This is a known effect of NT-3 on neurones, and has been shown to be the 
result of stimulation of the Akt pathway (Liot, Gabriel et al. 2004).  In the study by 
Liot, the dose that was found to give the maximal survival was 10ng/ml, identical to 
the optimum concentration found in this study.  However, it must be born in mind that 
Liot did not report the effect of any doses higher than 10ng/ml and used a serum-
deprivation paradigm.  
 
It is interesting that rhNT-3 did not promote neurite outgrowth of DRGN in the 
experiments described above.  On examination of the literature, the neurite growth 
promoting activity of NT-3 appears to be a topic of some controversy.   Most reports 
showing positive effects of NT-3 on neurite outgrowth employ explants, usually from 
embryonic or early post-natal animals (usually rat and chick).  A PubMed search 
using the terms “nt-3 neurite outgrowth” yielded 108 hits, with only 3 papers 
describing results from experiments using dissociated adult rat DRG cultures 
(Mohiuddin, Fernandez et al. 1995; Kimpinski, Campenot et al. 1997; Gavazzi, 
Kumar et al. 1999).  The paper by Mohiuddin et al. used dissociated cultures of DRG 
from adult Wistar rats exposed to rhNT-3, and showed a positive effect on neurite 
outgrowth from DRGN at a concentration of 10ng/ml.  However, Gavazzi et al. 
showed no effect of rhNT-3 on neurite length in dissociated DRG cultures, whilst 
Kimpinski et al. showed no neurite growth promotion in dissociated DRG cultures 
grown in a compartmented culture system. 
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Closer examination of the papers described above reveals that the way in which they 
quantify neurite outgrowth is different.  Kimpinski et al. used a non-conventional 
dissociated culture system, and so will be excluded from the following discussion.  
Mohiuddin et al. used a method based upon neurite density, applying a Weibel grid to 
micrographs of cultures and then counting the number of intersections of DRGN 
neurites with gridlines.  Gavazzi et al. measured three separate parameters relating 
to neurite outgrowth by conventional means: percentage of process-bearing DRGN, 
length of the longest neurite per DRGN (i.e. the single longest neurite) and total 
neurite length per DRGN (i.e. the sum of the lengths of all neurites for a given 
DRGN).  The measure used by Mohiuddin et al. is most closely correlated with „total 
neurite length‟ used by Gavazzi et al.  At a concentration of 50ng/ml rhNT-3, 
Mohiuddin et al. showed 4 times greater neurite outgrowth compared with control.  At 
the same concentration of rhNT-3, Gavazzi et al. also showed an increase in total 
neurite length but only of small magnitude (~1.5 times greater compared with control) 
and restricted to medium-diameter DRGN.  Thus it appears that the parameter used 
to quantify neurite outgrowth in the present study was inappropriate for 
demonstrating an effect of NT-3 on neurite outgrowth.  However, the fact remains 
that biological activity of rhNT-3 in DRG cultures was demonstrated, and agreed with 
reports already published in the literature.   
 
 The failure of the mitotic inhibitor 5-FDU to reveal an effect on neurite outgrowth is 
clear following the discussion above.  Recalling that the rationale for adding 5-FDU 
was to remove NT produced by non-neuronal cells in DRG cultures, it is also 
interesting to note that just after the experiment being discussed here was 
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performed, it was discovered by Zubair Ahmed and the author that conditioned 
medium from dissociated DRG cultures does not actually contain detectable or 
physiological levels of NT (Ahmed, Jacques et al. 2009).  This result is likely to be 
due to failure of DRG cultures to synthesise NT-3 but could be caused by 
sequestration of NT-3 by the ECM.   
 
3.3.2 Detection of NT3-FLAG 
The major aim of the experiments described in section 3.5.1 was to demonstrate that 
NT-3 was in fact produced when cells were transfected with pAAV-CMV-NT3-IRES-
hrGFP.  That NT-3 was detected came as no surprise given that the sequence of the 
NT-3 coding region of the plasmid was known to be correct.  Two points will be 
discussed in further detail below: (i) the concept of experimental repetition and, (ii) 
the relevance of the concentration of NT-3 found in vitro.   
 
The author acknowledges that the Western blot and ELISA for NT3-FLAG should 
have been repeated at least three times.  Three major factors contributed to this 
inadequacy, namely cost, time and the questionable relevance of the concentration 
of NT-3 found in conditioned medium.  To run a single Emax ELISA plate costs in 
excess of £100, not to mention the cost of producing the conditioned medium.  
Additionally, to run such an ELISA plate required a three day protocol to be 
performed.  Finally, it must be stressed that it was known that COS-1 cells do not 
produce NT-3 (Farhadi, Mowla et al. 2000).  Thus, any NT-3 detected in COS-1 cell 
conditioned media must have been from an exogenous source, resulting in the 
experimental question becoming not one of how much NT-3 is produced by 
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transfected versus untransfected COS-1 cells but rather whether NT-3 is produced at 
all after transfection with an NT-3 containing construct.  Finally, it must be stressed 
that NT-3 production by COS-1 cells transfected with pAAV-CMV-NT3-FLAG-IRES-
hrGFP has been shown in three independent trials employing three different 
techniques: Western blotting (Figure 3.4B), ELISA and immunoprecipitation (Figure 
3.6).    
 
It was found, in one batch of conditioned medium from COS-1 cells transfected with 
pAAV-CMV-NT3-FLAG-IRES-hrGFP, that the concentration of NT-3 was 64ng/ml.  
Superficially, this appeared to be an encouraging result showing that a biologically 
active amount of NT-3 is produced by transfection of cells with a particular plasmid.  
However, it must be borne in mind that such in vitro experiments employing plasmids 
have many limitations and must only be extrapolated to the in vivo situation with 
caution.  First, recall that it was pFBGR-CMV-NT3-IRES-hrGFP that was used to 
manufacture the viral vector AAV8hrGFP-NT3, not pAAV-IRES-hrGFP (the plasmid used 
in the experiments discussed above).   This was due to there needing to be a change 
of strategy relatively late on in the project in order to produce the viral vectors.  The 
pFBGR plasmids were constructed, but there was insufficient time to test them.  NT-3 
production by pFBGR-CMV-NT3--IRES-hrGFP was shown by ELISA, however.  
Secondly, how can the concentration of NT-3 in conditioned medium be extrapolated 
to the concentration of NT-3 in vivo?  Such extrapolation is impossible, since in vitro 
a transfected, proliferating cell line from a green monkey (COS-1 cells) is being 
grown in 2 dimensions in an enclosed compartment in a specified volume of medium.  
In vivo, transduced non-proliferating cells (DRGN) are growing in 3 dimensions in a 
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complex and varying milieu with the added complications of the immune system etc.  
The only comment that can be made about the value of 64ng/ml of NT-3 in COS-1 
cell conditioned medium is that it is a lot, and would probably correspond to a lot 
being made in vivo using a viral vector.  Further experiments must be performed to 
show how much additional NT-3 is produced in vivo.   
 
3.3.3 The biological activity of NT3-FLAG was not convincingly demonstrated 
The attempts to show biological activity of NT3-FLAG represented an arduous and 
frustrating time for the author.  Given the successful reports in the literature 
demonstrating the activity of virally delivered or recombinant NT-3, these experiments 
were embarked upon with great optimism (Dijkhuizen, Hermens et al. 1997; Blits, 
Oudega et al. 2003).  Closer examination of these reports, however, reveals some 
essential differences that may explain the difficulties faced in this study.   
 
Blits et al. applied conditioned media to embryonic DRG explants, and used neurite 
outgrowth from the explant as their main measure for NT-3 activity.  In the present 
study, conditioned media were applied to dissociated adult rat DRG cultures, using 
survival to demonstrate rhNT-3 activity.  Blits et al. demonstrated positive effects on 
DRGN neurite outgrowth in the presence of rhNT-3 and NT-3 applied in conditioned 
media with an apparent absence of toxicity.  In the present study, no strong positive 
biological effects of NT-3 containing conditioned medium were demonstrated; in fact, 
conditioned media appeared to be toxic.  Three factors may explain the failure of the 
present study compared with Blits et al.  Firstly, Blits et al. used DRG explants, 
compared with the dissociated cultures in this study.  Explants are likely to be more 
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biologically relevant than dissociated cultures, since the DRG tissue is intact.  
Dissociated cultures were used by the author since this is the technique that the 
Molecular Neuroscience Group is most familiar with.  Also, the author attempted to 
perform some experiments using explants which failed, due to them becoming 
detached from the culture dish.  The use of explants by Blits et al. may have 
protected the DRGN within from toxic agents within the conditioned media, since the 
DRG capsules would presumably have been intact.  Dissociated DRG cultures may 
be more susceptible to toxicity since DRGN are in direct contact with culture medium.   
 
The second factor likely to have a role is the age of the neurones used in 
experiments.  The Molecular Neuroscience Group has historically used adult 
neurones in cell culture experiments.  The use of cells from adult animals makes 
good sense from the point of view of translation, since most of the pathologies that 
are the subject of intense research in the neurodegeneration/repair field affect adults 
predominantly.   A survival effect of NT-3 on DRG cultures may not have been 
observed due to the fact that adult neurones are less dependent on NTs than their 
embryonic counterparts (Snider and Silos-Santiago 1996).   
 
Finally, it may be possible that the way in which conditioned media were prepared 
could have a bearing on the failure of the experiments described here.  Conditioned 
media used in the experiments described above had been prepared by leaving 
transfected COS-1 cells for 7d, compared with 3d in the case of Blits et al.  Over 7d, 
many toxic compounds are likely to have accumulated in the conditioned media 
including small molecules such as urea and ammonia.  Additionally, nutrients will 
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have been depleted from the media.  It is likely that the conditioned media, used by 
Blits et al. were less nutrient depleted and contained lower concentrations of 
metabolites than those used in the present study.   
 
3.3.4 NT3-FLAG could not be purified in sufficient quantities allowing 
assessment of biological activity 
Given the apparent toxicity of whole conditioned media it was decided to attempt to 
purify the FLAG-tagged NT3 by using immunoaffinity chromatography.  Acid elution 
yielded a (barely) detectable amount of NT3-FLAG, and FLAG peptide elution failed.   
 
At this point, the issue of why so much emphasis was placed upon demonstrating 
biological activity of NT3-FLAG must be discussed.  The presence of a FLAG tag is 
beneficial mainly from the point of view of ease of detection.  Neurotrophins are 
notoriously difficult to detect, particularly on Western blots (personal communications, 
various sources).  By FLAG-tagging them, NTs can be detected easily with the well 
validated anti-FLAG monoclonal antibody.  However, whenever a tag is applied to a 
protein it must always be borne in mind that there exists a theoretical possibility that 
the activity of the tagged protein may differ from the untagged state (Terpe 2003).  
Despite the fact that most tag sequences are small, they may still have the potential 
to interfere with protein-protein interactions, and in the case of NT-3 they may 
interfere with its interaction with TrkC.   
 
As a consequence of the failure to demonstrate that NT3-FLAG has identical 
biological activity, it was decided to instead produce an AAV8 vector containing 
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untagged NT3.  This was not ideal, since using this virus renders it impossible to 
differentiate between endogenous and exogenous NT3, since the sequences of the 
human and rat proteins are identical.   
 
3.4 Further work 
Much additional work is required to complete the investigations discussed above.  
This work was not completed by the author due mainly to time constraints within the 
project framework.  The following described the major additional experiments the 
author would like to perform.  Additionally, the author would like to increase the n 
numbers in those experiments described with less than three replicates. 
 
Further characterisation of DRGN neurite outgrowth parameters affected by 
NT-3 
As mentioned in the discussion, it is likely that the measure of neurite outgrowth 
employed in this study was inappropriate for demonstrating NT-3 bioactivity.  Thus, it 
would be informative to measure additional parameters such as number of neurites 
per DRGN, total neurite length and branching.  Assessment of these parameters may 
reveal an effect of NT-3 (or indeed any of the conditioned media) on neurite 
outgrowth. 
 
Optimisation of NT3-FLAG purification 
It would be beneficial to spend more time attempting to maximise the yield of NT3-
FLAG.  This could possibly be achieved by increasing the concentration of FLAG 
peptide used for elution, altering the conditions of elution (e.g. increasing the 
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temperature during elution, agitation, alteration of pH) or by employing a different 
type of affinity tag.   
 
In vitro testing of the shRNARhoA sequence 
Despite the fact that knockdown of overexpressed rat RhoA in COS-1 cells was 
shown by Dr Michael Douglas, it would be useful to examine the effect of this shRNA 
sequence on neurones grown in the presence of an inhibitory substrate.  This could 
be achieved by transfecting DRGN with a plasmid containing the shRNARhoA 
sequence and then exposing these neurones to an inhibitory substance such as 
myelin.  The Molecular Neuroscience Group has an established inhibitory assay that 
could be used (Ahmed, Dent et al. 2005).  The major difficulty with such an 
experiment would be in transfecting the DRGN, since they are post-mitotic and hence 
refractory to traditional transfection reagents such as Lipofectamine.  One technique 
that could be employed is electroporation, where neurones are exposed to plasmids 
in the presence of an electrical field.  This has been shown to be successful in both 
retinal ganglion cells and DRGN (Leclere, Panjwani et al. 2005).   
 
Generation of a plasmid enabling manufacture of an shRNA-only containing 
AAV8 vector 
It remains unclear why it proved impossible to generate a plasmid containing the 
shRNA construct alone.  Further work is required, probably involving greater numbers 
of ligations and optimisation of ligation conditions. 
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Chapter 4 
Assessment of the cellular tropism of AAV8 in 
the DRG using two different delivery methods 
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4.1.1 Viral tropism in the DRG 
Viral tropism has been defined as the ability of a virus to infect a particular cell type, 
tissue or host.  To a virologist interested in tropism, „infection‟ occurs if the virus is 
able to enter the proliferative phase of its life cycle (McFadden, Mohamed et al. 
2009).  However, from the point of view of gene therapy, lytic infection is not usually 
desirable, so tropism in this context refers to the ability of a given virus to transduce 
(i.e. mediate the expression of a transgene such as gfp) a particular cell, tissue or 
host.  The focus of the following account will be on cellular tropism of AAV8 in the 
DRG. 
 
The importance of assessing the tropism of a given gene therapy vector is 
paramount.  Lack of knowledge of which cells or tissues a viral vector transduces 
renders one unable to predict the effects (or side effects) of a virally delivered 
transgene product.  At the time that these studies were performed, no published 
reports existed that described the detailed neuronal tropism of AAV8 in DRG (recall 
that DRGN have been sub-classified, discussed below), although it was known that 
this vector was able to target sensory neurones in the PNS and a variety of neuronal 
types in the CNS (Klein, Dayton et al. 2006; Storek, Reinhardt et al. 2008).   
 
4.1.2 Determinants of viral tropism 
Viral tropism is determined by a diverse array of factors at various points in the life-
cycle of the virus from attachment to the host cell membrane, to trafficking of the 
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particle in the cytoplasm and processing of the viral genome (McFadden, Mohamed 
et al. 2009).  Additionally, the detection of a transduced cell depends upon that cell 
being capable of manufacturing the transgene product within the experimental 
timescale, and that product not being overtly toxic or immunogenic (i.e. a viral vector 
may be capable of transducing cells, but the transgene delivered may kill cells or be 
cleared by the immune system, leading to an artefactual negative result).  
Furthermore, the promoter driving the transcription of the transgene mRNA must be 
appropriate to the cell being targetted, for example using a neuron-specific promoter 
to give expression in neurones but not glia.   
 
In the case of AAV8 versus other serotypes such as AAV2, relatively little is known of 
the precise mechanisms whereby the virus is able to enter cells.  It was recently 
shown that the multi-functional 67 kDa laminin receptor (LMR) can act as a receptor 
for a variety of AAV serotypes, including AAV8 (Akache, Grimm et al. 2006).  
However, at the time of writing no other receptors for AAV8 have been identified.  
Given the roles of molecules such as LMR, heparan sulphate proteoglycans and 
integrins in AAV transduction, it seems likely that the ECM plays a role in determining 
viral entry and hence may influence cellular tropism (Pajusola, Gruchala et al. 2002; 
Daya and Berns 2008).   
 
It is likely that AAV8 enters the cytoplasm in a clathrin-dependent manner, and is 
able to escape from endocytic vesicles by the enzymatic degradation of the vesicle 
membrane by capsid proteins (Daya and Berns 2008).  However, the mechanism of 
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AAV trafficking from the cytosol to the nucleus still remains unclear, with even the 
role of the nuclear pore complex yet to be elucidated.  It is probable that there are 
differences in the trafficking of different capsid proteins, which may impact upon 
cellular tropism.    
 
In the case of standard recombinant AAV vectors, once in the nucleus, the viral 
genome must be released from the capsid proteins and gain access to the nuclear 
machinery where its ssDNA genome can be converted into dsDNA.  This is thought 
to be a rate-limiting factor in AAV transduction and has led to the development of 
self-complementary AAV vectors, in which the second strand is reconstituted much 
more quickly than in standard recombinant (rAAV) vectors (Goncalves 2005).  The 
above events may impinge upon the cellular tropism observed if different vectors are 
given different genome structures leading to differential processing within the 
nucleus.  Additionally, different capsid proteins may traffic to the nucleus at different 
rates, meaning that the length of time between delivery and assessment of 
transduction rate is important – if a vector is slow to traffic, early time points may 
show spuriously poor transduction rates.  Additionally, if different cell types traffic 
vectors differentially, tropism profiles may vary at different time points.   
 
4.1.3 DRGN sub-populations 
Classification of DRGN by size is one of the commonest and most convenient 
methods in use, and has yielded unimodal, bimodal and trimodal distributions (Willis 
and Coggeshall 2004).  Bimodal size distributions are seen most commonly, leading 
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to the conclusion that DRGN can be split into two major classes – small and large 
cells (Schmalbruch 1987; McLachlan, Janig et al. 1993).  However, there is a 
significant body of evidence showing that DRGN can in fact be split into three distinct 
groups based on size, and which correlate with neurophysiological parameters such 
as axon conduction velocity (Willis and Coggeshall 2004).  DRGN have been 
separated into small, medium and large diameter populations in this study since 
much of the literature describes this classification (particularly in neurophysiology).  
 
4.1.4 AAV based vectors in the nervous system 
That AAV vectors are capable of transducing DRGN was first demonstrated 10 years 
ago by Fleming et al. who showed that an AAV2 vector expressing GFP could 
transduce all three of the major cell types of the DRG in vitro (Fleming, Ginn et al. 
2001).  This was followed by a report describing the delivery of an AAV2 vector to the 
DRG in vivo by Xu et al. who compared the transduction characteristics in the DRG 
after delivery by a variety of routes including intra-DRG and intrathecal injection (Xu, 
Gu et al. 2003).  They showed strong preferential targeting of DRGN after intra-DRG 
injection, and also transduction of dorsal horn neurones but not DRGN after 
intrathecal injection.   
 
The first description of AAV8 delivery to the nervous system was from Klein et al. 
who were able to deliver neurotoxic levels of proteins including GFP to the substantia 
nigra (Klein, Dayton et al. 2006).  Soon, DRGN were shown also to be targetted by 
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AAV8, although no data were published showing preferential transduction of DRGN 
sub-types (Foust, Poirier et al. 2008; Storek, Reinhardt et al. 2008).   
 
4.1.5 Intra-DRG versus intrathecal injection 
The two delivery techniques employed in this study each have distinct advantages 
and disadvantages in the context of spinal cord repair.  Intra-DRG injection allows 
localised delivery of relatively high concentrations of therapeutics to the DRG, 
whereas intrathecal injection is capable of delivering substances to the entire 
neuraxis, but usually at lower doses than intra-DRG injection (Fischer, Kostic et al. 
2011).  Surgically, intra-DRG injection is more traumatic and less well tolerated than 
the relatively non-invasive intrathecal injection.  If viral vectors become commonplace 
in the clinic, either of these methods of delivery are likely to be used in different 
circumstances. 
 
4.1.6 Some important assumptions 
Given the above remarks, it becomes clear that the concept of cellular tropism is a 
difficult one to explicitly define in the complex milieu of the whole animal.  Many 
factors contribute and interact, necessarily leading one to make certain assumptions 
to simplify the design of experiments and the interpretation of results.  In the case of 
the experiments performed in this chapter, it has been assumed that the intracellular 
processing of AAV8 is the same in all sub-populations of DRGN.  This is probably a 
reasonable assumption, since all DRGN share the same embryological origin and 
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hence probably process viruses in a similar manner.  Using this assumption, one can 
then state that any differential expression of transgene delivered by AAV8 is due to 
differences either in the way the virus accesses DRGN or the way it interacts with 
DRGN.  To control for the way AAV8 accesses DRGN, this study has employed two 
different delivery paradigms – one would predict that if the same cellular tropism is 
seen using more than one delivery method, it is likely that the tropism is due to how 
the virus interacts with cells and not how it gets to them.   
 
The methods of delivery employed are described in detail in Chapter 2.  Briefly, intra-
DRG injection involved surgical exposure and injection under direct vision of the left 
L4 and L5 DRG.  Intrathecal injection was performed by accessing the subarachnoid 
space in the lumbar cistern using a small needle and injecting virus into the CSF.  
AAV8gfp was kindly generated and provided by Dr. Ronald Klein.  This virus encoded 
eGFP under the control of a hybrid CMV/β-actin promoter and contained the 3' 
enhancer woodchuck hepatitis virus posttranscriptional regulatory element.   
 
4.1.7.1 Specific hypotheses 
 AAV8 transduces all subtypes of DRGN with equal frequency in vitro and in 
vivo regardless of delivery route – there is no cellular tropism 
 Transduction of DRGN will correlate with the level of expression of LMR 
 The central projections of DRGN will be completely filled with GFP 
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4.1.7.2 Specific aims 
 To classify DRGN based on their diameters and assess which of these are 
GFP+ in vitro, and also in vivo, after intra-DRG and intrathecal injection 
 To trace the central projections of GFP+ DRGN and correlate the trajectories 
of these projections with those of known populations of DRGN 
 To correlate GFP positivity in DRGN with the presence of LMR and 
parvalbumin in vivo 
 
Section 4.1.8 Brief description of methods 
A total of 18 animals (200-220g) were used in this study:  6 intra-DRG injection of 
AAV8gfp; 3 intra-DRG injection of PBS; 3 intrathecal injection of AAV8gfp; 3 intrathecal 
injection of PBS; and 3 uninjected rats comprised controls.  
 
The nine animals receiving intra-DRG PBS or AAV8gfp received injections of 10µl 
PBS alone or 1010 vg in 10µl PBS to the left L4 and L5 (L4/L5) DRG using a glass 
micropipette inserted into the DRG under direct vision, and were sacrificed 28d later, 
this being a timepoint when expression is likely to be at high levels due to the need 
for second strand synthesis (Ferrari, Samulski et al. 1996).  Animals undergoing 
intrathecal injections received either 30µl PBS alone or 1012 vg AAV8gfp in 30µl PBS 
using a 25G needle inserted into the subarachnoid space in the lumbar spine.   
 
GFP expression within DRGN was analysed by photographing entire sections of the 
DRG at an exposure time that demonstrated zero background staining in uninjected 
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animals.  All DRGN were counted and their diameters‟ recorded.  GFP positivity was 
also recorded, allowing assessment of the diameter of GFP+ DRGN.   
 
LMR and PV expression were assessed using standard immunohistochemical 
techniques, with PV expression being quantified as above.   
 
AAV8 was applied to dissociated DRG cultures in vitro at a given multiplicity of 
infection (MOI).  The MOI refers to the number of viral particles delivered per neurone 
in each chamber of the culture dish.  Cultures were left for 7d and then analysed 
using a similar technique to that described above.   
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Results 
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4.2.1 AAV8 targeted DRGN independent of delivery route   
After both intra-DRG and intrathecal injection, GFP expression (Figure 4.1A and B) 
was restricted to DRGN and their axons in DRG. No non-neuronal cells were 
transduced by AAV8gfp.  The mean transduction rate of DRGN after intra-DRG 
injection was 11.36 ± 1.63% compared to 1.48 ± 0.48% after intrathecal injection 
(Table 4.1).  A small number of DRGN were GFP+ in uninjected contralateral DRG 
after intra-DRG injection (data not shown).  The intrathecal injection experiment was 
repeated using a glass micropipette instead of a 25G needle.  Unfortunately, there 
was no transduction of any DRGN.  No GFP+ axons were seen in the cord or dorsal 
roots. 
 
4.2.2 AAV8 preferentially transduced large-diameter, parvalbumin+ DRGN   
(i) After intra-DRG injection, only 2.04 ± 0.66% small diameter DRGN were GFP+, 
compared with 14.95 ± 1.98% medium diameter DRGN and 31.79 ± 10.55% large 
diameter DRGN (Figure 4.2 Bi), correlated with a significant shift to the right of the 
size distribution of GFP+ DRGN (Figure 4.2 Bii; Mann-Whitney U test, p=6 x 10-36, 
n=6).  Additionally, the method of Vulchanova et al. was used to analyse the 
proportion of GFP+ DRGN that were less than or above 22µm in diameter 
(Vulchanova, Schuster et al. 2010).  This revealed that there were significantly more 
GFP+ DRGN with diameters greater than 22µm than GFP+ DRGN with diameters 
<22µm, implying that large-diameter DRGN were over-represented in the GFP+ 
population (t-test, p=4.4x10-7, n=6).  (ii) Similar differences in transduction rates were 
recorded after intrathecal injection of 0.04 ± 0.04% for small diameter compared with 
Figure 4.1 Cells targeted by AAV8gfp.  A.  Many GFP+/ßIII-tubulin+ DRGN cell bodies 
(asterisks) and their axons (arrowheads) were present in the DRG.  (B)  Low 
magnification view of a horizontal section through the centre of a DRG 28d after 
intra-DRG injection of AAV8gfp.  Note widespread DRGN transduction and minimal 
gross tissue disruption. (SN=spinal nerve, DR=dorsal root.  Scale bar in A = 500µm, in 
B = 50µm). 
 
SN DR 
A 
DAPI GFP ßIII-tubulin 
* * 
A 
B 
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* 
* 
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A(ii) 
B(i) 
B(ii) 
Figure 4.2  Size distribution of GFP+ and GFP- DRGN. Proportions (%) of small (0-29µm), medium (30-59µm) and large 
(>60µm) diameter (A(i) and B(i)) and size distribution (A(ii) and B(ii)) of GFP+ DRGN (green bars= GFP+; blue bars = total 
DRG population) after intrathecal (A) and intra-DRG injection (B), respectively.  A: n=3, B: n=6 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.1 Percentage transduction and diameters of total and GFP+ populations of DRGN after intra-DRG (A) and intrathecal (B) 
injection.  Alternating bold and non-bold text refers to DRGs from different animals.  In the intrathecal injection experiment one DRG 
was not analysed due to there being no ganglion tissue in any sections. 
 L4 L5 L4 L5 L4 L5 L4 L5 L4 L5 L4 L5 
Overall 
mean 
% Transduction 12.1 5.4 13.7 9.4 14.0 16.3 10.3 23.1 5.9 8.1 2.5 15.5 
11.36 
Mean DRGN cell body 
diameter (µm) 33.5 28.4 37.8 35.2 53.5 57.4 36.0 37.6 31.8 36.2 34.3 33.7 
38.0 
Mean GFP+ DRGN cell 
body diameter (µm) 46.9 34.0 50.2 49.8 65.3 74.2 47.7 47.7 43.5 56.4 46.9 42.8 
50.5 
 L4 L5 L4 L5 L4 L5 L4 L5 L4 L5 L4 
Overall 
mean 
% Transduction 0.6 0 0 0.2 5.1 2.7 1.7 1.8 2.5 0.6 1.1 
1.5 
Mean DRGN cell body 
diameter (µm) 31 33 31 31 37.8 35 61 36 33 35 36 
36.3 
Mean GFP+ DRGN cell 
body diameter (µm) 51 n/a n/a 26 54.8 52 53 51 54 54 59 
50.5 
A 
B 
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1.83 ± 0.52% medium and 16.53 ± 10.24% for large diameter DRGN (Figure 4.2Ai, ii; 
Mann-Whitney U, p=1,57 x 10-12; t-test, p=0.005, n=3).  Of medium and large 
diameter DRGN, 17.4% were parvalbumin+, compared with 33.3% of GFP+ DRGN 
(t-test, p=0.046; Figure 4.3 A, B).  
 
4.2.3 All DRGN were LMR+  
Qualitatively, all sizes of GFP+ and GFP- DRGN expressed LMR (Figure 4.4) 
suggesting that LMR may not be used exclusively by AAV8 to transduce DRGN. 
 
4.2.4 The central projections of DRGN were labelled with GFP   
(i) After intra-DRG injection (Figure 4.5), GFP+ axons entered the spinal cord at the 
DREZ, invaded the ipsilateral dorsal column and dorsal horn, and projected to the 
ventral horn, but none penetrated the contralateral grey matter, although a few were 
seen in the contralateral DREZ.  GFP+ axons projected in the ipsilateral lumbar and 
thoracic gracile fasciculi (Figure 4.5 A, B), containing less GFP at more rostral levels 
(Figure 4.5 A-C).  In longitudinal sections of the rostral lumbar cord, GFP+ axons 
exclusively projected in the ipsilateral gracile fasciculus (Figure 4.5 D).  There were 
very faint GFP+ axons in the gracile fasciculus of the cervical cord, but none in the 
medulla at the level of the ipsilateral gracile nucleus (data not shown).  No GFP+ 
neuronal somata were seen in either the spinal cord, or brainstem grey matter.  (ii) 
After intrathecal injection, the central projections of large diameter DRGN at all levels 
of the cord were labelled (Figure 4.6 A-C).  The dorsal roots and dorsal columns 
contained GFP+ axons at all cord levels, terminating in the deeper parts of the dorsal 
horn, particularly at lumbar (Figure 4.6 A) and thoracic (Figure 4.6 B) levels, with 
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Figure 4.3 Proportion of GFP+/parvalbumin+ DRGN after intrathecal injection. A.
Expression of parvalbumin in GFP- (arrows) and GFP+ (arrowheads) DRGN. B.
Proportion (%) of total parvalbumin+ DRGN compared with parvalbumin+/GFP+ 
DRGN after intrathecal injection; (t-test; p=0.046, n=3) 
A 
PV GFP merged 
A 
Figure 4.4 67 kDa laminin receptor expression in the DRG. Both GFP+ (arrows) and GFP- 
(arrowheads) DRGN expressed the LMR. Scale bar 50µm. 
LMR GFP merged 
Figure 4.5 The central projections of DRGN in the left gracile fasciculus were clearly labelled by GFP.  A. L4 
dorsal root entry zone; B. Rostral lumbar cord; C. Mid-thoracic cord (not to scale, composed of merged fields at 
100X magnification).  D.  Longitudinal section of the rostral lumbar cord (dashed line represents dorsal median 
sulcus).  a-c refer to insets demonstrated by the red boxes in A, B and C, respectively.  DREZ=solid arrow; 
gracile fasciculus=arrow heads; GFP+ axons=open arrows; dorsal horn=asterisks; ventral horn=daggers.  
Scale bar 50μm.  
A B C 
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Figure 4.6  The central projections of DRGN were clearly labelled with GFP after IT injection.  A.  Rostral lumbar cord.  
B.  Mid-thoracic cord.  C.  Mid-cervical cord.  Clarke’s column=solid arrows; cuneate fasciculus=open arrows.  Scale bar 
500µm.   
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Clarke‟s column clearly defined in the latter.  The intensity of labelling in the gracile 
fasciculus diminished in successively rostral segments, and very little was observed 
in the cervical cord (Figure 4.6 C). 
 
4.2.5 Preferential transduction of large diameter DRGN is lost in vitro 
At a multiplicity of infection (MOI) of 2 x 1010, 18.20% (S.E.M. 0.70%) of DRGN were 
GFP+.  The lack of any significant shift in the size distribution of GFP+ DRGN 
compared with total DRGN demonstrated that there was no preferential targeting of 
DRGN by AAV8gfp in vitro (Figure 4.7 A.  Mann-Whitney U; p=0.628).   Furthermore, 
there was no significant difference in the survival of DRGN in cultures exposed to 
AAV8gfp compared with those exposed to PBS (Figure 4.7 B.  t-test; p=0.744).  In 
culture, GFP+ DRGN appeared grossly normal, with neuritic trees extensively filled 
with GFP (Figure 4.7 Ci).  Additionally, Schwann cells (appearing fusiform in vitro) 
were also seen to be transduced in DRG cultures (Figure 4.7 Cii).   
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Figure 4.7  Cellular tropism of AAV8gfp in vitro.  A.  Histogram showing the 
size distribution of all DRGN and GFP+ DRGN at an MOI of 2 x 1010.  There 
was no significant difference between the distributions for total DRGN and 
GFP+ DRGN (Mann-Whitney U; p=0.628).  B.  Histogram showing survival 
counts of DRGN in cultures exposed to AAV8gfp or PBS as control.  There was 
no significant difference between the two groups (t-test; p=0.744).  C.  The 
appearance of a large diameter GFP+ DRGN in vitro (i).  Note the labelling of 
the neuritic tree.  Targeting in vitro was much less specific than in vivo, with 
many transduced Schwann cells present in culture (ii).   
n=3 
n=3 
i 
ii 
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4.3.1 DRGN transduced with AAV8gfp did not die 
Although not definitive, the correspondence between the size distribution data from 
this study and other published accounts suggests that there was no DRGN death 
after both intra-DRG and intrathecal delivery AAV8gfp (McLachlan, Janig et al. 1993).  
These observations are further backed up by the lack of toxicity observed in vitro, 
where an extremely high multiplicity of infection (MOI) was employed.  No evidence 
of gross damage was observed in the DRG after either delivery method, an 
observation in agreement with Mason (2010) who compared AAV gene delivery in 
the DRG across serotypes (Mason, Ehlert et al. 2010).  There was no evidence of 
Wallerian degeneration in the dorsal columns.  
 
The above findings are extremely interesting, given that neuronal death does occur 
when gfp is delivered to the CNS under the control of the CMV promoter (Klein, 
Dayton et al. 2006).  In Klein‟s study, toxicity attributable to AAV8 was excluded by 
showing no detrimental effects of an empty AAV8 vector.  Thus GFP may be less 
toxic to neurones of the PNS compared with those of the CNS since no cell death 
was observed in the DRG.  However, it must be emphasised that stereological 
techniques were not used to establish definitive counts of surviving DRGN.  See 
Chapter 5 for a more in-depth discussion of toxicity related to AAV8gfp.   
 
4.3.2 AAV8 targeted predominantly large diameter proprioceptive DRGN in vivo 
but not in vitro 
Size distributions of adult rat DRGN reported in the literature correlate closely with 
the results from this study, with a positively skewed distribution and modal diameter 
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of ~30µm (Natalie, William et al. 2002; Gaudet, Williams et al. 2004; Lu, Zhang et al. 
2006).  Similar distributions have been reported in studies examining cell profile 
areas after a simple square root transformation of the data (Jamieson, Liu et al. 
2005).  Here, the first detailed comparison of the cellular tropism of AAV8 after intra-
DRG and intrathecal injection is presented, which supports the assertion of 
preferential transduction by AAV8 of proprioceptive sensory neurones.  These 
neurones are large diameter, LMR+, PV+ DRGN with central projections in the dorsal 
root, ventral and dorsal horn, and dorsal columns where axons terminate in Clarke‟s 
column to be relayed in the dorsal spinocerebellar tract.  The diminution of dorsal 
column GFP labelling in successively rostral cord segments after intra-DRG injection 
is consistent with GFP+ axons leaving the dorsal column and terminating in the deep 
dorsal horn, predominantly Clarke‟s column in the thoracic and rostral lumbar cord.  
Given its tropism for large diameter, proprioceptive DRGN, AAV8 holds much 
promise for therapies directed at regaining locomotor function after SCI, since an 
essential factor for a normal gait is proprioceptive input to the spinal cord and brain 
which may be restored by therapies delivered using AAV8 vectors.   
 
The mechanism of preferential transduction of large diameter DRGN by AAV8 is not 
known.  Interaction of AAV8 with receptors differentially displayed on specific size 
classes of DRGN could explain the differential transduction of DRGN observed.  The 
archetypal AAV serotype (AAV2) enters cells by exploitation of the heparan sulphate 
proteoglycans, integrins and fibroblast growth factor receptors (Goncalves 2005) and 
AAV8 transduces mouse hepatocytes in vivo after binding LMR (Akache, Grimm et 
al. 2006).  However, this study failed to observe any relationship between the 
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expression pattern of laminin receptor and the transduction efficiency of AAV8, 
suggesting that laminin receptor is not necessary or sufficient for DRGN transduction 
by AAV8.  The finding that preferential targeting of DRGN by AAV8 is lost in vitro has 
some interesting possible explanations.  One compelling idea, consistent with what is 
already known about AAV in general, is that the ECM has a role in transduction of 
DRGN.  In vitro, the ECM will be considerably different to that seen in vivo, possible 
leading to deficiency of ECM components necessary for transduction of large 
diameter DRGN by AAV8.  However, the results of the in vitro experiment described 
must be interpreted carefully due to the high dose of AAV8 used.  Such high 
concentrations of vector could possibly overcome a putative „threshold‟ level for 
smaller diameter DRGN leading to the result obtained, although if this were true then 
one may just see even higher levels of transduction of large diameter DRGN than 
seen in vivo.   
 
AAV8 based vectors are useful to research groups using the dorsal column injury 
model, since many of the axons comprising the dorsal column project from large 
diameter DRGN.  The exclusion of small diameter DRGN as AAV8 targets would 
reduce the incidence of NGF-induced lowered pain thresholds after AAV8ngf 
therapeutic delivery (Dyck, Peroutka et al. 1997).  Moreover, intracerebro-ventricular 
delivery of NGF stimulates sympathetic axon sprouting within DRG, which could also 
contribute to neuropathic pain (Nauta, Wehman et al. 1999). 
 
An assessment of viral vector neuronal tropism is also important in the selection CNS 
injury models for gene therapy treatments.  For example, mid-thoracic (T8) cord 
139 
 
transections are commonly used to evaluate the success of gene based therapeutics 
delivered to L4/L5 DRG in axon regeneration studies (Gonzalez, Berry et al. 2006).  
However, given that almost 50% of AAV8-transduced DRGN are PV+, whose dorsal 
column projections terminate in the caudal half of Clarke‟s column (LaMotte, Kapadia 
et al. 1991), a T8 lesion would fail to transect proprioceptive axons from L4/L5 DRG; 
a lesion placed more caudally (i.e., at L1) would be required to transect GFP+ 
proprioceptive axons in this paradigm (see Figure 2.3). 
 
4.3.3 AAV8gfp transduces DRGN via the CSF   
The transduction rate of DRGN after intrathecal delivery was low, and comparable to 
that seen in other reports (Vulchanova, Schuster et al. 2010).   
 
Delivery of AAV8 successfully transduces neurones (Klein, Dayton et al. 2006) in, for 
example: (1), multiple brain regions including neocortex and striatum after intra-
cerebral ventricular injection (Broekman, Comer et al. 2006); (2), the cord after 
intrathecal injection (Storek, Reinhardt et al. 2008); and (3), in DRG where DRGN 
become transduced after intramuscular (Zheng, Qiao et al. 2009), intravenous, and 
intraperitoneal  injections Foust, 2008 #266}.  These and our findings are consistent 
with AAV8 being unable to cross the ependyma, pia and blood-brain barriers. 
 
The routes of access of AAV8 to DRG from the CSF are unknown, although diffusion 
across the arachnoid membrane is most likely since epidurally delivered HRP quickly 
enters DRG, probably by direct diffusion (Byrod, Rydevik et al. 2000).  Diffusion may 
be facilitated at portals of entry where CSF and DRG neuropil are in continuity at: (1), 
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the DREZ where a sleeve of the relatively impermeable dorsal root sheath is open 
(Haller, Haller et al. 1972); and (2), the „lateral arachnoid recess‟ of the DRG (an 
evagination of the arachnoid, usually filled with macrophages) (Himango and Low 
1971).  It is likely that, after intra-DRG injection of AAV8, these portals allow the 
egress of the vector into the CSF accounting for occasional transduction of DRGN in 
contralateral uninjected DRG. 
 
The failure of the second intrathecal injection experiment where a pulled glass 
micropipette was used instead of a 25G needle is puzzling.  An identical amount of 
AAV8 gfp was injected and confirmation of injection to the subarachnoid space was 
made by observation of CSF entering the glass capillary tube.  Animals made an 
unremarkable recovery, and the dissected tissues (DRG, dorsal roots and cords) 
appeared no different from tissues from animals from the previous experiment.  Two 
possible explanations arise: experimental error or some essential difference between 
injection with a metal needle compared with injection using a glass micropipette. 
 
Experimental error seems unlikely in this case, since the author made up the 
appropriate dilution of AAV8 gfp in two batches on two separate days.  These dilutions 
were, however, made using the same batch of undiluted virus.  To determine if the 
original viral batch was active, some of this was applied to COS-1 cells in vitro.  From 
1-2 days post inoculation, COS-1 cells were seen to be GFP+ although no 
comparison was made with a „gold-standard‟ batch of virus.   
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The second possible explanation could be that there is something about intrathecal 
injection using a metal needle that facilitates transduction of DRGN or something 
about injection using a glass micropipette that inhibits transduction.  It is certain that 
needle injection is more traumatic to the animal than when using a glass 
micropipette.  Both injections employ the same surgical approach, but the needle is 
advanced much further into the lumbar cistern than the glass micropipette.  Much of 
the CSF refluxing into the needle cup was blood-stained compared with almost none 
of the CSF entering the glass micropipette.  Perhaps trauma and/or subarachnoid 
haemorrhage facilitate transduction of DRGN by AAV8 gfp?  A study by Murata et al. 
showed that peri-DRG inflammation induced by application of nucleus pulposus led 
to increased permeability of the DRG capsule (Murata, Rydevik et al. 2005).  Nucleus 
pulposus, the jelly-like material forming the core of intervertebral discs, is a 
commonly used pro-inflammatory substance injected into the tissues around the 
DRG.  It is feasible that the use of a needle to inject AAV8gfp intrathecally could have 
led to inadvertent rupture of intervertebral discs, particularly because one of the signs 
of successful injection was a tail-flick caused by contact of the needle with ventral 
roots which lie close to the dorsal aspect of the intervertebral discs.  Also, it is 
possible that the presence of blood in the CSF has similar pro-inflammatory effects to 
nucleus pulposus.   
 
A second possibility is that the presence of blood within the CSF after needle 
injection could have sealed off the hole created in the meninges, inhibiting egress of 
the virus from the CSF into surrounding tissues.  The lack of bleeding after glass 
micropipette injection may have left a hole in the meninges that did not seal.  This 
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seems an unlikely explanation, since the glass micropipette was left in situ for around 
10s after injection, to allow the injectate to distribute within the CSF.  Also, one would 
expect some transduction since the probability of egress of all of the viral particles 
injected seems highly unlikely.   
Additionally, there are potential technical issues surrounding the use of glass 
micropipettes, such as the possibility of AAV8 particles binding to the glass itself 
(Ann Logan, personal communication).  However, this seems unlikely as an 
explanation here since glass micropipettes were used to perform intra-DRG injections 
which were successful.   
 
4.3.4 Can the predilection of AAV8 for large DRGN be explained by the data 
presented above? 
The evidence for AAV8 showing a preference for transducing large diameter DRGN 
is strong.  That this phenomenology exists and can be replicated in a number of 
different delivery paradigms shows that it has great potential in a clinical setting.  
However, the question of how AAV8 does this remains a pertinent one from both the 
point of view of the basic scientist and that of the clinician who may wish to 
pseudotype other vectors to confer upon them a tropism for large DRGN.  The 
mechanism of the cellular tropism described could be explained under one (or more) 
of the following headings: physical, chemical and artefactual. 
 
Two major physical mechanisms that could have roles with respect to AAV8 and 
DRGN are surface area and volume.  If it is assumed that in 100 DRGN within an 
hypothetical DRG, 20 are large diameter (say 60µm) and 80 are small diameter (say 
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10µm), then some simple calculations reveal that, despite the fact that the large 
diameter DRGN are in the minority, they actually possess some 90% of the surface 
area and 98% of the volume of the ganglion as a whole (excluding gaps between 
cells).  Hence it would appear that there is a very simple explanation for the observed 
cellular tropism.  However, closer inspection of the data reveals that surface area is 
unlikely to be solely responsible, since one would predict an exponential relationship 
between DRGN diameter and frequency of GFP+ DRGN as opposed to the observed 
normal distribution of GFP+ DRGN diameters.  Furthermore, it is likely that surface 
area to volume ratio is a more valid physical parameter than either measure alone.  
Within the parameters set out above, small diameter DRGN are seen to have surface 
area to volume ratios around 6 times greater than larger cells – so this would predict 
that smaller DRGN should be preferentially transduced.  Hence, it seems unlikely that 
physical factors are solely responsible for the cellular tropism seen. 
 
Probably the most likely explanation for the observed cellular tropism of AAV8 is the 
presence of specific surface molecules on a sub-population of DRGN that facilitate 
viral entry.  The expression of such molecules is likely to be normally distributed on a 
particular subset of cells, which would explain the normal distribution of diameters of 
GFP+ DRGN.  It is already known that one receptor exploited by AAV8 to transduce 
hepatocytes is LMR (Akache, Grimm et al. 2006), although a defining role for this has 
been excluded in this study since all DRGN were found to be LMR+.  It must be 
emphasised, however, that this finding was qualitative – no quantification of LMR 
expression was performed, which may have revealed a small but statistically 
significant effect.  Also, since histochemical detection of LMR in the DRG is novel, it 
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would have been ideal to fully validate the findings (see below in further work).  
Other, yet to be discovered, molecules are likely to be exploited by AAV8 to enter 
DRGN.  This study has highlighted the potentially important role of ECM components 
in AAV8 transduction.   
Finally, the contribution of experimental artefacts to the results obtained must be 
considered.  The term „artefact‟ describes an uncontrolled factor in an experiment, 
usually in the tissue processing, data capture and analysis stages.  Great care was 
taken to ensure that tissue distortion during sample preparation and cryostat 
sectioning was minimised by examining selected sections under phase contrast 
microscopy to ensure that DRGN cell bodies were not artefactually distorted.  Tissue 
blocks and sections were always stored appropriately and in the same conditions for 
all groups.  Micrographs were taken using identical exposure settings where 
appropriate, and sections were stored in the dark to minimise bleaching of GFP.  
DRGN were counted using strict criteria by one experienced individual, described in 
Chapter 2.   
 
Artefacts arising from technical factors are generally easier to control for than those 
due to unforeseen effects of an agent.  In the experiments described above, it has 
already been noted that there was no formal assessment of DRGN survival in vivo.  
This deficiency is due to lack of experience of the author with stereological 
techniques and lack of time to become trained in these methods.  It would have taken 
the author a number of months to become sufficiently competent in the theory and 
practice of stereological methods necessary for this study, and a lack of time 
prevented this.  The specific problems caused by lack of survival data could include: 
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(i) AAV8gfp may have transduced small diameter DRGN, but these neurones may be 
highly susceptible to GFP toxicity.  Their death would have led to an apparent shift in 
the GFP+ DRGN size distribution; (ii) AAV8 gfp may enter DRGN with large surface 
areas, but these cells may have died due to high viral loads, giving the appearance of 
a normally distributed GFP+ DRGN population, or (iii) some other, more subtle factor 
due to the inflammatory response in the DRG to AAV8 gfp inoculation may be at play, 
altering the size distribution of total DRGN.  Furthermore, it may be possible that 
GFP+ DRGN are swollen by an as yet unidentified effect of GFP, although this 
seems unlikely since the central projections of these cells are consistent with large 
diameter DRGN.  See Chapter 5 for more detail on inflammatory responses due to 
AAV8 gfp.   
 
4.4 Further work 
The elucidation of molecular mechanisms determining the tropism of viral vectors is a 
growing and fruitful field.  Identification of the ways in which viruses enter cells in 
order to transduce them allows one to pseudotype other viruses, thus targeting them 
to a cell of interest.  Additionally, one may be able to increase the transducibility of 
cells that are refractory to viral transduction (e.g. by ECM manipulation).  The work 
presented here is primarily phenomenological, showing that AAV8 is capable of 
preferentially transducing a particular sub-population of DRGN.  However, if the 
precise mechanism of this phenomenon is to be found then more detailed 
experimental work must be undertaken. 
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Dose-response studies 
Due to constraints on time and resources, various doses of AAV8 were not use in 
vitro or in vivo.  Such studies are necessary in order to find the optimum dose of 
AAV8 that gives the maximal transduction with minimal toxicity.  It may be the case 
that the transduction rates of different sub-populations of DRGN are different at 
different doses of AAV8.  Also, if a lower dose was found to give equivalent 
transduction rates as higher doses this would be preferred on both economical and 
ethical grounds.   
 
Stereological assessment of DRGN death 
Due to reasons described above, it is necessary to accurately quantify DRGN 
survival after injection of AAV8.  Without this, one cannot be fully convinced that the 
results shown were not confounded by toxicity. 
 
The use of a labelled AAV8 particle 
In order to follow the route which AAV8 takes in order to access DRGN, it would be 
interesting to add a tag to the viral capsid (e.g. GFP or other fluorophore).  This 
tagged virus could be injected and animals sacrificed at different time-points (short 
(minutes to days), medium (days to weeks) and long-term (weeks to months)) to see 
where the particles have travelled.   
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Studies to identify the molecular events in AAV8 transduction 
This study showed qualitatively that LMR has no role in transduction of DRGN by 
AAV8.  Further, quantitative studies must be performed in order to confirm this and to 
show if any other molecules have a role to play.  The methodology used to quantify 
parvalbumin expression could be used for other candidates (e.g. integrins).  If a 
candidate was found, its role could be further confirmed by injecting AAV8 into the 
DRG alongside an antibody to the candidate molecule.  It would be predicted that the 
antibody would lead to lower DRGN transduction rates compared to control injections 
using a neutral antibody (e.g. anti-GFP).   
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Chapter 5 
Inflammatory and glial responses to AAV8-
mediated transgene delivery 
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An important step that should ideally be included in the validation of viral vectors for 
gene therapy is the evaluation of immunological responses to (i), the vector particle 
itself and (ii), the transgene product that is to be delivered.  This is vital not only from 
the point of view of translation into humans, but also with respect to experimental 
confounding – an issue that will be discussed below. 
 
5.1.1 Basic immunology – a brief review 
The mammalian immune system consists of a complex, interacting network of cellular 
and biochemical defences.  The reader is referred to the excellent textbook by 
Murphy et al. for further information on generic aspects of immunology (Murphy, 
Travers et al. 2008).  Unless an additional citation is provided, Murphy et al. was the 
source for the rest of this section.   
 
One must consider immune responses both with respect to the mechanism of the 
response and the tissue in which the response is occurring.  The immune system has 
two major ways in which it is able to deal with pathogens or other tissue insults (for 
the purposes of this section, AAV8 can be considered a „pathogen‟ even though the 
wild-type virus has no known role in disease).  A response can either be innate or 
adaptive, and each of these contains humoral and cellular elements.  The innate 
immune response has ancient origins, and is found in most animals.  It is able to act 
rapidly, in a non-specific way to clear pathogens or tissue debris.  Humoral 
components of the innate immune system include complement (a protein network 
capable of binding to pathogens, marking them for destruction by cellular elements) 
and lytic enzymes such as lysozyme.  Cellular elements of the innate immune system 
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include macrophages, neutrophils and mast cells.  These cells are able to react to 
insults non-specifically by phagocytosing pathogens or tissue debris or releasing 
cytokines that serve to augment the response.   
 
Components of the innate immune response are usually the first to arrive at the onset 
of an insult.  They rapidly clear any pathogenic material, but their effects are 
relatively short-lived and they have no memory of previous insults.  Adaptive 
immunity is required for a longer term response which is capable of being re-
activated at short notice in the future by the same pathogen (immunological 
memory).  As with innate immunity, the adaptive immune system consists of cellular 
and humoral elements.  The major cellular elements include B-cells, T-cells and 
antigen presenting cells (APC). Adaptive immune responses are initiated by an APC 
phagocytosing an antigen, processing it and presenting it in a suitable form on its cell 
surface.  Cells that behave as APCs include macrophages and B-cells, which present 
fragments of pathogen-derived antigen on the major histocompatibility complex class 
II molecule (MHCII).   
 
Macrophages bind antigen via molecules expressed on their cell surface such as 
scavenger receptors (e.g. CD68).  These receptors are non-specific and bind to a 
wide range of pathogenic material.  B-cells are coated with a specific immunoglobulin 
(the B-cell receptor) which binds a single, specific antigen.  Binding of antigen to 
either scavenger receptors or B-cell receptor leads to endocytosis of the resulting 
complex and intracellular proteolytic degradation.  The resulting peptide fragments 
are loaded onto MHCII and displayed on the surface of the macrophage or B-cell.   
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APCs displaying antigen fragments on MHCII travel to lymph nodes where they are 
able to encounter T-helper cells, which recognise single, specific antigen fragments.  
Binding of the T-cell receptor to the displayed antigen fragment on a macrophage or 
B-cell leads to clonal expansion of the T cell (including production of some memory 
T-cells, primed for future insults) and a further cascade of events depending upon the 
APC.  Activation of macrophages by T-helper cells leads to the release of 
macrophage activating signals such as interferon-ɣ (IFN-ɣ) that attract macrophages 
and augment their phagocytic abilities (including up-regulation of scavenger 
receptors).  Activation of B-cells by T-helper cells leads to clonal expansion of the B-
cell into a plasma cell population (cells which produce antibody – basically a soluble 
form of the B-cell receptor) and a memory B-cell population.   
 
The pathways described above are effective in dealing with extracellular pathogens 
such as bacteria, which are bound by antibodies and cleared by phagocytes.  Viruses 
pose a different challenge to the immune system, in that they are present within cells 
for a large part of their life-cycles.  The immune system is capable of repelling viral 
attacks thanks to the presence of so-called cytotoxic T-cells.  Most cells in the body 
(except neurones, see below) express the major histocompatibility complex class I 
molecule (MHCI).  Much like MHCII, MHCI displays small peptides derived from 
antigens.  The source of the antigens for MHCI is intracellular proteins that have 
been degraded by the proteasome, an intracellular proteolytic complex.  The 
proteasome degrades most endogenous proteins, the resulting fragments of which 
are loaded onto MHCI and lead to no immune response.  Exogenous intracellular 
proteins, such as those derived from viruses being manufactured within the cell, are 
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also expressed on MHCI.  Cytotoxic T-cells bind MHCI and will kill the cell if it is 
displaying foreign proteins.  Such cell killing will serve to halt the production of virus 
within that cell and so curb an infection.   
 
5.1.2 The concept of immunological privilege 
The events described above occur in most body regions that are accessible to the 
immune system.  Certain tissues, however, have a specialised milieu that is capable 
of regulating (usually attenuating) the immune response that occurs following an 
insult.  The classic model of immunological privilege arose from skin grafting 
experiments into the brain, performed by Medawar (Medawar 1948).  In these 
experiments, Medawar noted that the implantation of a piece of skin from one animal 
into the brain of another failed to elicit an immune response.  However, if skin was 
implanted into the brain and into the skin, an immune response to the skin within the 
brain was seen.  The interpretation of these findings was that the brain was capable 
of being the recipient of an immune response (i.e. it had an efferent arm) but could 
not initiate an immune response itself (i.e. it did not have an afferent arm).  An 
interpretation of these findings was that the BBB was regulating the activity of the 
immune response in the brain.  The work of Medawar and many others both before 
and after him led to the formation of a number of erroneous interpretations about the 
properties of the BBB, many of which persist today (Bechmann, Galea et al. 2007).  It 
is probably best to consider the CNS not as being devoid of an immune response, 
but as regulating inflammatory responses in such a way that damage to its precious 
neurones is minimised.  The reader is reminded that frequently immune responses 
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are destructive, often leading to the death of many cells (consider the role of 
cytotoxic T cells in viral infections, see above).   
 
Much less is known about the immune status of the PNS than the CNS.  What can be 
said is that there is a blood-nerve barrier similar to that seen in the CNS, but probably 
not as „hermetic‟ (Kieseier, Hartung et al. 2006).  Most of what is known about PNS 
neuroimmunology comes from clinical studies or those using mice induced to 
develop so-called experimental acute neuritis.  There is a paucity of reports 
examining the basic immunological processes occurring within PNS.  One interesting 
feature of the PNS, however, is the relatively permeable environment of the DRG 
compared to peripheral nerves and roots.  After injection of fluorescein, a small 
fluorescent molecule by routes including intravenous and intrathecal, the DRG was 
seen to contain a large amount of fluorescence whereas the sciatic nerve had 
minimal signal (Abram, Yi et al. 2006).  The results of this experiment and a previous 
report using HRP support the idea that the DRG has permeable vessels, and is likely 
to be freely patrolled by elements of the immune system (Byrod, Rydevik et al. 2000).  
However, there are still many unknowns concerning PNS immunology, not least 
being the lack of data concerning lymphatic drainage of peripheral nerves and the 
DRG.   
 
5.1.3 Why look for inflammatory responses to gene therapy vectors? 
It must be stressed that the experiments described hereafter were not performed 
from a purely esoteric point of view.  There are sound biological reasons why 
inflammatory responses to therapies need to be elucidated, particularly in the field of 
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CNS axon regeneration.  The experiments employing injection of AAV8gfp were the 
necessary prequel to subsequent studies looking at the effect in animals receiving 
DC lesions of AAV8 vectors containing nt-3 and/or shRNARhoA (see Chapters 3 and 
6).   
The significance of inflammation in the study of spinal cord injury is a subject of much 
controversy (Chan 2008).  Clearly, without inflammatory responses elements such as 
the glial scar would be unlikely to form.  However, there is also a large body of 
evidence pointing to the ability of inflammation to stimulate axon regeneration.  For 
example, it has been shown that initiation of an inflammatory response in the DRG 
can augment regeneration of DRGN central projections in the dorsal root (Lu and 
Richardson 1991).  Conditioning lesions have some inflammatory features, and it is 
well documented that previous sciatic nerve injury can improve axon regeneration in 
the subsequently lesioned DC (Neumann and Woolf 1999).  Furthermore, injection of 
pro-inflammatory molecules such as zymosan into the vitreous chamber of the eye 
leads to robust axon regeneration in the crushed optic nerve (Ahmed, Aslam et al. 
2010).  It seems from these data that inflammation at or near the cell body of a 
neurone can increase its regenerative capacity.  Of course, this is beneficial and 
opens many avenues for therapies.  However, it is a possibility that inflammation can 
be introduced into experiments as a consequence of viral vector delivery.  This has 
the potential to confound experiments, particularly if the inflammatory characteristics 
of, say, the experimental viruses have not previously been examined in comparison 
to a control virus.   
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5.1.4.1 Specific hypotheses 
 The delivery of AAV8gfp does not lead to an appreciable inflammatory 
response after either intra-DRG or intrathecal injection 
 The delivery of AAV8gfp does not lead to an appreciable change in the level of 
CNS glial activation after either intra-DRG or intrathecal injection 
 The delivery of AAV8gfp does not lead to degeneration of DRGN central 
projections 
 
5.1.4.2 Specific aims 
 To assess the inflammatory response in the DRG to intra-DRG and intrathecal 
injection of AAV8gfp compared with injection of PBS alone.  Specifically, the 
responses of macrophages and satellite cells will be assessed using 
immunohistochemistry 
 To assess the levels of microglial and astrocytic activation in various regions 
of the rostral lumbar spinal cord after intra-DRG and intrathecal injection of 
AAV8gfp using immunohistochemistry and image analysis 
 To assess whether there is Wallerian degeneration of DRGN central 
projections in the DC after intra-DRG injection of AAV8gfp using Oil Red O 
staining 
 
5.1.5 Brief description of methods 
The tissue obtained from the animals used in the experiment described in Chapter 4 
were analysed for evidence of glial activation and inflammatory responses.  To re-
iterate, a total of 18 animals (200-220g) were used in this study:  6 intra-DRG 
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injection of AAV8gfp; 3 intra-DRG injection of PBS; 3 intrathecal injection of AAV8gfp; 3 
intrathecal injection of PBS; and 3 uninjected rats comprised controls.  
 
The six animals receiving intra-DRG PBS or AAV8gfp received injections of 10µl PBS 
alone or 1010 vg in 10µl PBS to the left L4/L5 DRG using a glass micropipette 
inserted into the DRG under direct vision, and were sacrificed 28d later.  Animals 
undergoing intrathecal injections received either 30µl PBS alone or 1012 vg AAV8gfp 
in 30µl PBS using a 25G needle inserted into the subarachnoid space in the lumbar 
spine.   
 
The presence of inflammatory and glial cells in DRG and cord sections was assessed 
using standard immunohistochemical techniques.  Glial (astrocytic and microglial) 
activation was quantified by taking photomicrographs of various regions white and 
grey matter in the rostral lumbar cord, using an exposure time that yielded no 
background in tissue from uninjected animals.  A pixel-counting methodology was 
applied to fields of view taken from the various regions in animals injected with PBS 
and AAV8, allowing assessment of the level of glial activation.   
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Results 
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5.2.1 Macrophages infiltrated the DRG after both intra-DRG and intrathecal 
delivery and satellite cells upregulated expression of CD68   
 
The DRG from control, uninjected animals contained sparse CD68+ macrophages, in 
contrast to DRG from animals receiving intrathecal PBS, where a few macrophages 
could be seen (Figure 5.1A).  Intra-DRG (Figure 5.2) and intrathecal (Figure 5.1) 
injection of AAV8gfp resulted in high levels of CD68
+ immunoreactivity in the DRG, 
within morphologically identified haematogenous macrophages and satellite cells.  
Macrophages were not seen to enter the spinal cord after intrathecal injection of PBS 
or AAV8gfp, their presence ending abruptly at the DREZ (Figure 5.3 C).   
 
5.2.2 Microglia and astrocyte activation after AAV8gfp injection   
After intra-DRG injection of AAV8gfp, CD11b (a microglial marker) immunoreactivity in 
the ipsilateral deep dorsal horn was upregulated compared with PBS injected 
animals (t-test with Bonferroni correction (alpha=0.0083). p=0.0018; Fig. 5.4).  
Interestingly, there appeared to be a trend towards a reciprocal decrease in CD11b 
staining in white matter compared to grey matter.  After intrathecal injection of either 
PBS, or AAV8gfp, microglial activation in the cord was qualitatively no different from 
that of uninjected rats (Figure 5.5).  A spatial correlation was observed between the 
presence of AAV8gfp within grey matter projection areas of the cord (such as Clarke‟s 
column) and CD11b expression. 
 
Compared to intra-DRG PBS injected controls, after AAV8gfp delivery there was a 
quantitative increase in astrocyte activation in the rostral lumbar cord in all regions 
Figure 5.1 CD68 staining in DRG sections from (A) intrathecal PBS injected controls and (B) intrathecal AAV8gfp injected 
animals. There is an increase in the number of CD68+ macrophages (white arrows) in DRG from AAV8gfp injected animals 
(D) compared to control (C). Morphologically identified CD68+ satellite cells (green arrow) are also present in the DRG 
from AAV8gfp injected animals. SN = spinal nerve, DR = dorsal root, VR = ventral root. Scale bar for composites (A+B) = 
500μm. Scale bar for individual images (C+D) = 50µm.  
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Figure 5.2 CD68 immunoreactivity in the DRG after intra-DRG and intrathecal 
injection of AAV8gfp. CD68+ macrophages (arrows) can be differentiated from 
CD68+ satellite cells (arrowheads) on morphological grounds. Scale bar = 50μm.
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Figure 5.3 CD68 staining in coronal lumbar spinal cord sections from (A) un-
injected controls, (B) intrathecal PBS injected controls and (C) intrathecal 
AAV8gfp injected animals. Scale bar for composites (A – C) = 500μm. White 
arrow indicates CD68+ macrophages in the dorsal root.  Scale bar for individual 
images (D – I) = 50µm.  
 
H 
CD68 DAPI GFP  
A 
B 
GFP  CD11b  DAPI 
* 
Figure 5.4 Assessment of microglial activation by CD11b immunohistochemistry in 
various regions of the rostral lumbar cord after PBS versus AAV8gfp intra-DRG 
injection.  A.  Morphological appearance of activated microglia within Clarke’s 
column ipsilateral to an L4/L5 intra-DRG injection of AAV8gfp.  Scale bar=50μm.  B.  
Quantification of microglial activation in various regions of the rostral lumbar spinal 
cord after PBS (blue bars) and AAV8gfp (green bars) intra-DRG injection.  LDC – 
left dorsal column, RDC – right dorsal column, LSDH – left superficial dorsal horn, 
RSDH – right superficial dorsal horn, LDDH – left deep dorsal horn, RDDH – right 
deep dorsal horn. t-test with Bonferroni correction (alpha=0.0083). *: p<0.0083 
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Figure 5.5 CD11b staining in coronal lumbar spinal cord sections from (A) un-
injected controls, (B) intra-DRG PBS injected controls and (C) intra-DRG 
AAV8gfp injected animals. Scale bar for composites (A-C) = 500μm. Scale bar for 
individual images (D-I) = 50µm.  
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examined (Fig. 5.6).  However, only in the contralateral dorsal column did the 
increase in GFAP immunoreactivity reached significance (t-test with Bonferroni 
correction (alpha=0.0083) : p=0.0047).  Intra-DRG PBS injection did not increase the 
level of astrocyte activation (not shown).  Qualitatively, there was no evidence of 
astrocyte activation on the basis of GFAP immunohistochemistry after intrathecal 
injection of PBS or AAV8gfp compared with uninjected controls (Figure 5.7). 
 
5.2.3 No degeneration of DRGN central axon projections after intra-DRG 
delivery of AAV8gfp   
Oil-Red-O staining revealed no evidence of myelin breakdown products within the 
dorsal columns after intra-DRG injection of AAV8gfp (Figure 5.8 A, B).  A positive 
control using optic nerve sections 14d after an optic nerve crush injury that transects 
all axons (Berry, Carlile et al. 1996; Berry, Carlile et al. 1999) revealed clear Oil-Red-
O staining in the distal optic nerve stump and lesion site (Figure 5.8, C-E). 
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Figure 5.6 Assessment of astrocytic activation by GFAP immunohistochemistry in 
various regions of the rostral lumbar cord after PBS versus AAV8gfp intra-DRG 
injection.  A.  Morphological appearance of activated astrocytes within Clarke’s column 
ipsilateral to an L4/L5 intra-DRG injection of AAV8gfp.  Scale bar=50μm.  B.  
Quantification of astrocytic activation in various regions of the rostral lumbar spinal 
cord after PBS (blue bars) and AAV8gfp injection.  LDC – left dorsal column, RDC – 
right dorsal column, LSDH – left superficial dorsal horn, RSDH – right superficial 
dorsal horn, LDDH – left deep dorsal horn, RDDH – right deep dorsal horn. t-test with 
Bonferroni correction (alpha=0.0083). *: p<0.0083 
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Figure 5.7 GFAP staining in coronal spinal cord sections from (A) un-injected 
controls, (B) intrathecal PBS injected controls and (C) intrathecal AAV8gfp 
injected animals. Scale bar for composites (A-C) = 500μm. Scale bar for 
individual images (D-I) = 50µm.  
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Figure 5.8 Oil-Red-O staining reveals no evidence of Wallerian degeneration 
within the DC.  A.  Overview of horizontal section of cord at ~0.75mm depth from 
dorsal surface.  B.  High power view of left DC shown in A.  C.  Distal stump of 
optic nerve, crushed 14d previously, demonstrating strong red staining, indicative 
of axon degeneration.  D, E.  High power views of distal stump (D) and lesion site 
(E) demonstrating the expected appearance of Wallerian degeneration in the optic 
nerve including lipid droplets at the lesion site (asterisk).  Scale bar = 50µm.  
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5.3.1 Why look for inflammatory responses? 
At the onset of this study, it was felt that gene therapy vectors based on AAV8 were 
probably harmless due to the inability of AAV to cause any known disease.  
Additionally, fluorescent proteins were considered harmless and non-toxic due mainly 
to their widespread use as reporters in gene therapy studies and the „received 
wisdom‟ from many workers that they were inert within the cell.  However, some early 
results seemed to suggest that delivery of AAV8gfp to DRGN was not without 
problems.  After intra-DRG injection, GFP+ axons of AAV8gfp transduced DRGN had 
grossly enlarged calibres, often seen as swellings between segments of apparently 
normal axon (see Figure 4.5).  Normally, axons in the DC have diameters of around 
1-2µm, whereas some of those seen in the transduced DC had diameters an order of 
magnitude higher at around 10-15µm (Nashmi and Fehlings 2001).  This was clearly 
abnormal and prompted an effort to look for inflammatory responses to this vector in 
the DRG and cord.   Interesting questions remained, however, concerning the 
mechanism of this axonal swelling and whether it could be a cause (or an effect) of 
an inflammatory response (see below). 
 
5.3.2 The DRG contains a sparse resident macrophage population 
The observation that the DRG contains occasional CD68+ macrophages is in 
keeping with a number of reports in the literature (Hu and McLachlan 2003; Hu, 
Bembrick et al. 2007; Kim and Moalem-Taylor 2011).  The ED1 (anti-CD68) antibody, 
used to detect macrophages in this study, is known to detect up to 98% of 
macrophages in the rat (Dijkstra, Dopp et al. 1985).  As with macrophages found in 
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other tissues, the function of these cells in the DRG is to act as part of the initial, 
innate immune response to tissue damage or infection.  Around 35% of the 
macrophages within intact DRGs are also positive for MHCII, implying that they have 
a role in antigen presentation and possibly elicitation of T cell responses (Hu and 
McLachlan 2003).  Additionally, it is known that these macrophages phagocytose 
neuronal debris within the DRG (Hu and McLachlan 2003).   
 
An interesting question concerning the macrophages seen in naive DRGs relates to 
the proportion of them which are truly resident.  The term „resident‟ in this context 
refers to cells that stay within their tissue, and are not simply passing through.   It has 
been shown using bone-marrow chimaeric mice that there is a turnover of 
macrophages in the DRG of around 80% (Muller, Leonhard et al. 2010).  This implies 
that around 20% of the macrophages seen in the DRG are truly resident.  It is likely 
that these resident macrophages have important roles as first-line defences, being 
capable of mobilising the migration of additional macrophages into the DRG following 
tissue insults.  A richer knowledge of these resident macrophages may provide the 
potential for finer tuning of inflammatory responses in the DRG following insults.   
 
5.3.3 Intrathecal and intra-DRG injection of AAV8gfp led to a robust 
macrophage response in the DRG 
Regardless of delivery method, macrophages became activated and more numerous 
in the DRG 28d after injection of AAV8gfp but not after PBS injection.  This 
observation strongly suggests that macrophages were activated as a consequence of 
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the viral vector and not due to direct trauma following intra-DRG injection.  It is not 
appropriate to discuss the degree of macrophage activation seen in the two delivery 
paradigms due to essential differences between the two techniques – particularly the 
fact that the concentration of AAV8gfp particles in the DRG in either paradigm is 
unknown.   
 
So how are DRG macrophages activated by AAV8gfp?  This question is ostensibly a 
simple one to answer, but further enquiry regarding the specifics of the immune 
response to AAV vectors leads one to the conclusion that AAV immunology is still in 
its infancy.  A full explanation of the observed phenomenology is impossible without 
much further work. 
 
In a tissue such as the DRG, whose immune response has not been extensively 
elucidated, one must be cautious when discussing immunological phenomena.  If 
extrapolations are to be made from other tissues, it must be ascertained that the 
immunological components found in those tissues are also present within the DRG.  
Furthermore, available data must be used to determine whether those components 
behave in the same way as is seen in other tissues.  A paucity of data on basic 
immunological responses in the PNS makes this a challenging task. 
 
Before discussing immunology, it must be assumed that AAV particles are present in 
the DRG after injection by both routes.  Clearly, this must be the case after intra-DRG 
165 
 
injection and it is reasonable to suppose that vector particles must access cell bodies 
to transduce DRGN after intrathecal injection (see Chapter 4).  One must also be 
aware that it is possible that some AAV particles enter the lymph draining the DRG or 
the CSF, potentially leading to both local and systemic inflammatory responses.  
However, there is only very limited evidence demonstrating lymphatic drainage from 
the DRG, although it is known that CSF does drain to the cervical lymph nodes 
(Kuhlmann, Bitsch et al. 2001; Weller, Galea et al. 2010).   
 
It is becoming increasingly recognised that components of the innate immune system 
known as Toll-like receptors (TLRs) are important in initiating immune responses to 
AAV vectors (Zhu, Huang et al. 2009).  TLRs, of which around 10 have been 
identified in humans, are part of the innate immune response and are capable of 
detecting a wide range of pathogenic material (Murphy, Travers et al. 2008).  TLRs 
are present both extracellularly on the plasma membrane and intracellularly within 
endosomes and respond to a diverse array of pathogen-derived ligands such as 
lipopolysaccharide, double-stranded RNA and DNA in various forms.  Responses to 
TLR activation vary depending on the type of receptor activated.   
 
In the paper by Zhu et al., various cell types including plasmacytoid dendritic cells 
(pDCs), conventional dendritic cells and macrophages were exposed to AAV2 
encoding LacZ.  Following exposure to AAV, cell medium was collected and 
analysed for a range of soluble inflammatory mediators.  The only cell type which 
responded to the presence of AAV was pDCs, which displayed a strong Type-I 
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interferon response (a typical anti-viral cytokine response).  pDCs taken from TLR9 
double knockout mice showed no ability to mount a response.  Additionally, if parts of 
the downstream signalling pathways for TLR9 were deleted, no response was 
initiated.  No other cell type, including macrophages, was directly stimulated by AAV 
application.   
The Type-I interferon response involves release of interferon-α and interferon-β 
predominantly.  These cytokines are potent activators of macrophages, stimulating 
their phagocytic activity (Murphy, Travers et al. 2008).  Additionally, the Type-I 
interferon response causes cells to up-regulate their endogenous anti-viral defences 
and activates other components of the innate immune response such as natural killer 
cells.  If the mechanism elucidated by Zhu et al. (i.e. TLR9 mediated pDC activation 
followed by Type-I interferon response) is to be proposed as that which leads to 
macrophage activation in the DRG, then several criteria must be met.  (i), are pDC 
present in the DRG? (ii) does the timescale described by Zhu et al. correspond to 
that seen in the experiments described above? (iii) is it likely that AAV8 leads to a 
similar response to AAV2? (iv) are there any other possible mechanisms that could 
be responsible for the observed phenomena? 
 
No publications could be found describing the presence of pDCs in the DRG.  
However, this is not necessarily surprising since these cells are known to exist 
predominantly in the circulation, although they have been seen to migrate to virally 
infected tissues (Schuster, Boscheinen et al. 2011).  If pDCs are to be implicated in 
DRG inflammation, then their attraction to the virally infected DRG must be 
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explained.  So what else could be detecting the presence of AAV8, which could in 
turn lead to the ingress of pDCs?  A recent publication has implicated TLR9 mediated 
cytokine release from DRGN as a possible mechanism for this (Qi, Buzas et al. 
2011).  Qi et al. demonstrated that human and murine DRGN express a variety of 
TLRs including TLR9.  They showed that this neuronal TLR9 could be activated 
leading to the release of mediators such as CCL5 (RANTES), CXCL10 (IP-10), IL-1α, 
IL-1β, and PGE(2).  Some of these molecules are known to be chemoattractants for 
leukocytes (e.g. CCL5) and to be capable of directly activating macrophages (e.g. IL-
1α).   
 
Although very difficult to reconcile with the results described in the present study, the 
experiments performed by Zhu et al. were analysed after a similar time point (Zhu et 
al. took samples after 36d, the present study took samples after 28d).  Comparison of 
the two studies would have been less valid had the time points been considerably 
different, since different immune processes would be likely to predominate after, say, 
days compared with months.   
 
When examining the literature concerning immune responses to viral vectors, it must 
be realised that it is probably not sufficient to assume that the immune response is 
the same across all serotypes of virus.  This is because most of the antigenicity of a 
virus (particularly a viral vector) arises from the viral coat proteins, which are 
necessarily different between serotypes.  With respect to AAV vectors, all rAAVs 
have the same basic genomic structure (ITRs derived from AAV2, see Introduction).  
168 
 
Thus, any differences between serotypes must be due to the capsid.  Zhu et al. 
examined the effect of serotype on the responses of pDCs, and showed that there 
were predominantly quantitative rather than qualitative differences between AAV1, 
AAV2 and AAV9 (Zhu, Huang et al. 2009).  From these data it seems reasonable to 
conclude that AAV8 leads to a Type-I interferon response.   
 
As the reader will appreciate from the above discussion, immune responses to AAV 
vectors are complex and multifactorial.  It is highly probable that there are other 
mechanisms at work that are responsible for macrophage activation in the DRG after 
AAV8 injection.  This study has been hampered by the lack of any temporal data 
concerning DRG inflammatory responses.  If a time-course for inflammation could be 
produced, then it may become apparent that different mechanisms predominated at 
different time points.  For example, it may be that TLR9 mediated events 
predominate early (over days) followed by a more organised adaptive immune 
response driven by T cells.  These issues cannot be addressed at present due to 
insufficient data.   
 
5.3.4 Satellite cells were seen to express CD68 after delivery of AAV8gfp 
Morphologically identified satellite cells that surrounded DRGN were seen to be 
CD68+.  This is a novel finding in the rat, and contradicts one previous report that  
CD68+ cells in the DRG were not positive for known satellite cell markers such as 
GFAP and p75 (Hu and McLachlan 2003).  It could indeed be the case that the cells 
that have been identified here as CD68+ satellite cells are in fact macrophages, 
169 
 
however two main points suggest that this may not be the case.  Firstly, the location 
and frequency of these cells is highly suggestive of satellite cells, although it is 
known that macrophages can insinuate themselves between individual satellite cells 
to make contact with DRGN cell bodies (Lu and Richardson 1993).  Secondly, it has 
been observed in human trigeminal ganglia that satellite cells have an antigen-
presenting cell phenotype, including expression of CD68 detected by fluorescence 
activated cell sorting (van Velzen, Laman et al. 2009).  Further co-localisation studies 
are needed to fully define the nature of these cells.   
 
5.3.5 Macrophages were not seen to cross the DREZ from the dorsal root into 
the spinal cord 
After intrathecal injection of AAV8gfp, macrophages were seen in the dorsal root, but 
they were not seen in the spinal cord, their presence ending abruptly at the DREZ.  
This pattern of inflammation has been seen previously in chickens with acute 
neuroinflammation (Bader, Kothlow et al. 2010).  Thus, it appears that the PNS/CNS 
boundary at the DREZ provides a barrier to macrophage migration.  This could be 
due either to an inability of macrophages to cross the BBB or an inability of 
macrophages to enter the CNS from the PNS.  Although the study of the BBB is 
undergoing considerable change, with regular paradigm shifts, it is clear that 
leukocytes (including macrophages) do not cross the BBB in large numbers 
(Bechmann, Galea et al. 2007).  It is unknown whether the BBB is abnormal in 
animals injected with AAV8gfp, although this seems unlikely.   
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A second, interesting mechanism that could be at play in restricting the migration of 
macrophages into the CNS from the dorsal root is the presence of the Fas ligand 
(FasL) on astrocytes of the glia limitans (Bechmann, Mor et al. 1999).  FasL, through 
its binding to Fas found on leukocytes, leads to apoptosis.  Macrophages have been 
shown to express Fas, possibly providing the mechanism whereby macrophage 
migration across the DREZ is inhibited (Richardson, Lalwani et al. 1994).  
  
5.3.6 Intrathecal injection did not activate central glia whereas intra-DRG 
injection led to clear microglial and astrocytic activation 
Although CNS glial activation was not quantified after intrathecal injection, it was 
qualitatively clear that delivery of PBS or AAV8gfp by this method failed to provoke 
astrogliosis or microgliosis in the rostral lumbar cord.  Contrast this with intra-DRG 
injection, where a strong quantitative activation of microglia was observed, 
accompanied by a trend towards activation of astrocytes in all cord regions in rats 
receiving AAV8gfp compared with those receiving PBS alone.  It must be stressed at 
this point that the method used to quantify glial activation did not allow statistical 
comparisons to be made between naive animals and those receiving an injection.  
Tissue from naive animals was used to derive a threshold value in order to perform 
pixel counts on tissue from injected animals.  Also, naive tissue is probably not the 
best control in this situation, since the act of inserting a needle into the DRG or 
subarachnoid space without injecting is likely to result in an inflammatory response.  
Hence, a sham injected group would be useful to have.  The rest of this discussion 
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will be based around comparisons between PBS injected animals and those 
receiving AAV8gfp. 
 
Two major differences exist between intra-DRG and intrathecal injection.  First, 
intrathecal injection leads to a lower dose of vector being delivered to each DRGN 
(i.e. a lower multiplicity of infection) compared with intra-DRG injection where a high 
concentration of vector particles is delivered directly to DRGN.  Secondly, intrathecal 
injection is not likely to lead to direct injury of DRGN cell bodies or axons within the 
DRG.  Intra-DRG injection, using a glass micropipette inserted directly into the DRG 
parenchyma is likely to lead to considerable tissue disruption.   
 
Dose-response studies have been performed using AAV vectors in the DRG, 
particularly looking at the level of transgene expression seen at various doses.  It 
appears that, at least in the case of AAV5, increasing the dose of vector has a 
positive effect on the level of transgene expression (Klein, Hamby et al. 2002; 
Mason, Ehlert et al. 2010).  This result, although intuitive, is not necessarily what was 
to be expected since previous studies on adenovirus have shown lower levels of 
transgene expression after injection of high titres compared with lower titres 
(Thomas, Birkett et al. 2001).  Hence, it seems that in the DRG injected with AAV it is 
irrelevant whether it is the vector itself or the transgene that leads to an inflammatory 
response since higher titres lead to higher levels of transgene expression.  
Therefore, the results presented here are in keeping with what is currently known 
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(intrathecal injection leads to lower multiplicities of infection, lower levels of transgene 
expression and a lower level of glial activation).   
 
If the stronger glial activation was solely due to trauma associated with intra-DRG 
injection, one would expect to see equal magnitudes of gliosis in the PBS and 
AAV8gfp injected animals.  This is not the case – intra-DRG injection of AAV8gfp 
generally leads to higher levels of CNS glial activation.  One possible explanation for 
this could be based around the idea of a double or even triple „hit‟.  The three hits 
could come in the form of (i), trauma associated with injection; (ii), entry of viral 
particles with concomitant innate immune response and (iii), subsequent expression 
of transgene (gfp).   
In the case of (i) it is clear that intra-DRG injection is much more traumatic than 
intrathecal injection for the target neurones.  Indeed, in the present study it is likely 
that the volume injected into the DRG (10µl) was excessively high.  This volume was 
selected as it was felt that it would be difficult to deliver smaller volumes accurately 
with this method.  Other workers have used much smaller injection volumes and not 
reported any inflammatory responses (Mason, Ehlert et al. 2010; Fischer, Kostic et al. 
2011) .  However, in the case of Mason et al., only gross morphology of the DRG 
after haematoxylin and eosin staining was provided.  After intra-DRG injection in the 
present study, no gross morphological abnormalities were observed.  Macrophage 
infiltration and glial activation could still have been present in the animals injected by 
Mason et al.   
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What is the mechanism whereby DRG trauma could lead to CNS glial activation? The 
answer may lie in the extensive literature on neuropathic pain.  Neuropathic pain 
often occurs after injuries to the PNS (and also the CNS) and is characterised by 
lowered pain thresholds and the perception of non-painful stimuli as being noxious 
(Scholz and Woolf 2007).  The neurological basis of such pain states is believed to 
be extensive plastic change within the cord, associated with glial activation.  It is 
known that damage to a peripheral nerve (this can include DRGN cell bodies and 
processes) leads to high frequency firing of the DRGN and release of mediators such 
as adenosine triphosphate (ATP), BDNF and nitric oxide at their central terminals 
(Vallejo, Tilley et al. 2010).  ATP is chemoattractant for microglia and stimulates their 
activation.  Nitric oxide is known to activate astrocytes (Brahmachari, Fung et al. 
2006)s.  Indeed, ATP can attract microglia from up to 100µm away from its site of 
release, and this does go some way to explaining the bilateral microglial activation 
seen in the deep dorsal horn (Vallejo, Tilley et al. 2010).  This model provides an 
explanation for how direct DRG damage can lead to central glial activation, although 
three main criticisms arise.  Firstly, if direct DRG damage after intra-DRG injection is 
responsible for these findings, why is the magnitude of the glial activation not equal 
after PBS and AAV8 injection?  Secondly, behavioural measures of neuropathic pain 
in rats are not grossly affected 2 weeks after intra-DRG injection of 4µl PBS.  Thirdly, 
there is no evidence of Wallerian degeneration in the DC after intra-DRG injection of 
AAV8gfp.  It is known that axotomy of the peripheral projection of DRGN leads to 
about 30% DRGN death (McKay Hart, Brannstrom et al. 2002).  Surely, if intra-DRG 
injection axotomised DRGN then some CNS degeneration in the DC would be 
detectable?  Thus it seems that, even if DRG injury has a role in the observed CNS 
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glial activation, it is likely that this is only sufficient at earlier time points.  Something 
is presumably perpetuating the glial activation in animals receiving intra-DRG 
AAV8gfp. 
The factors responsible for the continuing glial activation seen in the cord after intra-
DRG AAV8gfp may include the ongoing inflammatory response within the DRG (see 
above) or the onset of expression of GFP from transduced DRGN.  At this point, it is 
worth re-iterating that intrathecal injection of AAV8gfp led to levels of transduction 
approximately an order of magnitude lower than seen after intra-DRG injection (see 
Chapter 4).  Thus, if there is a threshold level of GFP expression that leads to CNS 
glial activation, this may not have been reached in animals receiving intrathecal 
injection.   
 
Occasional GFP+ DRGN are seen at 1 week after intra-DRG injection of AAV5, with 
expression increasing to high levels after 4 weeks (Mason, Ehlert et al. 2010).  It is 
believed that a major factor contributing to this time lag is the conversion of the 
ssDNA genome of AAV into a useable, transcriptionally-competent dsDNA molecule 
(Ferrari, Samulski et al. 1996).  In the DRG it seems likely that high levels of GFP are 
seen from around 1-2 weeks post injection.  So is it possible that GFP could be 
contributing to this scenario – is GFP neurotoxic? 
 
There are a variety of fluorescent proteins currently used as reporter genes in many 
different branches of biological science.  The two major forms are those derived from 
jellyfish (GFP, yellow fluorescent protein (YFP) and others) and those derived from 
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the sea pansy (hrGFP) (Shaner, Steinbach et al. 2005).  Clearly, these molecules are 
extremely useful and enable visualisation of many diverse biological phenomena.  If 
one speaks to researchers regularly using fluorescent proteins as reporters, they will 
frequently state that these molecules are non-toxic and essentially inert within the 
cell.  However, the findings presented above led the author to question this dogma 
and to perform a thorough literature search looking for any evidence of toxicity 
associated with fluorescent proteins. 
An early study discussing the toxicity of GFP actually used AAV8 to deliver this 
transgene to the rat striatum (Klein, Dayton et al. 2006).  Klein et al. demonstrated 
that it was possible to kill neurones of the substantia nigra by delivering AAV8gfp 
alone.  Furthermore, it was shown that no neuronal death occurred after injection of 
an equivalent amount of an empty AAV8 particle.  This provided convincing evidence 
that GFP, when delivered in large quantities, was toxic to neurones.  In vitro studies 
have also shown the capacity of GFP to form intracellular aggregates in HEK 293 
cells (Link, Fonte et al. 2006) and neurones when co-expressed with other proteins 
(Krestel, Mihaljevic et al. 2004).  Furthermore, axonal spheroids have been observed 
in aged mice of the YFP-H line (Bridge, Berg et al. 2009) and Drosophila expressing 
neuronal GFP have been shown to display neurological deficits (Mawhinney and 
Staveley 2011).  Of course, the evidence presented above must be taken in the 
context of the many successful studies employing GFP.  However, there is probably 
enough data to suggest that in certain contexts GFP can be toxic to neurones, or at 
least is capable of modulating inflammatory responses. 
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So to return to the original three hit hypothesis.  After intra-DRG injection, there is a 
transient injury to DRGN cell bodies and axons (neuropraxia) followed by the influx of 
AAV8 particles.  This sets up an inflammatory reaction in the DRG in the context of 
vulnerable neurones.  As time progresses, GFP levels in transduced neurones 
increase leading to further neuronal toxicity.  The level of insult to the neurone 
exceeds a threshold, beyond which inflammatory mediators are released from central 
terminals and CNS glia become activated.  Intrathecal injection does not lead to any 
direct DRG damage, the levels of AAV8 particles in each DRG are lower and the 
amount of GFP expressed by individual DRGN is lower.  Hence, DRGN do not 
exceed the threshold level after intrathecal injection and so do not release 
inflammatory mediators from their central terminals.  Thus, intrathecal injection does 
not lead to CNS glial activation.   
 
Clearly, much further work needs to be performed to confirm this intriguing 
hypothesis.  However, the results as they stand should stimulate researchers working 
with fluorescent proteins in the nervous system to look for any signs of overt toxicity.  
  
5.3.7 Astrocytes showed evidence of widespread activation after intra-DRG 
injection of AAV8gfp 
Although only one region of the cord displayed a statistically significant effect, it was 
still intriguing to see the consistent trend towards activation of astrocytes in all cord 
regions and on both sides after intra-DRG injection of AAV8gfp.  Clearly, in order to 
confirm this, additional animals need to be examined. 
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A phenomenon that may explain this global astrocyte activation arises from the 
literature on neuropathic pain.  Some patients with neuropathic pain states arising 
from unilateral pathologies have been known to develop pain on the contralateral 
side, with no contralateral pathology (e.g. a nerve injury in the left arm leads to 
bilateral neuropathic pain).  This is known as „mirror-image‟ pain and has been 
extensively described in the literature (Hansson 2006).  A number of theories have 
been proposed to explain this pattern of pain, the most compelling from the point of 
the present study being the propagation of calcium waves in astrocytes.  Astrocytes 
are known to be connected to each other in what is known as a functional syncytium 
(Verkhratski and Butt 2007).  The molecular basis for this arrangement is the 
presence of gap junctions between adjacent astrocytes, which are known to allow the 
propagation of calcium waves over long distances through the syncytium.  It is 
possible that the widespread activation of astrocytes seen in this study is the result of 
syncytial interactions between activated astrocytes.   
 
5.3.8 Central projections of DRGN did not show signs of degeneration after 
intra-DRG injection of AAV8gfp 
As already discussed in Chapter 4, no stereological counts of DRGN in the various 
injection paradigms were made.  This means that any comments regarding the 
survival of DRGN are based upon indirect measures.  One such measure used was 
the assessment of Wallerian degeneration in the DC using the Oil Red O technique.  
Oil Red O exploits the fact that lipophilic dyes are less soluble in organised, laminar 
myelin than in the lipid droplets associated with degenerated myelin (Kiernan 2007).  
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Thus, a signal is obtained when degenerated myelin is present.  In the present study, 
no signal was detected in the dorsal column of rats injected with AAV8gfp.  This was 
in the context of a positive control showing strong signal in the lesion site and distal 
stump of an optic nerve examined 14d post transection.  Due to the fact that 
Wallerian degeneration is a very slow process in the CNS, taking months to years to 
complete, it is reasonable to assume that there will be detectable degenerating 
myelin after 28d (Vargas and Barres 2007).  One must, however, be cautious in 
concluding that there was no axon degeneration present, due to the fact that only a 
small proportion (probably much fewer than 1%) of axons in the DC would have been 
transduced.  Thus, it is possible that the signal to noise ratio would have been 
insufficient to detect any axonal degeneration.  Indeed, there was high background in 
the tissues examined due to the high density of axons and the large number of 
haematoxylin stained nuclei.  The signal to noise ratio could probably be increased 
by using thinner sections and omitting the haematoxylin counter-stain.   
 
5.4 Further work 
As the reader will undoubtedly have gathered from the preceding pages, the study of 
inflammatory responses to AAV8 in the nervous system is difficult, not helped by a 
paucity of data concerning both the specifics of AAV immune responses and 
neuroimmunology in general.  Necessarily, much speculation has been included in 
the interpretation of the results obtained in this chapter, but most of the uncertainties 
raised could probably be addressed by the following additional experiments. 
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Assessment of the kinetics of AAV8 delivery to the DRG 
Due to a lack of time and resources, dose-response and time course experiments 
were not performed.  Instead, the maximum reasonable dose of AAV8gfp was 
delivered in each injection paradigm.  Dose-response studies may uncover an 
optimal amount of AAV to deliver in a minimum volume to effect the greatest amount 
of DRGN transduction in the context of minimal inflammation (although this seems 
unlikely from the work of Mason et al. on AAV5, see above).  Time-course studies 
may uncover dynamic aspects of the inflammatory response to AAV8, possibly 
helping to answer some of the more difficult questions surrounding the „three-hit 
hypothesis‟.   
 
Staining for additional components of the immune system 
It would be extremely interesting to look at the DRG (and spinal cord) for evidence of 
invasion by other cellular elements of the immune system such as T-cells, B-cells 
and dendritic cells.  Additionally, immunohistochemistry could be performed to 
identify the presence of relevant cytokines and chemokines and to quantify their 
levels in the different injection paradigms.  Introducing a quantitative element to the 
work on inflammatory responses would be very interesting.  Furthermore, techniques 
such as microdialysis and serial sampling of CSF may be illuminating. 
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Sham injections 
As mentioned above, naive animals are probably not the ideal control for these 
experiments.  Much more useful would be animals that had undergone the entire 
injection procedure but not the actual injection itself (i.e. insert the needle but don‟t 
inject).  This would facilitate the estimation of the inflammatory response attributable 
to the procedure itself. 
 
Quantification of axonal calibres in the DC 
The stimulus for assessing inflammatory responses to AAV8gfp came from the 
observation of axonal swelling in the DC.  As mentioned above, this has been 
observed in YFP transgenic mice.  It would be informative to measure the axonal 
diameters of the total population of DC axons compared with GFP+ axons and to 
correlate this with quantified parameters of the inflammatory response.   
 
Test viral stocks for LPS 
Despite the fact that the viral vectors were prepared with in vivo experiments in mind, 
and obtained from reputable sources with good quality control systems, it would be 
ideal to test each batch for the presence of endotoxin, which is known to be a potent 
stimulant of inflammatory responses.   
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A pilot experiment to examine the effect of 
AAV2/8 mediated delivery of NT-3 and 
shRNARhoA to DRGN on regeneration in the 
DC 
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The following introductory sections will specifically address studies employing viral 
vectors to deliver NT-3 and AGIL neutralisation strategies directly to components of 
the injured spinal cord.  The reader is reminded that many other studies have 
delivered these therapeutics (particularly NT-3) by transducing cells, such as neural 
stem cells or olfactory ensheathing cells with a virus ex vivo and then injecting these 
cells into the cord (Liu, Himes et al. 1999; Ruitenberg, Levison et al. 2005).   
 
6.1.1 Viral vector-mediated delivery of NT-3 to the spinal cord 
The first demonstration that NT-3 delivered using a viral vector to the injured spinal 
cord can lead to regeneration of sensory axons came from a collaboration between 
the laboratories of Patrick Anderson and Joost Verhaagen (Zhang, Dijkhuizen et al. 
1998).  In the study by Zhang et al., NT-3 was delivered to motor neurone cell bodies 
in the ventral horn using an adenoviral vector (Ad-NT3).  Being the natural target for 
many large diameter TrkC+ DRGN central projections, it was hypothesised that 
overexpression of NT-3 in motor neurones would lead to chemotaxis of avulsed 
DRGN projections in the re-anastomosed dorsal root towards the ventral horn.  In 
order to maximise regenerative potential, a preconditioning sciatic nerve lesion was 
also performed.  It was found that many regenerating axons penetrated into the 
spinal cord grey matter as deep as lamina V in Ad-NT3 treated animals.  No axons 
were seen to enter the cord after application of a control vector, Ad-LacZ.   
 
The study by Zhang et al. demonstrated a phenomenon that has been repeated a 
number of times – namely, that NT-3 is capable of guiding lesioned axons through 
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the CNS parenchyma.  However, it must be stressed that in the study by Zhang et al. 
there was not significant damage done to the spinal cord itself, which is likely to 
liberate a high concentration of soluble AGIL.  A study by Blits et al., where AAV-NT3 
was injected caudal to a complete transection filled with a Schwann cell graft, 
showed numerous axons entering the graft but none were seen to regenerate into 
the caudal spinal cord (Blits, Oudega et al. 2003).   
 
A second interesting property of NT-3 is that it is capable of stimulating plasticity in 
the injured spinal cord.  Zhou et al. showed that, after unilateral corticospinal tract 
lesion at the level of the medulla, adenovirally-mediated delivery of NT-3 to ventral 
horn motor neurones stimulated midline crossing of intact CST projections to the 
lesioned side (Zhou, Baumgartner et al. 2003).   
 
It seems that NT-3 mediated chemotaxis is not sufficient to stimulate regeneration of 
axons in the spinal cord.  Have studies delivering NT-3 directly to cell bodies of 
axotomised neurones fared any better?  It was demonstrated in 1997 that AAV-
mediated delivery of NT-3 to DRG explants in vitro resulted in a robust neurite 
outgrowth response (Dijkhuizen, Hermens et al. 1997).  However, in the study by 
Dijkhuizen et al., AGIL were not present.  At the time of writing, no publications could 
be found reporting the effect of virally-delivered NT-3 directly to neuronal cell bodies 
in vivo.  It is known from other studies, however, that application of neurotrophins 
including NT-3 to neurones in vitro can activate their growth state as evidenced by 
their up-regulation of growth-associated protein 43 (Mohiuddin, Fernandez et al. 
185 
 
1995).  It must, however, be acknowledged that NT-3 application to the neuronal cell 
body alone has no effect on neurite outgrowth (Kimpinski, Campenot et al. 1997).  
The reader is reminded that in the present study it is an nt-3-encoding virus that has 
been applied to neuronal cell bodies.  The fate of the synthesised NT-3 protein is 
currently unknown, although it seems likely that much of it will be released at both 
peripheral and central terminals, as well as into the DRG itself from the cell body.  
Such release from terminals provides a rationale for this approach and allows the 
current study to be compared with previous work where NT-3 was applied directly to 
the lesion site (Bradbury, Khemani et al. 1999).   
To conclude this section, it is known that NT-3 is beneficial for neuronal plasticity and 
regeneration and it seems reasonable to expect that AAV-mediated delivery of NT-3 
to DRGN cell bodies will augment the regenerative capacity of their axons.  However, 
it is also known that single therapies often fail, so a combined approach employing 
the delivery of an AGIL neutralisation therapy is likely to be more fruitful (see 
Introduction for more details).   
 
6.1.2 Viral vector-mediated delivery of AGIL neutralisation therapies to the 
spinal cord 
In 2004, Fischer et al. demonstrated that AAV-mediated delivery of a dominant-
negative form of NgR to RGC resulted in significant amounts of axon regeneration in 
the optic nerve, only when combined with activation of the RGC growth state 
(Fischer, He et al. 2004).  Most of the literature reporting effects of virally-mediated 
knockdown of NgR is from China and shows encouraging results suggesting that 
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adenoviral and lentiviral delivery of RNAi against NgR results in functional 
improvements in animal models of stroke and SCI (Lu, Yuan et al. 2010; Wang, 
Wang et al. 2010; Xu, Liu et al. 2011).   
 
Other studies have looked at the effects of virally-delivered inhibitors of RhoA and its 
downstream effectors.  A recent study described positive effects on peripheral nerve 
regeneration after delivery of an adenovirus expressing dominant-negative forms of 
RhoA and Rac1 to the proximal nerve stump (Kusano, Enomoto et al. 2011).  
Similarly, a dominant-negative form of ROCK was administered to the red nucleus 
using a lentiviral vector followed by lesioning of the rubrospinal tract (Wu, Yang et al. 
2009).  This single therapy resulted in improved functional recovery and enhanced 
regeneration of rubrospinal axons caudal to the lesion.  In this study, the authors 
themselves state that it is likely that combinatorial therapies including ROCK 
inhibition are likely to give higher levels of axon regeneration. 
 
At the time of writing, no published reports describing the effect of virally delivered 
RNAi targeted at RhoA were available.  However, this approach has been 
convincingly validated in vitro using both transfection of siRNA against RhoA into 
primary retinal cultures (Suggate, Ahmed et al. 2009) and delivery of a plasmid 
encoding shRNARhoA to PC12 cells (Fan, Pang et al. 2008).  Both of these studies 
demonstrated significant levels of disinhibited neurite outgrowth.   
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A final, cautionary note must be included regarding a recent paper from the lab of 
Joost Verhaagen (Ehlert, Eggers et al. 2010).  In the paper by Ehlert et al., neuronal 
toxicity was noted when therapeutic and control shRNAs were delivered using an 
AAV1-based vector to the red nucleus.  A significant inflammatory response 
accompanied by neuronal degeneration in the red nucleus was observed.  
Fortunately, from the point of view of the present study, minimal toxicity was seen in 
the DRG after intra-DRG injection of the same shRNAs using AAV5.  However, this 
study serves to highlight that caution must be exercised when over-expressing 
therapeutic genes in neurones.   
 
6.1.3 Combining viral delivery of growth factors with neutralisation of AGIL in 
the injured spinal cord 
The present study is, to the best of the author‟s knowledge, the first account of the 
use of a single viral vector containing both a growth factor and an AGIL neutralisation 
therapy (i.e. AAV8hrgfp-nt3-shrnarhoa).  Indeed, it is the first study to specifically look at the 
effect of combining NT-3 administration with RhoA knockdown in vivo.  The rationale 
for the production of this vector is founded upon an established evidence base 
emphasising the need for activation of a neurone‟s growth state and inactivation of 
myelin-derived inhibitors to effect CNS axon regeneration.   
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6.1.4 How can previous findings inform experimental design? 
The results presented in Chapters 4 had great significance with respect to the design 
of the experiment described in this chapter.  The discovery that AAV8 preferentially 
transduces large-diameter proprioceptive DRGN projecting to Clarke‟s column led to 
the requirement for the DC lesion to be performed at the L1 spinal level (see Figure 
2.2).  It is known that the Clarke‟s column projections of the sciatic nerve terminate in 
the caudal half of the thoracic cord (LaMotte, Kapadia et al. 1991).  Thus, a T8 lesion 
(the „traditional‟ level for DC lesions in the Molecular Neuroscience Group) would be 
likely to fail to transect the vast majority of central projections of transduced DRGN.  
A lesion at a level too caudal (e.g. L5 cord level) would not be conducive to axonal 
tracing using intra-sciatic nerve CTB, since the sciatic nerve in the rat takes its origin 
predominantly from the L4 and L5 spinal nerves (Craigie, Innes et al. 1963).  Thus, it 
was decided to perform the lesion at L1.  Furthermore, a DC lesion at L1 is much less 
likely to interfere with the function of other nerves (L2 may affect the femoral nerve) 
or the locomotor function of the animal (mid-lumbar may affect the sciatic nerve or 
circuitry involved in the regulation of the central pattern generator for gait).   
 
6.1.5.1 Specific hypothesis 
AAV8hrgfp-nt3-shrna-rhoa and AAV8hrgfp-nt3 transduction of DRGN in vivo mediates neurone 
disinhibited regeneration of DC axons 
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6.1.5.2 Specific aims 
 To confirm that AAV8hrgfp-nt3-shrnarhoa and AAV8hrgfp-nt3 transduce DRGN in vivo 
and that these neurones are also CTB+ using immunohistochemistry 
 To examine the gross pathological appearance of DC lesion sites from 
animals receiving AAV8gfp, AAV8hrgfp-nt3-shrna-rhoa and AAV8hrgfp-nt3 
 To assess the completeness of DC lesions using CTB immunohistochemistry 
in a selected animal from each group 
 To qualitatively examine the characteristics of the DC lesion site in a selected 
animal from each group using GFAP immunohistochemistry 
 To use CTB immunohistochemistry to evaluate the extent of axon 
regeneration across the DC lesion site in a selected animal from each group 
 
Section 6.1.6 Brief description of methods 
The experimental design comprised three groups with a total of 14 animals (200-
220g).  At day 0, animals received intra-DRG injections to the left L4 and L5 DRG of 
AAV8gfp (“GFP”: n=4, 10
11 viral genomes per DRG in 10µl); AAV8hrgfp-nt3 (NT-3”: n=5, 
1011 viral genomes per DRG in 10µl) and AAV8hrgfp-nt3-shrnarhoa (“NT3-shRNA”: n=5, 
1011 viral genomes per DRG in 10µl).  At 28d post injection, animals received 
bilateral DC crush lesions at the L1 spinal cord level.  Professor Martin Berry, who 
performed the lesions, was blinded with respect to which group each animal 
belonged to.  At 26dpl, animals received intra-neural injections of 2µl 1% CTB to the 
left sciatic nerve.  At 28dpl animals were sacrificed, perfused with 4% formaldehyde 
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and dissected, harvesting the lesion sites, left L4/L5 DRG and medulla.  DRG were 
cut into 15µm sections, those from the centre of each ganglion being selected for 
CTB immunohistochemistry.  Medullas were cut into 15µm sections, those at the 
level of the obex were selected for CTB immunohistochemistry.  Lesion sites were 
cut into 25µm sections in the parasagittal plane – immunohistochemistry for GFAP 
and CTB was performed on sections taken approximately 200µm to the left of the 
mid-line.  
 
DRG and lesion sites were examined using standard immunohistochemical 
techniques.  
 
Unfortunately, due to a lack of time, only tissues from one animal from each group 
were analysed immunohistochemically.  The reader is reminded at this stage, 
therefore, that only preliminary conclusions can be drawn from the results described 
below.  Much further work is required.   
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Results 
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6.2.1 GFP was present in large-diameter DRGN, co-localising with CTB 
CTB immunoreactivity was seen in the cell bodies of many DRGN within the DRG 
from all animals examined (Figure 6.1).  Expression appeared maximal in cell bodies 
of large diameter DRGN.  GFP expression, as previously observed, was also 
predominantly seen in cell bodies of large diameter DRGN.  Additionally, GFP was 
seen in axons within the DRG.  No co-localisation of GFP with CTB in axons was 
observed in the DRG (Figure 6.1) or the spinal cord (Figure 6.7 D).   
 
6.2.2 No differences were observed in the gross pathological appearance of 
lesion sites from animals in different treatment groups 
Qualitatively, no differences were observed in the gross appearance of the lesion 
sites from all of the animals studied.  Lesions frequently appeared cystic (by their 
dark appearance), located at the rostral end of the lumbar enlargement (Figure 6.2, 
arrow).  All lesions were localised to within approximately 1mm of their epicentre, with 
no evidence of rostral cavitation.   
 
6.2.3 GFP+/CTB+ terminals were seen in the medullas from the three animals 
that were analysed 
In the gracile nuclei from the three animals studied, GFP+ terminals were seen to co-
localise with CTB (Figure 6.3 arrows and arrowheads, repectively).  The animals in 
the NT3-shRNARhoA group displayed the highest level of expression of GFP and CTB.  
Figure 6.1 Co-localisation of CTB and GFP in the DRG.  Large diameter GFP+ DRGN (arrows) are seen in particular to 
co-express CTB.  GFP+ axons (arrowheads) display minimal CTB immunoreactivity in the DRG.  Scale bar = 50μm.    
CTB GFP Merge + DAPI 
AAV8gfp 
AAV8hrgfp-nt3 
AAV8hrgfp-nt3-shrnarhoa 
Figure 6.2 Gross pathological appearances of L1 DC crush sites 28dpl.  AAV8 vectors were administered to 
the left (ipsilateral) L4 and L5 DRG 28d prior to lesioning.  Note typical cystic lesion sites (e.g. arrow) 
extending between the left and right dorsal root entry zones.  The lesions labelled with a (*) were subjected 
to further histological analysis.  Scale bar = 1mm.   
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Figure 6.3 CTB and GFP expression in the gracile nucleus at the level of the obex in AAV8-injected, DC lesioned 
animals.  In most cases, GFP+ terminals (arrows) are seen to co-express CTB (arrowheads).  Scale bar = 50μm.   
CTB GFP Merge + DAPI 
AAV8gfp 
AAV8hrgfp-nt3 
AAV8hrgfp-nt3-shrnarhoa 
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The animal from the NT3 group showed only very low levels of GFP and CTB in the 
gracile nucleus.   
 
6.2.4 Differences were seen in the appearance of the lesions and surrounding 
cord in the three animals that were analysed using GFAP 
immunohistochemistry 
The lesion site from the animal analysed in the GFP group was cystic, extending 
approximately 1mm into the dorsal spinal cord, with a clearly defined accessory glia 
limitans (Figure 6.4 A, white arrowhead).  Occasional morphologically identified 
macrophages were seen in the core of the lesion, but many were seen in the white 
matter 1mm rostral to the lesion (Figure 6.7 arrows).  Additionally, there was what 
appeared to be GFP+ debris occasionally within and caudal to the lesion, but mostly 
in the 1mm rostral to the lesion (Figure 6.7, arrowheads).  Very infrequent GFP+ 
axons in the DC were seen rostral (Figure 6.4 C) and caudal (Figure 6.4 D) to the 
lesion.   
 
The lesion site from the animal in the NT-3 group was cystic, extending 
approximately 750µm into the dorsal spinal cord with a relatively weakly GFAP+ 
accessory glia limitans (Figure 6.5 A, 6.7).  The lesion core was filled with 
macrophages and GFP+ debris.  There was a large amount of hrGFP in the grey 
matter deep to the lesion.  Much of this hrGFP seemed to be present within 
neurones, identified by their large DAPI+ nuclei.  What were presumed to be hrGFP+ 
axons were seen caudal to the lesion in the DC, although the pattern of hrGFP 
Figure 6.4 Expression of GFP and GFAP after DC lesion in an animal receiving intra-DRG AAV8gfp to the left L4/L5 
DRG 28d prior to lesioning.  A.  Composite image of a parasagittal section from approximately 200µm to the left of the 
midline (depicted in B).  White arrowhead indicates accessory glia limitans.  C.  High magnification view of a GFP+ 
axon (arrow) rostral to the lesion in region in Ac.  D.  High magnification view of a GFP+ axon (arrow) caudal to the 
lesion in region Ad.  Scale bar for A = 1mm, C, D = 50µm.   
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Figure 6.5 Expression of hrGFP and GFAP after DC lesion in an animal receiving intra-DRG AAV8hrgfp-nt3 to the left 
L4/L5 DRG 28d prior to lesioning.  A.  Composite image of a parasagittal section from approximately 200µm to the left 
of the midline (depicted in B).  C.  High magnification view of an hrGFP+ axon (arrow) rostral to the lesion in region in 
Ac.  D.  High magnification view of an hrGFP+ axon (arrow) caudal to the lesion in region Ad. Scale bar for A = 1mm, 
C, D = 50µm 
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expression was predominantly linearly punctuate, with few very obvious, intact axons 
(Figure 6.5 D).  Rostral to the lesion, extremely infrequent axons were seen, 
expressing low levels of hrGFP (Figure 6.5 C).   
 
In the NT3-shRNARhoA animal, the lesion site had a different morphology compared to 
the other groups.  The lesion cavity appeared to be smaller and there was a poorly 
defined accessory glia limitans making assessment of its extent difficult (Figure 6.6 
A).  The lesion core contained macrophages and occasional hrGFP+ debris.  The 
number of macrophages in the lesion and rostrally were much higher than in the 
other two groups.  Also, there was much more hrGFP+ debris rostral to the lesion 
(Figure 6.7).  Caudal to the lesion, many intact hrGFP+ axons were seen as well as 
hrGFP in a linear punctuate arrangement (Figure 6.6 D).  At the level of the lesion in 
the DC, occasional intact hrGFP+ axons were seen, following the familiar trajectory 
of DC axons (Figure 6.6 E), whereas rostral to the lesion some hrGFP+ axons 
possessing terminal swellings were observed in the DC (Figure 6.6 C).   
 
6.2.5 CTB immunostaining failed to demonstrate axons adequately  
CTB immunohistochemistry proved disappointing, leading to very high background 
levels and consequent poor signal-to-noise ratios (Figure 6.8).  CTB was 
predominantly seen in terminals ending in the dorsal horn (Figure 6.8 A, C), and 
never seen to be present in axons (Figure 6.8 D).  This is to be contrasted with GFP 
expression, which does label axons and terminals with a high signal-to-noise ratio.   
Figure 6.6 Expression of hrGFP and GFAP after DC lesion in an animal receiving intra-DRG AAV8hrgfp-nt3 -shrnarhoato the 
left L4/L5 DRG 28d prior to lesioning.  A.  Composite image of a parasagittal section from approximately 200µm to the 
left of the midline (depicted in B).  C.  High magnification view of an hrGFP+ axon (arrow) rostral to the lesion in region 
in Ac.  D.  High magnification view of an hrGFP+ axon (arrow) caudal to the lesion in region Ad.  E. High magnification 
view of an hrGFP+ axon (arrow) at the level of the lesion site. Scale bar for A = 1mm, C, D = 50µm 
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Figure 6.7 GFAP immunohistochemistry on parasagittal sections of lesion sites showing more detailed morphology.  
Morphologically identified macrophages (arrows) can be seen within and occasionally rostral to the lesion site.  
Additionally, GFP+debris (arrowheads) can frequently be seen rostral to the lesion.  Scale bar = 50µm.   
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Figure 6.8 The appearance of CTB immunostaining in DC lesion sites from animals 
injected with AAV8gfp (A), AAV8hrgfp-nt3 (B) and AAV8hrgfp-nt3-shrnarhoa (C, D).  D is a high 
power view of the region demarcated by the yellow box in C, showing a GFP+ axon 
(arrow).  Scale bar = 50µm.   
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6.3.1 CTB and GFP were found to co-localise 
That CTB preferentially labels large-diameter DRGN is corroborated in the literature 
(Liu, Llewellyn-Smith et al. 1995).  The mechanism of this is probably differential 
expression of the ganglioside GM1 between different classes of DRGN (Gong, 
Tagawa et al. 2002).  The above observation, combined with the fact that AAV8 has 
a tropism for large diameter DRGN, makes CTB a promising tool for assessing axon 
regeneration in AAV8-treated animals.   
 
6.3.2 The gracile nuclei contained GFP and CTB 
The gracile nuclei were examined in order to assess the completeness of the lesion 
in each animal.  The presence of CTB and GFP in the gracile nuclei of all animals 
examined probably suggests that the lesions were incomplete.  The background to 
this was discussed in the Introduction, but it is worth re-iterating at this point.  When 
performing partial lesions, it is always a possibility that some axons may be spared – 
either missed or not completely transected (Steward, Zheng et al. 2003).  In order to 
account for this, one must take a number of precautions.  Firstly, the lesion must be 
planned carefully taking into account the species and age of animals and the 
necessary dimensions of the lesion.  Secondly, the lesion must be performed 
carefully and as accurately as possible to maximise the probability of transecting all 
of the axons in the region of interest.  Finally, one must ensure that lesioned animals 
are left for an appropriate amount of time before sacrificing.  These three points will 
be discussed below with respect to the present study. 
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The lesion was planned so as to transect the DC of adult rats bilaterally to a depth of 
1.5mm, medial to the dorsal root entry zones at the L1 spinal cord level.  Referring to 
a rat spinal cord atlas confirms that the depth and width of the planned lesion in adult 
animals was more than adequate to transect all of the axons in the DC (Watson 
2009).   
 
The lesion was performed by Professor Martin Berry, an expert in the field of CNS 
regeneration.  Fine jeweller‟s forceps were used, marked to a depth of 1.5mm.  The 
lesions were performed by hand under direct vision using operating microscope.  
Despite these rigorous precautions, it is likely that the fact that the lesions were 
performed by hand, along with other factors, contributed to their being incomplete.  
During the operation, the meninges were left intact.  This combined with the 
presence of blood and CSF within the wound may have led to the forceps being 
inserted to an inadequate depth since the „surface‟ of the cord would have been 
misjudged.  Additionally, any lesions performed by hand naturally will result in a 
higher variability than those performed using mechanical devices due to inherent 
human error.   
 
Animals were left for 28d after lesioning.  Although it is not known what the rate of 
regeneration in the spinal cord is, this is probably a reasonable period of time based 
on the estimates found in the literature (Steward, Zheng et al. 2003).  The work of 
Steward et al. postulates that the theoretical maximum rate of axon regeneration in 
the CNS is 1mm per day.  It is probably reasonable to assume that axon 
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regeneration occurs more slowly than this in the CNS due to the inhibitory 
environment.  Additionally, severed axons probably take some time to recover from 
transection.  In rats the distance from the L1 cord segment to the medulla is 
approximately 5cm, meaning that any CTB seen in the medulla 28dpl is extremely 
likely to represent spared axons and not regeneration.   
 
Thus, it seems likely that a high proportion of the lesions performed in the present 
study were incomplete.  However, one must also be mindful that treatments 
themselves may modulate the level of axon sparing, for example the possible 
conditioning effect of intra-DRG injection and the direct effects of NT-3 administration 
and RhoA antagonisation (see below for further discussion). 
 
6.3.3 The lesioned spinal cord in the animal from the GFP group manifested 
features consistent with the literature 
Consistent with the present findings, Lagord et al. observed axonal debris within 
macrophages within and rostral to the lesion 28d after a DC crush (Lagord, Berry et 
al. 2002).  Additionally, in agreement with the present study, Lagord et al. noted a 
GFAP+ accessory glia limitans had formed by the first week post lesion.   
 
The presence of morphologically identified macrophages rostral to the lesion 
probably correlates with a high level of phagocytic activity, necessary for the removal 
of degenerating axonal components.  It must be noted that on morphological grounds 
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it is very difficult to differentiate activated macrophages from fully activated microglia 
(David and Kroner 2011).   
 
6.3.4 Much more GFP+ material was seen in the animals from the NT-3 and 
NT3-shRNA groups than the animal in the GFP group 
Before making any further comments on comparative aspects of the morphology of 
the lesions examined in this study, the author would like to emphasise a technical 
point.  In preparing the tissues for this study, it was impossible to get the same 
orientation of the tissue specimens across all of the groups.  Specifically, it may be 
the case that lesion sites that were sectioned were angulated slightly differently 
leading to subtle differences in the appearance of the tissue.  This can be assessed 
by looking at the organisation of white and grey matter within each section.  Despite 
this, the reader is reassured that lesion sites are all from the same place 
(approximately 200µm to the left of the midline – this was achieved by taking the 
fourth section that came off after the central canal was seen at the level of the 
lesion), allowing reasonably valid comparisons to be made at lesion sites and the 
perilesional area.   
 
Hardly any GFP+ axons or debris was seen around the lesion in the animal from the 
GFP group.  This could be due to a number of reasons.  It may have been the case 
that the intra-DRG injections in this animal were unsatisfactory compared with those 
performed on the other animals.  The animal looked at in the GFP group was the first 
to be injected in this experiment.  Intra-DRG injections are not performed regularly by 
200 
 
Professor Berry, and it may be that a „training effect‟ occurred, as the operator 
performed more injections.  However, this seems unlikely since for every intra-DRG 
injection, the DRG is directly seen to swell.  However, it is worth reminding the reader 
of the inherent variability of this injection technique (see Chapter 4, Table 1).   
 
A second possibility is that a DC lesion provided a fourth „hit‟ to already damaged 
DRGN (see Chapter 5 for the „triple hit hypothesis‟).  The additional insult of a DC 
lesion may have led to catastrophic loss of DRGN and subsequent clearance of the 
GFP+ axonal debris.  Could the large amount of GFP seen in the animals injected 
with AAV8hrgfp-nt3 and AAV8hrgfp-nt3-shrnarhoa be due to neuroprotective effects of their 
therapeutic payloads?  The answer to this question is impossible to address without 
examining the other animals in each group.   
 
A final, vital point to consider is the fact that in this experiment two different types of 
GFP were delivered.  AAV8gfp gave expression of eGFP – a modified form of 
Aequorea GFP (Zhang, Gurtu et al. 1996).  AAV8hrgfp-nt3 and AAV8hrgfp-nt3-shrnarhoa give 
expression of hrGFP, derived from the sea pansy Renilla (Lorenz, Cormier et al. 
1996).  In the present study, only the inflammatory characteristics of eGFP delivered 
by AAV8 have been studied.  Nothing is known about inflammatory responses to 
hrGFP.  It may be the case that hrGFP is less toxic than eGFP, meaning that DRGN 
in animals injected with AAV8gfp may be under less cellular stress than those in the 
other two groups.  This issue cannot be resolved with the data available presently.   
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An interesting observation in the animal from the NT-3 group was the presence of 
large numbers of what may have been GFP+ neurones deep to the lesion site.  
Without further characterisation, it is possible that these could have been 
macrophages although their deep location and minimal auto-fluorescence seems to 
preclude this.  It is likely that after intra-DRG injection of AAV8 vectors, some 
particles enter the CSF, and are capable of transducing contralateral DRGN (see 
Chapter 4).  In the case of the result described above, it is possible that AAV8hrgfp-nt3 
present in the CSF could have been able to access neurones in the spinal cord grey 
matter following tissue disruption caused by the DC lesion.  It is known that AAV8 
cannot normally cross the spinal cord pia mater, so the above explanation seems 
plausible (see Chapter 4 Discussion).   
 
6.3.5 Animals from the NT-3 and NT3-shRNA groups showed features 
consistent with axonal degeneration 
Irrespective of whether differences exist between the inflammatory characteristics of 
eGFP and hrGFP, the issue of the high levels of axonal fragmentation must be 
addressed.  The morphology of the vast majority of axons in animals receiving 
AAV8hrgfp-nt3 and AAV8hrgfp-nt3-shrnarhoa was of linearly arranged, discontinuous GFP+ 
blebs.  This is clearly not normal, and contrasting to the situation seen in unlesioned 
animals, where many axons do display swellings, but often as part of an intact axon 
(see Chapters 4 and 5).   
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The phenomenon of axon dieback, where axon terminals are seen sometimes up to 
several millimetres from the lesion site is already recognised after SCI (Ramon y 
Cajal 1991; McPhail, Stirling et al. 2004).  Frequently these axons display abnormal 
morphologies including swellings, usually at or near their terminals.  The pattern of 
hrGFP expression seen in lesioned animals injected with AAV8hrgfp-nt3 and AAV8hrgfp-
nt3-shrnarhoa is not wholly consistent with simple axonal dieback, since GFP+ swellings 
are seen throughout the length of the axon both rostral and caudal to the lesion.  The 
picture is much more consistent with anterograde and retrograde axonal 
degeneration.   
 
The presence of features of anterograde (or Wallerian) axonal degeneration rostral to 
the lesion site does not come as a surprise in this study, since this is a phenomenon 
that has been observed repeatedly over at least the last century (Ramon y Cajal 
1991).  At the time of the lesion (28d post injection), many axons in the DC would 
have been GFP+, and their distal stumps would have undergone degeneration 
regardless of whether they eventually regenerated or not.  The fact that there is a 
large amount of GFP+ axonal debris rostral to the lesion even at 28dpl is consistent 
with the extremely slow rate of Wallerian degeneration in the CNS (Vargas and 
Barres 2007).  Studies of axonal degeneration in the spinal cord using mice stably 
expressing fluorescent proteins in neurones have shown similar appearances of 
axons undergoing anterograde degeneration to that found here, although at earlier 
time points (Kerschensteiner, Schwab et al. 2005).  Wallerian degeneration has also 
been studied in the PNS of YFP mice, displaying virtually identical features of 
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anterograde axonal degeneration seen in the present study, but occurring much 
more quickly (Beirowski, Adalbert et al. 2005). 
 
The observation of features consistent with retrograde degeneration in animals from 
the NT-3 and NT3-shRNA groups is interesting, and somewhat unexpected.  The 
mechanism of this phenomenon may be (i) the lesioned, transduced DRGN survive 
but the remnants of the proximal portions of their axons degenerate or (ii) the 
lesioned, transduced DRGN die and as a consequence all of their projections 
degenerate.  Unfortunately, the data available do not allow this issue to be resolved.  
In support of (i), it has been observed that axons proximal to a lesion can degenerate 
distances of up to 3mm (Wang, Hu et al. 2009).  However, in the present study, 
features of axon degeneration were seen throughout the proximal DC.  It is not clear 
what the proximal extent of retrograde axonal degeneration in the DC is.  
Furthermore, there were no features in the DRG consistent with DRGN death or 
degeneration of axons (e.g. GFP+ debris).  Thus, it would appear from this very 
preliminary study that transduced, axotomised DRGN do survive but undergo 
considerable levels of retrograde degeneration.  It must not be forgotten, however, 
that there were still intact axons observed caudal, rostral and in some cases at the 
level of the lesion. 
 
6.3.6 Did axon regeneration occur in any of the animals? 
Firstly, it must be emphasised that it appears that none of the lesions were complete 
as evidenced by the presence of GFP and CTB in the gracile nuclei of lesioned 
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animals.  Does this preclude any comment on axon regeneration? The answer is „not 
necessarily‟, although extreme caution must be exercised.  For a full analysis it is 
necessary to examine all of the lesioned animals in all groups and to repeat the 
experiment using a different protocol if lesions are consistently incomplete.   
 
Before discussing axon regeneration, it is worth considering any alternative 
explanations for the presence of GFP and CTB in the gracile nuclei of lesioned 
animals.  Could it be that the lesions were incomplete not as a consequence of 
technical factors, but because of some effect of the treatments?  In other words, 
could the treatments have protected axons from being damaged?  There are 
insufficient data to confirm or refute this idea, although feasible biological 
mechanisms exist related to both the viral vectors and their therapies.  For example, 
as shown in Chapter 5, AAV8gfp generates an inflammatory response in the DRG.  It 
is reasonable to assume that the therapeutic vectors also generate a similar 
response, and it is known that the presence of macrophages around neuronal cell 
bodies can have anti-apoptotic effects (Ahmed, Aslam et al. 2010).  Since axon 
degeneration shares many features with apoptosis, could it be possible that axons 
are protected from the effects of lesions by inflammation (Vargas and Barres 2007)?  
It does, however, seem difficult to accept that neuroprotective therapies could protect 
axons from direct physical damage.   
 
With respect to the therapeutic vectors, it is possible that NT-3 delivery could also 
have a protective effect on axons via the mechanism described above since NT-3 is 
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known to be anti-apoptotic (Kuo, Simpson et al. 2005).  Knockdown of RhoA may 
even be predicted to have an adverse effect on axonal resilience after injury, since 
this treatment may adversely affect cytoskeletal dynamics.   
 
Examination of the morphology of non-degenerating axons in the three groups 
reveals that the overwhelming majority look like normal DC axons.  This is consistent 
with an incomplete lesion.  The only axon with a morphology consistent with 
regeneration was seen in the animal treated with AAV8hrgfp-nt3-shrnarhoa (Figure 6.6 C).  
This axon, found in the DC rostral to the lesion had what appeared to be a hrGFP+ 
terminal growth cone.  This is unlikely to represent a dystrophic end-bulb as it lies 
approximately 1mm distal to the lesion.  It is of course possible that this could be an 
axonal swelling on an intact axon, the distal segment of which was not present in the 
section.  However, no other intact axons with swellings were seen in this region.   
 
6.3.7 CTB immunostaining failed to demonstrate axons adequately  
Disappointingly, CTB immunohistochemistry did not demonstrate axons adequately 
due to its high level of background staining and absence in axons.  The high 
background was probably due to the use of thick sections (25µm) and inadequate 
blocking.  Thick sections were used to give the best chance of preserving tissue 
morphology (thin sections fold on themselves and distort easily). 
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CTB staining was restricted to terminals of sensory neurones.  Indeed, CTB has 
frequently been used to label projection areas in grey matter (LaMotte, Kapadia et al. 
1991).  However, many other workers have used CTB to successfully demonstrate 
axons in tracts such as the DC (Bradbury, Khemani et al. 1999).  No essential 
differences existed between the protocol for CTB tracing used in the present study 
compared with the consensus in the literature, resulting in a frustrating situation 
(Zhang, Dijkhuizen et al. 1998; Bradbury, Khemani et al. 1999; Kadoya, Tsukada et 
al. 2009).  It is worthwhile attempting to optimise CTB delivery by altering parameters 
such as the batch or brand of toxin used, the quantity injected, the technique of 
injection and length of time before sacrificing animals.  Additionally, detection may be 
improved by increasing the concentration of blocking reagents, maximising tissue 
penetration of antibodies by increasing the concentration of detergents, using a 
different antibody or different detection technique (e.g. HRP versus 
immunofluorescence) or using thinner (or even thicker) sections.  From a recent 
discussion at the International Spinal Research Trust Network Meeting, it seems 
highly likely that protocols employing free-floating sections will be successful (Ann 
Logan, personal communication).   
 
6.4 Further work 
This Chapter has dealt with only very preliminary data from a pilot experiment.  The 
further work can be split into categories, namely: completion of replicates, further 
characterisation of the therapeutic vectors, confirmation of therapeutic bioactivity, 
further assessment of lesion characteristics and addition of further experimental 
groups. 
207 
 
Completion of replicates 
Clearly, in order to provide a full characterisation of the axon regenerative effects of 
the therapeutic vectors, all animal in each group must be subjected to 
immunohistochemical analysis 
 
Further characterisation of therapeutic vectors 
It is necessary to confirm that the transduction rates and tropisms of the therapeutic 
vectors are comparable to that seen for the control vector AAV8gfp in order to make 
valid comparisons between treatment and control groups.  Furthermore, it must be 
shown that the glial and inflammatory responses of the therapeutic vectors are 
comparable to the control. 
 
Confirmation of therapeutic bioactivity 
It is important to confirm that what was seen in vitro (see Chapter 3) was also present 
in vivo – namely, production of NT-3 in the DRG and knockdown of RhoA in DRGN.  
This could be shown by quantitative immunohistochemistry for NT-3 and RhoA on 
DRG sections.  Furthermore, the reader is reminded that the NT-3 that was delivered 
in these experiments was human.  Human and rat NT-3 share the same primary 
sequence but have differences in their signal peptides (Maisonpierre, Belluscio et al. 
1990; Maisonpierre, Le Beau et al. 1991).  It would be possible to show by 
quantitative PCR the relative amounts of human (exogenous) and rat (endogenous) 
NT-3 present in the DRG. 
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Further assessment of lesion characteristics 
If, upon completion of replicates, it was found that the majority of lesions were 
incomplete, it would be necessary to attempt to optimise the lesioning protocol.  This 
may involve calibration of lesion depth or even necessitate changing the lesioning 
technique, for example using a mechanical or stereotactic device.   
 
It would be informative to further characterise the lesions histologically and 
immunohistochemically, namely by measuring lesion volumes and staining for 
macrophages, activated microglia and oligodendrocytes.  Additionally, 
immunohistochemical amplification of the GFP signal may demonstrate more axons 
around the lesion site.   
 
 
Further experimental groups 
Ideally, a number of additional control groups should be added to the experiment.  
These were not included originally due to time and financial constraints.  He 
additional groups should include sham injected, lesioned animals; PBS injected 
lesioned animals; a group receiving AAV8hrgfp (this vector was not available) and a 
lesion and also a group receiving AAV8hrgfp-shrnarhoa (this vector was not available).  
Furthermore, it is necessary to ascertain whether the therapeutic vectors have any 
effects on the normal, uninjured spinal cord (e.g. increased sprouting, neuronal death 
etc.).   
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General Discussion 
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In this Chapter, the major findings of the present study will be presented followed by 
a distillation of these results, putting them into context and highlighting any important 
general principles.  The author hopes that the reader will some key „take-home‟ 
messages from the following pages.   
 
7.1 Summary of findings 
 
Chapter 3 – Production and validation of AAV constructs 
 
Specific hypotheses 
 
 Delivery of NT-3 to adult rat DRGN in vitro augments survival and stimulates 
neurite outgrowth  
 Knockdown of RhoA by transfection of an shRNA against RhoA will lead to 
disinhibited neurite outgrowth and diminution of RhoA protein levels 
 
Major findings 
 
 rhNT-3 supported survival but not neurite outgrowth of dissociated rat DRGN 
in vitro 
 High concentrations of FLAG-tagged NT-3 were detected by Western blotting 
and ELISA in conditioned medium from COS-1 cells transfected with pAAV-
CMV-NT3-FLAG-IRES-hrGFP 
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 NT3-FLAG was not amenable to assessment of its biological activity, so it was 
decided to produce plasmids containing untagged NT-3 
 pFBGR-IRES-hrGFP-MCS was generated by overlap extension PCR of a NotI 
site in pAAV-IRES-hrGFP followed by sub-cloning of its IRES-spanned region 
into pFBGR 
 A human NT-3 sequence was obtained, and its sequence confirmed (hNT-3) 
 The hNT-3 sequence was inserted into pFBGR-IRES-hrGFP-MCS yielding 
pFBGR-CMV-NT3-IRES-hrGFP 
 An shRNA sequence was identified that was capable of maximally knocking 
down the expression of RhoA (shRNARhoA) 
 The shRNARhoA sequence was inserted into pFBGR-CMV-NT3-IRES-hrGFP 
yielding pFBGR-IRES-hrGFP-NT3-shRNARhoA 
 pFBGR-CMV-NT3-IRES-hrGFP and pFBGR-IRES-hrGFP-NT3-shRNARhoA 
were sent to the University of Iowa‟s Gene Transfer Vector Core for production 
of AAV8hrgfp-nt3 and AAV8hrgfp-nt3-shrnarhoa, respectively 
Hypothesis 1 was partially supported, hypothesis 2 was not conclusively supported or 
refuted.   
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Chapter 4 - Assessment of the cellular tropism of AAV8 in the DRG using two 
different delivery methods 
 
Specific hypotheses 
 AAV8 transduces all subtypes of DRGN with equal frequency in vitro and in 
vivo regardless of delivery route – there is no cellular tropism 
 Transduction of DRGN will correlate with the level of expression of LMR 
 The central projections of DRGN will be completely filled with GFP 
 
Major findings 
 AAV8gfp was capable of transducing DRGN after both intra-DRG and 
intrathecal injection 
 AAV8gfp preferentially transduced large-diameter, parvalbumin
+ DRGN   
 All DRGN were LMR+  
 The central projections of AAV8gfp transduced DRGN were labelled with GFP   
 Preferential transduction of large diameter DRGN is lost in vitro 
Hypothesis 1 was refuted, hypothesis 2 was refuted, hypothesis 3 was supported.   
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Chapter 5 - Inflammatory and glial responses to AAV8 mediated transgene 
delivery 
 
Specific hypotheses 
 
 The delivery of AAV8gfp does not lead to an appreciable inflammatory 
response after either intra-DRG or intrathecal injection 
 The delivery of AAV8gfp does not lead to an appreciable change in the level of 
CNS glial activation after either intra-DRG or intrathecal injection 
 The delivery of AAV8gfp does not lead to degeneration of DRGN central 
projections 
 
Major findings 
 
 Macrophages infiltrated the DRG after intra-DRG and intrathecal delivery of 
AAV8gfp 
 Satellite cells upregulated expression of CD68  after intra-DRG and intrathecal 
delivery of AAV8gfp 
 Microglia and astrocytes were activated in the spinal cord after intra-DRG 
delivery of AAV8gfp 
 Microglia and astrocytes were not activated in the cord after intrathecal 
delivery of AAV8gfp 
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 No degeneration of DRGN central axon projections occurred after intra-DRG 
delivery of AAV8gfp   
 There was no evidence of DRGN death after intra-DRG or intrathecal delivery 
of AAV8gfp   
 
Hypotheses 1 and 2 were refuted, hypothesis 3 was supported.   
 
Chapter 6 - A pilot experiment to examine the effect of AAV8 mediated delivery 
of NT-3 and shRNARhoA to DRGN on axon regeneration in the DC 
 
Specific hypothesis 
 AAV8hrgfp-nt3-shrna-rhoa and AAV8hrgfp-nt3 transduction of DRGN in vivo mediates 
neurone survival and disinhibited regeneration of DC axons 
 
Major findings 
 After intra-DRG injection of AAV8hrgfp-nt3-shrna-rhoa and AAV8hrgfp-nt3, GFP was 
present in large-diameter DRGN, co-localising with CTB 
 No differences were observed in the gross pathological appearance of lesion 
sites from animals in different treatment groups 
 GFP+/CTB+ terminals were seen in the medullas from the three animals that 
were analysed 
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 Hints of axon regeneration were observed in the animal injected with 
AAV8hrgfp-nt3-shrna-rhoa 
 
It was not possible to state whether the hypothesis for this chapter was either 
supported or refuted.   
 
7.2 NT-3 is a worthwhile growth factor to use in SCI 
A large proportion of this study focussed on demonstrating that NT-3 was an 
appropriate growth factor to stimulate regeneration of DRGN axons.  Despite the fact 
that the present study failed to demonstrate any effect of NT-3 on neurite outgrowth 
in dissociated DRG cultures, it is very convincing from the literature that NT-3 is 
neuritogenic and activates the neurone‟s intrinsic growth state in vitro (Mohiuddin, 
Fernandez et al. 1995; Gavazzi, Kumar et al. 1999).  Furthermore, a number of 
reports have shown NT-3 bioactivity in the injured spinal cord in vivo, both as a 
chemotropic agent as well as a stimulant of regenerative axon growth (Bradbury, 
Khemani et al. 1999; Alto, Havton et al. 2009).   
 
The rationale for the delivery of an NT-3 expressing AAV vector to cell bodies in the 
DRG was to avoid the so-called „neurotrophic sink‟ phenomenon observed when a 
neurotrophin is applied at lesion sites.  Also, it was hoped that the long-term and 
stable levels of transgene expression provided by AAV vectors would provide a 
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strong and sustained trophic stimulus for axotomised DRGN.  Only further analysis 
will show if this is an effective strategy in the injured DC.   
 
7.3 The assessment of viral vector tropism both in vitro and in vivo should be 
an essential part of any gene therapy study 
The fact that viral vectors display varying cellular tropisms is not unexpected and 
actually extremely welcome, especially in the case of AAV vectors, which have many 
natural serotypes.  Only in recent years, however, has the detailed study of AAV 
tropism found prevalence in the literature (Vulchanova, Schuster et al. 2010; Fischer, 
Kostic et al. 2011).  The significance of viral vector tropism is particularly profound in 
the nervous system, which contains discrete collections of neurones, which are not 
necessarily functionally identical.  For example, the DRG houses a highly diverse 
population of sensory neurones that are known to project to CNS regions such as the 
dorsal horn, ventral horn, thoracic cord and medulla.  It becomes immediately 
obvious that problems may arise if one were to deliver a viral vector directed at 
„sensory neurones‟ without any prior knowledge of its cellular tropism.  Of course, 
there may be a place for widespread transduction of sensory neurones but this is 
unlikely to become a recognised treatment modality of the future due to the diverse 
trophic needs of sensory neurones (Gavazzi, Kumar et al. 1999; Huang and 
Reichardt 2001).  Aberrant stimulation of sprouting in, say, nociceptive neurones 
could lead to potentially disastrous consequences such as neuropathic pain 
(Eriksdotter Jonhagen, Nordberg et al. 1998; Nauta, Wehman et al. 1999).   
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A second, important observation from the present study was that the observed 
tropism of a viral vector can be modulated by the neuronal environment.  The fact 
that AAV8 does not target large diameter DRGN in vitro points to the importance of 
not assuming that in vitro results can be translated to the in vivo situation.  Clearly, 
this is a caveat that most biological scientists are aware of but it did come as 
something of a surprise to see this effect with AAV8 since it was assumed that viral 
tropism was predominantly determined by receptors on the cell surface.  This should 
be the subject of much further study since it offers the potential for further „fine-
tuning‟ of viral tropism, maybe by modulating the extracellular matrix.   
 
7.4 Potential inflammatory responses and neurotoxicity of viral vectors and 
transgenes must be taken seriously and be an essential part of any gene 
therapy study 
It was not expected that AAV8gfp would generate an inflammatory response in the 
DRG or spinal cord since previous reports had shown that AAV vectors (and GFP) 
were relatively immunologically inert (Daya and Berns 2008).  However, the results 
obtained in this study strongly pointed towards potential inflammatory responses to 
AAV8gfp, and a subsequent literature search produced a number of reports describing 
neurotoxicity of GFP overexpression in neurones (see Chapter 5 for more).  It is the 
author‟s opinion that there is significant publication bias in the literature concerning 
GFP neurotoxicity since many research groups rely extensively on animals that 
stably express fluorescent proteins.  Also, studies employing Cre-Lox technology 
frequently use GFP-expressing viral vectors as controls (Park, Liu et al. 2008).  Could 
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GFP-related neurotoxicity or inflammatory responses to viral vectors be confounding 
their results? 
 
7.5 Combinatorial strategies for the treatment of SCI are effective and hold 
much promise for the future 
Disappointingly, due to lack of time, the final analysis of axon regeneration in animals 
treated with the therapeutic viruses was not completed.  However, there were a 
number of promising features present in the animals treated with       AAV8hrgfp-nt3-
shrna-rhoa and AAV8hrgfp-nt3 – definitely enough to necessitate complete analysis of all 
the animals in the experiment in Chapter 6.  It seems highly likely that combinatorial 
therapies will prove useful in the future.  The majority of the most successful studies 
on axon regeneration have used combinations of therapies to elicit convincing 
anatomical restitution of damaged neural pathways.  Recent work from Tuszynski‟s 
laboratory provides a particularly good example of this approach (Alto, Havton et al. 
2009; Kadoya, Tsukada et al. 2009).   
 
7.6 Final conclusion 
The vast majority of scientific endeavour occurs as an incremental, often frustratingly 
slow progression of ideas.  The study of CNS axon regeneration is no exception, 
although its history has been punctuated by a number of paradigm shifts, e.g. the 
works of Windle and Raisman (Windle and Chambers 1950; Raisman, Cowan et al. 
1966).  The author is under no illusion about the modest import of the ideas 
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contained in the previous pages, but hopes that the data collected during the course 
of his three years in the laboratory will at least stimulate other workers who read this 
to think about the implications of the results presented.  For it is only by independent 
repetition and confirmation (or refutation) of experimental results that science can 
progress.   
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